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1110 General Introduction
FROM HEALTHY TO CANCEROUS CELLS
Cells in a living organism are designated with a functional role that can be classified by their 
tissue of origin. In human, there are many distinct cell types1,2 for which their function varies 
widely. In general, a cell (Figure 1A) contains a nucleus (Figure 1B) that contains the genetic 
instructions in the chromosomes which are essential for the development and functioning of a 
particular cell. In humans we count 46 individual chromosomes or 23 chromosome pairs (Figure 
1C), which consist of DeoxyriboNucleic Acid (DNA). Stretches of the DNA with specific functions 
are denoted as “genes”3,4 (Figure 1D). In order to get a healthy functioning cell, genes need to be 
transcribed to messenger RiboNucleic Acid (mRNA, Figure 1E) and then translated into proteins5 
(Figure 1F). The proteins are the functional units of the cell. In the human genome, approximately 
23000 protein-coding genes are identified6. The function of a particular cell depends on the 
combination of genes that are in “onset” or “offset”. The communication between genes and 
proteins is part of a complex system and errors in these crucial processes are responsible
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Figure 1. Overview of large scale measurements. The cell (A) which contains a nucleus (B), which in turn contains the 
chromosomes (C) containing all the genetic information. The following data are frequently measured large scale: mRNA 
expression by using Gene Expression Profiling (GEP) (D), Protein-protein interactions (PPI) (E), DNA-methylation levels 
(DMP or MeDIP-on-chip) (F), or protein-DNA-binding interactions (ChIP-on-chip or ChIP-Seq) (G). DNA helix is adapted 
from National Human Genome Research Institute. 
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SUMMARY
In the last decade, tiling-array and next-generation sequencing technologies allowed quantitative 
measurements of different cellular processes, such as mRNA expression, genomic changes 
including deletions or amplifications, DNA-methylation, chromatin modifications or Protein-
DNA-binding interactions. Using these technologies, thousands of features can now be measured 
simultaneously in a patient cell sample. The use of for instance mRNA expression profiles or 
DNA-methylation profiles have already provided new insight into the molecular biology of 
patients with Acute Myeloid Leukemia (AML). AML is a blood cell malignancy, in which primitive 
myeloid cells have been transformed and accumulate in the bone marrow and blood. Different 
forms of AML exist with different molecular abnormalities that associate with distinct responses 
to therapy. Many subgroups with comparable mRNA expression or DNA-methylation patterns 
were identified. These studies also revealed the existence of novel previously undefined AML 
subtypes. Among those was a group of patients with a mutation in a gene called CEBPA. CEBPA 
is a gene that encodes the transcription factor CCAAT Enhancer Binding Protein Alpha (C/EBPα), 
which controls the expression of genes in myeloid progenitor cells. Mutated CEBPA encodes a 
dysfunctional C/EBPα-protein, which consequently results in aberrant control of “target genes”. 
In this thesis we focus particularly on the role of CEBPA. We studied the predictive and prognostic 
relevance of mutated CEBPA, and analyzed in a genome wide fashion the mRNA expression, 
DNA-methylation and the protein-DNA-binding levels corresponding to (mutated) CEBPA in AML. 
For the analysis of protein-DNA-binding, we developed a novel statistical methodology. With this 
statistical methodology we studied the fundamental role of (mutant) C/EBPα binding and the 
effect on gene expression levels. We also integrated gene expression with DNA-methylation 
profiles of hundreds of AML patients and revealed the existence of two previously unidentified 
AML subtypes.
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for diseases such as cancer. A majority of genes are responsible for the maintenance of basic 
cellular functions7,8. Other genes encode for proteins that are needed for specific functions of a 
particular cell1. When DNA is damaged at the gene-locations, genes may become malfunctioning 
or non-functioning. When this happens, cancer may arise. Cancer is a generic term for a large 
group of diseases that have different incidence and mortality rates9. 
The one defining feature of cancer is that cells in tumorigenic state grow too fast and beyond 
their usual boundaries that may consequently result in an invasion to other body parts and 
organs, which is called metastasis10. Such a tumorigenic state can only be entered when existing 
fail-safe mechanisms are bypassed or are shutdown11, which is often due to genetic changes 
in genes that are controlling these mechanisms12. Two classes of genes can be discriminated 
that cause far reaching effects when damaged: oncogenes13 and tumor suppressor genes14. 
These genes do often have a role in the fail-safe mechanisms of a cell. Oncogenes will drive 
a cell towards tumorigenic activity once hyper-activated13. Conversely, shutting down a tumor 
suppressor gene may lead to increased tumorigenic activity as well14.
Leukemia is such a cancerous disease. As in other forms of cancer, mutations are observed in 
regulatory genes (in leukemia cells). Most mutations that cause cancer are of somatic origin15, 
meaning that the DNA damage is acquired, most likely as the result of environmental or 
endogenous carcinogenic agents. Mutations may sometimes be inherited or can be gained in 
a situation where individuals have increased susceptibility to develop cancer. Both somatic and 
germline mutations can result into abnormal cell growth and development. 
BLOOD CELL FORMATION AND ACUTE MYELOID LEUKEMIA
Blood cells arise from hematopoietic stem cells (HSCs), which reside in the bone marrow16. In a 
normal (healthy) situation, HSCs develops into primitive progenitor cells which may then mature 
into red blood cells (erythrocytes), platelets (thrombocytes) or different types of white blood 
cells (leukocytes) (Figure 2)16,17. However, mutations in genes can cause that HSCs or primitive 
lineage specific progenitor cells are unable to develop and remain immature. These immature 
cells accumulate in the blood and bone marrow causing less room for healthy blood cells. Such 
a cancerous process is called leukemia.
Acute Myeloid Leukemia (AML) is the most common myeloid disorder in adults9, and is 
the disease that is central in this thesis. The prevalence is on average 3.5 cases per 100000 
individuals world-wide but increases with age9. The median age of presentation is approximately 
67 years and the disease is known to be heterogeneous18, meaning that different forms 
of AML exist. As an example, there are groups of patients with chromosomal abnormalities, 
such as inversions of DNA-fragments (inv(16)) or the rearrangements of chromosomal parts 
that join two other separated genes, denoted as translocations (t(15;17), t(8;21)). Frequently 
such inversions and translocations cause gene fusions to occur, creating hybrid proteins. 
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Hematopoietic
stem cell
Common myeloid 
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Common lymphoid 
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Myeloid blast
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White blood cellsPlatelets
Figure 2. Overview of hematopoietic stem cell development. A hematopoietic stem cell matures into myeloid blasts or 
lymphoid blasts. The myeloid blast can subsequently mature into the Erythrocytes, Platelets or various types of white 
blood cells. A lymphoid blast matures into white blood cell such as, B-cells or T-cells63.
In other translocations, it has been suggested that a strong promoter of one gene is repositioned 
to the coding sequence of another, resulting in overexpression of that particular gene. Other 
known abnormalities in AML are subtle mutations in cancer-critical genes, such as for Internal 
Tandem Duplications of FLT3 (FLT3ITD) 19-23, nucleophosmin (NPM1)24,25 or “CCAAT enhancer 
binding protein alpha” (CEBPA) 26-28 (Figure 3A). These and many other abnormalities are 
nowadays used in the risk-classification of patients, i.e. to predict favorable, intermediate or 
poor treatment outcome29-32. 
The risk-classification of AML was until the late seventies based on the pathology and cytological 
examination of bone marrow and blood cells33. Nowadays, various subtypes of AML are known, 
each with different survival rates33. Classification of the disease is important to refine more 
“personalized” therapy, i.e. predicting which therapy may work the best for a (group of) patient(s), 
and thereby increase the chance to survive. However, not all AMLs can be classified into the 
known AML subtypes. To characterize the underlying abnormalities of these unclassifiable AMLs 
we first need to detect which DNA changes (i.e. mutations) and which mechanisms or pathways 
were involved.
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AML PATIENTS WITH ABNORMAL CEBPA EXPRESSION
CEBPA abnormalities are investigated for more than a decade27 but only since the emerging 
microarray technology18,34, the possibilities for fast mutational screening35, and the use of large 
databanks of patients cohorts, fast refinement and many new insights are provided. This section 
introduces 1. The discovery of CEBPA mutations, 2. The survival and treatment response of 
AML patients with CEBPA mutations, 3. The use of gene expression profiles to predict AML with 
CEBPA mutations, and 4. The interactions of C/EBPα to the DNA. 
It has been shown that CEBPA mutations occur mainly in cytogenetically normal AML (CN-AML) 
with an incidence of 5-14%27,28,31,36-42. Two main types of CEBPA mutations can be distinguished: 
N-terminal frame-shift mutations resulting in the translation of a 30-kDa protein only, and 
the C-terminal in-frame mutations in the basic zipper region affecting DNA-binding and 
homodimerization and heterodimerization28,43,44 (Figure 3A). It is known that CEBPA mutations 
can roughly be separated into two subgroups, i.e., AML patients with a single mutation (CEBPAsm) 
and those with double mutations (CEBPAdm)35,45-48. Favourable outcome is observed in AML 
with CEBPAdm but not for CEBPAsm 35,44, however it is unclear why the clinical outcome between 
CEBPAdm and CEBPAsm is different. In addition, the distribution of distinct CEBPA mutations, and 
presence or absence of the concurrent mutations in other genes for the same AMLs had not 
been established yet. We therefore investigating the distribution of CEBPA mutations in a large 
cohort of patients (Chapter 7). We show that in the majority of CEBPAdm AML, both alleles are 
mutated (Figure 3B). These biallelic mutations frequently harbour an N-terminal mutation on 
one allele and a C-terminal bZIP mutation on the other. In CEBPAsm AML, mutations occur mostly 
in the N-terminus, although single C-terminal mutants have been found as well (Figure 3B). We 
furthermore analysed in Chapter 7 the presence of concurrent mutations in CEBPAdm or CEBPAsm. 
We detected that these were significantly enriched for CEBPAsm AMLs. With this knowledge we 
could address why CEBPAdm differed in clinical outcome compared to CEBPAsm, and whether the 
outcome is affected by concurrent mutations.
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CEBPAdouble C-mutant (3.5%)
CEBPAsingle C-mutant (9.4%)
CEBPAsingle N-mutant (31.8%)
CEBPAdouble N+C mutant (52.4%)
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Figure 3. Overview of CEBPA. (A) Gene CEBPA lies at chromosome 19. There are two isoforms that are translated from 
the same mRNA: P42 and P30. Mutations in CEBPA are seen in the N-terminal and C-terminal regions. (B) The frequency 
of mutated CEBPA (N/C-terminal) for 170 AML patients (data is used from HOVON-SAKK and AMLSG-cohort44).
The prognosis for AMLs with a CEBPAdm is defined as favourable; 5-years overall survival is ranging 
between 50% and 70%35,44-48. These patients were consolidated with different types of therapy, 
such as intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation 
(autoHSCT or alloHSCT). After such treatment protocols, patients may enter a so called complete 
remission (CR), meaning that less than 5 percent blast cells are present in the bone marrow, and 
none can have a leukemic phenotype49,50. Relapse remains a major cause of treatment failure 
and occurs frequently within the first 2 years after entering a complete remission (CR). This has 
for instance raised the question whether a HSCT in first CR should be recommended in patients 
with this form of AML. Analyses according to type of post remission treatment in the subset of 
AML with mutant CEBPA, for clinical reasons useful, have so far not become available mainly due 
to limited patient numbers precluding meaningful statistical analyses. In Chapter 8 we studied 
AMLs CEBPA mutational status (age 18-60 years) in AML. The benefit of post remission stem cell 
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transplantation in AML patients that harbour CEBPAdm compared to CEBPAdm AMLs which were 
not treated with stem cell transplantation was investigated.
It has previously been discovered that CEBPAdm has a uniquely associated gene expression 
profile35 which stresses the notion to mark CEBPAdm AMLs as a distinctive disease entity. This 
means that these AMLs have very similar gene expression profiles which can subsequently be 
used for diagnostic purposes51, such as prediction of CEBPAdm AMLs given the gene expression 
profiles. A predictive gene signature35 has therefore been created but was hampered by AMLs with 
hypermethylation of the proximal promoter region of CEBPA34. In addition, it is unknown whether 
classification results are affected by homozygous N-terminal or C-terminal CEBPAdm mutations or 
because of germline mutations. In Chapter 7 we created a gene signature that has increased the 
power for CEBPAdm prediction, and we addressed the question whether homozygous N-terminal 
or C-terminal and germline CEBPAdm mutations showed differences in the classification. 
Although a very specific gene signature is created that describes CEBPAdm AMLs, it does not 
describe what the functional effect is of mutated CEBPA in primary AMLs. It is known that the 
N-terminal domain contributes to cell growth inhibition, whereas the C-Terminal domain that 
contains a basic region required for DNA-binding and a leucine zipper (bZIP) essential for homo 
and heterodimerization44,52-54. However, the functional effect of mutated CEBPA in primary AML 
cells is unknown. We studied the binding capacity of a mutated C-terminal CEBPA in Chapter 5 
and provide data that suggest that C-terminal mutant CEBPA is capable of (in) direct binding to 
the DNA. 
DETECTION OF FUNCTIONAL REGIONS IN THE GENOME
In the last decade, technology such as tiling-array hybridizations provided whole genome 
coverage by using probes and therefore useful for exploring the genome in an unbiased fashion. 
Tiling-array technology is valuable for different applications, such as 1. Protein-DNA-interaction 
by conducting chromatin immunoprecipitation followed by array (Chip) hybridization (ChIP-on-
chip, Figure 1H) experiments, 2. Epigenetic modifications by Methyl-DNA immunoprecipitation 
(MeDIP-on-chip, Figure 1G) or 3. Identification of DNAse hypersensitive sites, which can be used to 
predict regulatory elements such as promoter regions, enhancers and silencers. Each tiling-array 
produces quantitative signal intensity for each probe by the hybridization of labeled DNA. Probe 
intensities are illustrated by the different peaks in Figure 1H. Single probe-hybridization with 
high signal intensity suggests strong hybridization but it is not necessarily the result of specific 
hybridization of labeled DNA. Multiple contiguous probes that show increased signal intensity 
upon hybridization across a particular genomic region are more likely to be the result of true 
hybridization in a biological experiment. To detect biologically relevant genomic regions, probe 
intensity signals should be discriminated from non-specific signals. A challenge in the analysis 
of tiling-array data is finding those genomic regions where the signal significantly deviates from 
the general genome wide behavior. Determining these candidate regions is difficult as there is 
no “golden standard” that defines properties (e.g. signal intensity or size) of such region. We 
therefore developed a novel statistical methodology, Hypergeometric Analysis of Tiling-arrays 
(HAT), (Chapter 2) to identify candidate genomic regions in tiling-array data. The use of a dynamic 
window makes our model independent of size and therefore applicable for different biological 
tiling-array experiments (protein-DNA-binding, DNA-methylation, histone modifications). We 
used HAT to study the binding of mutated C/EBPα (Chapter 5), wild-type C/EBPα (Chapter 6), and 
to detect viral integration sites that potentially harbour new tumour suppressor genes (Chapter 4).
HAT showed to be successful55-57 for the analysis of tiling-array data. However, in the past few years 
Next-Generation Sequencing technology (NGS) has rapidly replaced tiling-array hybridization 
because of the increased resolution with which the interactions can be measured. Instead of using 
probes, the immunoprecipitated DNA-fragments in a ChIP experiment are sequenced and in turn 
aligned to the reference genome. We developed (Chapter 3) HATSEQ (Hypergeometric Analysis 
of Tiling-arrays and Sequence data), which is an extremely scaled version of HAT that can work on 
a base resolution, and has proven to be accurate in the detection of potential candidate regions.
DETECTION OF AML SUBTYPES BY USING GENE EXPRESSION AND DNA-
METHYLATION PROFILES
Ideally, when it comes to cancer, we want to reconstruct all the changes that occurred for 
a single cancer to determine exactly where, what and how it went wrong in the DNA. This 
requires measuring various different processes, such as DNA-methylation58 (Figure 1G) or 
mRNA expression levels18 (Figure 1E). Although this is possible, the analysis of large data sets 
is not a routine process. In our simplified scheme (Figure 1), DNA-methylation can be seen as 
a logical “AND” operator for the onset or offset of genes (Figure 1D). However, this process 
is not deterministic but rather a stochastic process, and may depend on other factors (such 
protein-DNA-binding, Figure 1H), and therefore difficult for routine analysis. These processes 
(Figure 1G, H, E and F) are so far investigated thoroughly but mostly independently from each 
other18,58-60. Gene expression profiling (GEP) has been used to analyse the mRNA gene expression 
profiles of hundreds of AML patients18. For the same patients, DNA-methylation profiles (DMP) 
are also measured58. Both technologies provided multiple data sets which could lead to novel 
insights into AML34,61,62, such as the discovery of novel AML subgroups. We hypothesized that the 
combined data results in specific patterns in cancer cells that may uncover novel AML subgroups. 
In Chapter 9 we developed an approach to combine the two data sets and we identified two 
novel AML subgroups that could not be identified using GEP18 or DMP58 alone.
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SCOPE AND AIM OF THE THESIS
The thesis presents work divided into four sections. The first section (Chapter 2, 3 and 4) deals 
with the detection of candidate regions in the genome using tiling-array and next-generation 
sequencing technology. These technologies have been developed to accurately determine 
potential functional regions in the genome, such as for the binding of proteins that regulate 
transcription. Chapter 2 describes the statistical method that we developed to detect candidate 
regions for tiling-array technology. Although the many successes of tiling-array technology, 
next-generation sequencing technology rapidly replaces tiling-arrays because of the increased 
resolution with which the interactions can be measured. In Chapter 3 we demonstrate how we 
optimized our methodology to work on a base resolution, and to detect potential candidate 
regions in the genome. This Chapter is followed by a case study where viral integration sites are 
identified that potentially harbour new tumour suppressor genes in a so called MeDIP-on-chip 
dataset (Chapter 4).
The second section (Chapter 5 and 6) of the thesis is concerned with the experimental 
interactions of C/EBPα in an inducible myeloid cell line model. In Chapter 5 we used our novel 
methodology, and asked the question whether we could identify potential targets of mutated 
C/EBPα. In AML patients it has previously been shown that silencing of CEBPA leads to cells with 
myeloid/T-lymphoid features. However, the exact role of C/EBPα in this process is unknown. In 
Chapter 6 we asked the question whether the newly developed computational technologies can 
be of use to study the mechanism by which silencing of CEBPA may play a role in transformation 
of cells with myeloid/T-lymphoid characteristics. 
The third section of the thesis (Chapter 7 and 8) focuses on AML patients with mutations in 
CEBPA. It is known that mutations in CEBPA occur in a biallelic (double) or mono allelic (single) 
fashion. AML patients with CEBPA double mutations are associated with favourable outcome 
whereas patients with single mutations in CEBPA showed unfavourable outcome. In Chapter 
7 we evaluated the outcome of CEBPA double and single mutations with respect to other 
concurrent mutations. In Chapter 8 we asked the question whether the favourable prognosis 
of AML with CEBPA double mutation is to be attributed to a distinct post remission strategy, i.e. 
treatment of allogeneic or autologous hemapoetic stem cell transplantation (alloHSCT, autoHSCT 
respectively), compared to patients treated with chemotherapy. 
The fourth, and final section (Chapter 9) centres on the questions whether the combined 
gene expression profiles and DNA-methylation profiles can be used to identify previously 
unrecognized subgroups of AML.
Chapter 10 provides a general discussion of the results and future perspectives are provided.
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ABSTRACT
Background: Tiling-arrays are applicable to multiple types of biological research questions. Due 
to its advantages (high sensitivity, resolution, unbiased), the technology is often employed in 
genome wide investigations. A major challenge in the analysis of tiling-array data is to define 
regions-of-interest, i.e., contiguous probes with increased signal intensity (as a result of 
hybridization of labeled DNA) in a region. Currently, no standard criteria are available to define 
these regions-of-interest as there is no single probe intensity cut-off level, different regions-of-
interest can contain various numbers of probes, and can vary in genomic width. Furthermore, 
the chromosomal distance between neighboring probes can vary across the genome among 
different arrays.
Results: We have developed Hypergeometric Analysis of Tiling-arrays (HAT), and first evaluated 
its performance for tiling-array datasets from a Chromatin Immunoprecipitation study on chip 
(ChIP-on-chip) for the identification of genome wide DNA-binding profiles of transcription factor 
C/EBPα (used for method comparison). Using this assay, we can refine the detection of regions-
of-interest by illustrating that regions detected by HAT are more highly enriched for expected 
motifs in comparison with an alternative detection method (MAT). Subsequently, data from a 
retroviral insertional mutagenesis screen were used to examine the performance of HAT among 
different applications of tiling-array datasets. In both studies, detected regions-of-interest have 
been validated with (q)PCR. 
Conclusions: We demonstrate that HAT has increased specificity for analysis of tiling-array data 
in comparison with the alternative method, and that it accurately detects regions-of-interest in 
two different applications of tiling-arrays. HAT has several advantages over previous methods: 
i) as there is no single cut-off level for probe intensity, HAT can detect regions-of-interest at 
various thresholds, ii) it can detect regions-of-interest of any size, iii) it is independent of probe-
resolution across the genome, and across tiling-array platforms and iv) it employs a single user 
defined parameter: the significance level. Regions-of-interest are detected by computing the 
Hypergeometric probability, while controlling the Family Wise Error. Furthermore, the method 
does not require experimental replicates, common regions-of-interest are indicated, a sequence 
of interest can be examined for every detected region-of-interest, and flanking genes can be 
reported.
BACKGROUND
Tiling-arrays are used for the identification of specific genomic DNA regions that can be 
enriched using various procedures to study certain molecular biological features. For example, 
DNA-fragments that are bound by a protein-of-interest, e.g., a transcription factor, can be 
enriched by using Chromatin Immunoprecipitation (ChIP). When these enriched fragments are 
hybridized to an array, a genome wide protein binding profile can be obtained that is associated 
with this particular protein-of-interest in the cell type that was studied (ChIP-on-chip64). Other 
applications of tiling-arrays65 are: Methylated DNA immunoprecipitation (MeDIP-on-chip66), 
transcriptome mapping67, recognition of hypersensitive sites such as segments of open 
chromatin that are cleaved more readily by DNaseI (DNase-chip68), or identification of copy 
number variations or breakpoints (Array CGH69). The use of tiling-arrays to detect enriched DNA 
regions has several advantages such as i) high sensitivity, which allows the detection of small 
DNA-fragments associating with rare molecules and, ii) high probe-resolution, which results in 
accurate acquisition of unbiased data.
A tiling-array is an array of short DNA-fragments, which represent ‘probes’ that cover the entire 
genome, or contigs of the genome. The hybridization of labeled DNA to an array (for example 
DNA enriched using ChIP), will produce a quantitative signal intensity for each probe. Multiple 
contiguous probes with increased signal intensity across a particular genomic region, is a putative 
region-of-interest, and suggests the presence of a protein binding site.
As there are no standard criteria to accurately define a region-of-interest, a major challenge in 
the analysis of tiling-array data is to define such a region, and discriminate a positive signal from 
non-specific signals70. Defining regions-of-interest requires intensity thresholds on continuous 
probe intensity levels. Following this, the decision of the number of consecutive probes above the 
threshold needs to be made before a region-of-interest is called. This threshold, and the number 
of probes above the threshold, directly influence the size of the region-of-interest that can be 
detected. As biologically relevant regions may vary in intensity, employing a single threshold is 
insufficient. Additionally, as the probe-resolution varies across the genome, and across different 
tiling-array platforms, choosing a fixed number of consecutive probes as a region-of-interest is 
also inadequate. Various methods have been developed to detect regions-of-interest in ChIP-
on-chip data such as Welch t-test, HMM, TileMap, MAT, Mixture model approach, CMARRT, 
Starr and Ringo71 72-78. MAT (Model-based analysis of tiling-arrays for ChIP-on-chip)74 is one of the 
most cited methods for analyzing ChIP-on-chip data and it has been shown to outperform Welch 
t-test, HMM and TileMap71-73. MAT uses various user defined parameters to model a region-
of-interest, such as maximum bandwidth, maximum gap size between probes, the minimum 
number of probes in a region, and the use of a fixed threshold. A major limitation of this method 
is that it assumes a uniform probe-resolution across the genome, and depends on many user 
defined parameters.
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Figure 1. Illustration of the method. The different steps of the method, illustrated as blocks (A, B, C, D and E), are needed 
to process raw probe intensity data, detection of unique candidate regions and mapping of the detected regions-of-
interest to the 5’ transcriptional-start-site of nearby located genes. HAT is indicated with the blocks B, C, D and E. These 
are representative for the detection of unique candidate regions-of-interest in single, as well as multiple samples.
Here, we propose a statistical framework (HAT: Hypergeometric Analysis of Tiling-arrays) 
to identify regions of-interest in tiling-array data. HAT has several advantages over previous 
methods including MAT: i) as there is no single cut-off level for probe intensity, HAT can detect 
regions-of-interest for a large number of thresholds, ii) it can detect regions-of-interest of any 
size, iii) it is independent of probe-resolution across the genome and across tiling-array platforms 
and iv) it employs only a single user defined parameter: the significance level. HAT can be seen as 
a generalization of the transcript discovery approach used in Bertone et al 67.
A detailed description of our framework (Figure 1) can be found in the method section. Briefly, 
instead of a single probe intensity cut-off level, HAT evaluates a large number of thresholds. Each 
threshold transforms the continuous signal intensity levels into discrete calls for each probe; 
referred to as positive probes where the probe intensity exceeds the threshold, and negative 
probes where it does not. In order to define regions-of-interest, all probes within the window of 
each positive probe are evaluated and the P-value is defined based on the ratio of both positive 
and negative probes using the Hypergeometric distribution. To detect regions-of-interest of any 
size, the width of the window is also varied across all relevant window widths, where a relevant 
window is defined by the expected fragment size in the experimental procedure (e.g., due to 
sonication). The resulting regions-of-interest for each setting of the threshold and each window 
width are combined by taking the union of the significant window positions. The Family Wise 
Error (FWE) is controlled by employing a Bonferroni correction.
We have used two datasets using promoter tiling-arrays to evaluate HAT. In the first assay, tiling-
array data was employed to identify genome wide DNA-binding profiles of the transcription 
factor C/EBPα, in a cell line model. Using these data, we have shown that although HAT detected 
fewer regions-of-interest than MAT, the detected regions are more highly enriched for CEBP 
binding motifs, and include known C/EBPα target genes. In the second experiment, a retroviral 
insertional mutagenesis assay, HAT identified novel putative transforming loci that may play a 
role in tumor development. Two of these loci were subsequently validated using PCR.
HAT can also detect and compare regions-of-interest across multiple samples. Each sample is 
analyzed independently, but when multiple samples within one experiment are used, detected 
regions-of-interest at the same genomic location among different samples are combined 
into ‘common regions-of-interest’, thereby increasing the confidence. In addition, HAT can 
incorporate sequence information for the detection of pre-defined sequences (e.g., binding 
location within or near the region). These are highlighted in the graphical output for every 
detected region-of-interest and indicated in the output file.
RESULTS AND DISCUSSION
Data
Two distinct experimental datasets were used in this study: ChIP-on-chip data derived from 
an inducible CEBPA expressing myeloid cell line model and data obtained from genomic DNA 
from retrovirus induced murine leukemias. Data were generated using the Affymetrix GeneChip 
Mouse Promoter 1.0 Array. This chip generates 4.6 million perfect match probes over 28000 
mouse promoter regions. Promoter regions cover 6 Kb upstream to 2.5 Kb downstream of 5’ 
transcription start sites. Each probe has a size of 25nt.
Detection of regions-of-interest for C/EBPα chromatin immunoprecipitation by applying HAT
To compare different methods and to analyze the promoter array data, we made use of a 
dataset that was obtained from a ChIP of beta-estradiol induced C/EBPα in a myeloid cell line, 
32D, followed by promoter array hybridizations. The data were used to examine the validity 
of detected regions-of-interest in two ways: i) at the ‘CCAAT’ binding level; C/EBPα interacts 
with the nucleotide sequence ‘CCAAT’ within the promoter regions represented on the chip, 
therefore CEBP binding motifs are expected to be enriched, and ii) at the gene level; examination 
of the presence of known C/EBPα target genes, by taking the genes flanking the detected region-
of-interest into account. Furthermore, one selected region-of-interest was validated by Real 
Time Quantitative PCR (qPCR).
The experimental setup was as follows: clones were derived from a myeloid cell line model (32D), 
that expresses either beta-estradiol inducible C/EBPα-ER (3 clones) or control-ER (2 clones). 
Chromatin immunoprecipitations were carried out using an antibody directed against ER in the 
beta-estradiol treated cells and the DNA obtained from these cells, after immunoprecipitation, 
was hybridized to Affymetrix promoter chips.
For method comparison we used Model-based analysis of tiling-arrays for ChIP-on-chip (MAT), 
with the default parameters for the detection of regions-of-interest (bandwidth of 300bp; 
resulting in 2*bandwidth probe positions, 300bp of maximum gap size between positive probes, 
minimum of 8 probes for MAT-score, and enriched fragments at the 1×10-5 significance level). 
The default settings agree with the average sonicated fragment sizes, being 600bp, and the 
distance between two consecutive probes being approximately 35bp. Using the default criteria 
in MAT, 4784 unique regions-of-interest were detected in at least one of the 32D-C/EBPα-ER 
clones (n = 3) and absent in control samples 32D-ER (n = 2). Using HAT, the same significance level 
Ch
ap
te
r 2
2726 HAT: Hypergeometric Analysis of Tiling-arrays with Application to Promoter-GeneChip DataChapter 2
and maximum fragment size (1×10-5 and 600bp respectively) were chosen to detect statistically 
significant regions-of-interest. Applying these parameters, 1679 statistically significant regions-
of-interest were detected in any of the 32D-C/EBPα-ER clones; 80% (1318) of these regions 
were detected in two or more clones (common regions-of-interest). This corresponds to 856 
unique chromosomal regions-of-interest. HAT detected approximately one fifth of the regions-
of-interest in comparison with MAT for the same significance level, and 99.9% (855) of these 
unique detected regions in HAT overlapped with the regions detected by MAT (Figure 2).
To investigate the validity of these detected regions-of-interest (for both HAT and MAT) on the 
sequence level, a motif enrichment analysis was performed. This was carried out using the Cis-
regulatory Element Annotation System (CEAS79), where a P-value is computed for each known 
motif, and the motifs that are significantly enriched in the regions-of-interest are reported. The 
top 10 enriched motifs are indicated in Table 1 for both methods. These data showed that HAT 
detects regions that are highly enriched for the CEBP motif binding sites, whereas MAT does not 
show a clear enrichment for these sites. Note that the detected regions-of-interest by HAT, are 
a subset of MAT.
HAT (4784)
(856)
(1664)
64 (A)
719 (B)
652 (C)
70 (D)
1
MAT
Starr
3092 (E)
Figure 2. Venn diagram depiction the overlapping regions-of-interest between HAT, Starr and MAT. Detected regions-
of-interest by HAT (blue: 856), Starr (red: 1664) and MAT (green: 4784) are indicated with the number of overlapping 
regions between the methods. The overlap of regions detected by all three methods (pink: 719) showed high enrichment 
for CEBP binding motifs. Overlapping regions between HAT and MAT (64: blue) and Starr and MAT (orange: 652) also 
showed high enrichment for CEBP binding motifs. Uniquely detected regions by Starr (red: 70) showed no significantly 
enriched motifs, and MAT (green: 3092) showed limited motifs enriched for CEBP. Note that the number of overlapping 
regions can contain multiple regions-of-interest detected by a single method.
Table 1. Motif enrichment analysis
MAT HAT
Nr Motif Hits Fold-change P-value Motif Hits Fold-change P-value
1 AP2alpha 9735 1.606 0 M00117.CEBPbeta 1532 2.325 2.84E-185
2 Elk-1 5380 1.707 9.23E-286 M00770.CEBP 3076 1.766 2.23E-183
3 M00470.AP-2 gamma 5938 1.641 1.82E-274 M00912.C-EBP 3036 1.715 1.31E-164
4 M00109.CEBPbeta 6170 1.617 3.52E-269 cEBP 1928 1.965 1.89E-157
5 M00695.ETF 3449 1.885 3.05E-250 M00116.CEBPalpha 2689 1.722 4.30E-148
6 M00025.Elk-1 2979 1.949 1.76E-237 M00109.CEBPbeta 1278 2.161 2.35E-132
7 M00446.Spz1 4863 1.665 3.90E-237 M00190.CEBP 2402 1.719 9.67E-132
8 M00008.Sp1 5135 1.625 1.04E-228 M00098.Pax-2 1799 1.578 8.57E-73
9 E74A 3635 1.691 7.08E-188 M00496.STAT1 1909 1.545 8.88E-71
10 M00771.ETS 3756 1.674 2.37E-187 M00971.Ets 1917 1.508 4.42E-64
The top 10 motifs enriched in the detected regions-of-interest (α = 1×10-5) by HAT and MAT for the C/EBPα-study (ChIP-
on-chip). Among the top 10 motifs enriched in the regions-of-interest detected with HAT, seven contained the CEBP 
binding motif whereas for MAT, only one contained the CEBP binding motif. For each reported motif, the number of hits 
within the regions-of-interest are counted, their fold change computed, and the P-value derived using the binomial test
To investigate detected regions-of-interest based on their flanking genes, regions-of-interest 
were mapped to the closest 5’ transcriptional-start-site of a gene. Mapping is applied on the 
forward and reverse DNA strands, with a maximum distance of 300 kb upstream and downstream 
(NCBI murine genome build 36). This resulted in 2174 unique genes for the 856 unique detected 
regions-of-interest using HAT (10.7% out of the total set of unique genes present in mouse). 
These mouse genes were subsequently overlaid with 169 known homologous human C/EBPα 
target genes (derived from Ingenuity Pathway Analysis, IPA), demonstrating that 40 C/EBPα 
target genes being detected by HAT (P ≤ 4×10-7) and 86 by MAT (P ≤ 3×10-5). Note that MAT 
has detected approximately five times more regions-of-interest (4784) resulting in 7238 unique 
genes (35.8% out of the total set of unique genes present in mouse). Some of the detected 
C/EBPα target genes have previously been described, such as: myc, hp, mpo and il6ra52,80-82. 
Enrichment of the il-6 receptor alpha (il6ra) transcriptional-start-site (Figure 3) was subsequently 
validated by qPCR.
An alternative comparison can be performed using the number of regions-of-interest, instead of 
the significance level. For HAT; 856 unique regions-of-interest were detected with a significance 
level α = 1×10-5. To gain approximately the same number of regions-of-interest using MAT, we 
would need to set the α level at 1×10-19, resulting in 893 regions-of-interest. The regions-of-
interest detected by HAT showed 84% (718/856) overlap with MAT whereas the overlap of 
detected regions of MAT with HAT was 83% (742/893). Both methods show a high enrichment 
for the CEBP binding motifs. Comparing the detected regions-of-interest with respect to 
MAT (4827 for α = 1×10-5), we need to set the α level higher than 0.05 in HAT, but this may 
compromise the reliability of detected regions-of-interest. For this reason, we have set the α 
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level at 0.05 and hereby detected 1910 unique regions-of-interest. These were highly enriched 
for CEBP binding motifs based on the motif enrichment analysis (Table 2), whereas the detected 
regions-of-interest by MAT were not highly enriched for CEBP binding motifs (Table 1). The 
regions-of-interest detected by HAT showed 98% (1879/1910) overlap with MAT whereas the 
overlap of detected regions of MAT with HAT was 39% (1874/4784).
In addition, the HAT and MAT results were also compared with the detected regions of Starr77. 
Starr implements the CMARRT algorithm76 and thereby incorporates the correlation structure 
for the identification of regions-of-interest in tiling-array data. For the detection of regions-of-
interest, we have utilized similar parameter settings (fragment size = 600bp, minimum number 
of probes in a region = 8 and α = 1×10-5) as used in HAT and MAT. Using these parameter settings, 
Starr detected 1664 regions-of-interest and showed high enrichment for CEBP binding motifs 
(Additional file 1: Supplemental Table S1).
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Figure 3. Graphical output of a detected region-of-interest from the C/EBPα-study. It was confirmed with qPCR that the 
C/EBPα protein targets and regulates the proximal promoter region of the il-6 receptor alpha gene, which lies down-
stream of the region-of-interest (negative DNA strand). The top panel (A), indicates the probes, represented as vertical 
blue lollipops, the left y-axis the probe intensities, and the right y-axis illustrates the contribution of each probe sepa-
rately to the region (probe-significance). The x-axis indicates the genomic probe positions, and illustrates with a down-
wards facing green bar; the sequence of interest. The sequence, ‘CCAAT’, was found on the negative DNA strand. 
Furthermore, flanking genes to this detected region are indicated with distances in base pairs to the 5’ transcriptional-
start-site. In the bottom panel (B), the detected regions-of-interest for various windows and probes are shown. The colors 
represent the detection of regions-of-interest, for a number of different top probes and window sizes. The merged 
region-of-interest has a fragment width of 853bp, and lies in the proximal promoter region of il6ra on the negative DNA 
strand.
Following this, we have examined the overlap of regions-of-interest detected by all methods as 
depicted in Figure 2. All regions-of-interest detected by HAT (except one) were also detected 
by MAT alone or together with Starr (64 and 791 respectively). Note that the number of 
overlapping regions can contain multiple regions-of-interest detected by a single method. To 
assess the validity of the detected regions-of-interest by HAT, Starr and MAT, we have examined 
the enrichment for CEBP binding motifs for the different parts in the Venn diagram, depicted as 
different colors in Figure 2 (blue, red, green, orange and pink). High enrichment for CEBP motifs 
are found for; i) the overlap of HAT with the other two methods (pink: 719), ii) the overlap of HAT 
with MAT (blue: 64) and, iii) the overlap between Starr and MAT (orange: 652). No significant 
enriched motifs are found in the regions detected only by Starr (red: 70) and limited motifs 
are enriched for CEBP in the regions detected only by MAT (green: 3092). Therefore we can 
conclude that HAT had the highest specificity as it was able to detect regions-of-interest highly 
enriched for CEBP binding motifs.
Detection of retroviral insertion sites by HAT
Retroviral Integration Mutagenesis (RIM) in mice is a powerful tool to identify new genes playing 
an important role in oncogenesis. Mice are injected with retroviruses that potentially integrate 
into the murine genome upon infection. Viral integration can lead to gene deregulation, 
and depending on the genes affected, tumors may develop. Genes located proximal to viral 
integration sites are potentially oncogenic, leading to tumor development. Genomic regions 
that have been targeted by proviral DNA in multiple tumors are called common viral integration 
sites (VIS), and are likely driving tumor development. Using retroviral insertional mutagenesis, 
many oncogenes have been identified using large sequencing screens in multiple tumors83-86. 
Table 2. HAT: Motif enrichment analysis using α = 0.05 
Nr Motif Hits Fold-change P-value
1 M00117.CEBPbeta 3236 2.082 6.19E-304
2 M00770.CEBP 6688 1.628 8.95E-299
3 M00912.C-EBP 6609 1.583 6.70E-265
4 M00116.CEBPalpha 5858 1.591 1.12E-239
5 cEBP 4068 1.758 1.88E-238
6 M00190.CEBP 5245 1.592 2.81E-215
7 M00716.ZF5 3927 1.706 2.12E-208
8 M00109.CEBPbeta 2645 1.896 3.06E-195
9 M00098.Pax-2 4355 1.619 1.76E-191
10 M00428.E2F-1 4374 1.572 4.67E-171
The top 10 motifs enriched in the 1910 detected regions-of-interest using HAT (α = 0.05) in the C/EBPα-study. There is a 
high enrichment for binding motif CEBP. For each reported motif, the number of hits within the regions-of-interest are 
counted, their fold change computed, and the P-value derived using the binomial test.
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We hypothesize that within tumors, genes may be silenced as a result of proviral integration 
caused by hypermethylation of the CpGs in the viral long terminal repeat, and subsequently in 
the promoters of their target genes. The identification of methylated genes by means of retroviral 
insertional mutagenesis may be studied by Methyl-DNA immunopreciptitation (MeDIP-on-chip), 
followed by inverse PCR, using long terminal repeat (LTR) specific primers. After combining these 
two technologies, we hybridized samples to Affymetrix promoter chips to identify genomic 
locations involved in viral integration that potentially harbor new tumor suppressor genes (TSG). 
Regions-of-interest within this dataset differ from the C/EBPα-study as they have; i) a higher 
variability in fragment sizes and, ii) contain specific sequences within the identified regions. 
Therefore these data are used to examine the performance and broad applicability of HAT among 
different applications of tiling-array data. Using HAT, we have identified candidate TSGs in mouse 
tumors by considering regions with a maximum fragment size of 1000bp and a significance level 
α = 0.05. With these parameters, we detected 15 methylated Viral Integration Sites (mVIS); of 
which one appeared to be a common methylated VIS (cmVIS) among two samples (Figure 4). 
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Figure 4. Graphical output of a detected cmVIS in the MeDIP-study. A region-of-interest detected in two samples, is 
illustrated in Panels A and B. Panel A shows 840 subregions that are merged with a total length of 1567bp. The restriction 
sites, indicated as green bars, are located in and around the detected region, and are present on both DNA strands due to 
the palindrome sequence: ‘GATC’. The region-of-interest detected in the second tumor (Panel B), exists of 28 subregions, 
with a fragment width of 949bp.
Besides the detection of candidate regions based on a statistical framework, we have attached 
additional mouse genomic sequence information (MM8) to the model, in order to determine the 
sequence of interest based on the restriction enzyme used in the inverse PCR. Within this assay, 
a restriction enzyme (DpnII) will cleave DNA at sequence ‘GATC’, within the integrated viral 
sequence and the flanking genome. Note that because of this property, it is expected that every 
detected region must contain a nearby restriction site, which can easily be verified with HAT. 
HAT showed that all detected mVISs contain a nearby restriction site, conforming specificity of 
the identified region as being a viral insertion site. For PCR validation of the method, two mVISs 
were selected based on their location to a nearby 5’ transcriptional-start-site, and confirmed. 
One of the validated regions is illustrated in Figure 5.
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Figure 5. Graphical output of a detected and validated mVIS in the MeDIP-study. Panel A illustrates the detected mVIS 
which are subject to DNA-methylation. Only a section of the detected region-of-interest has an increased probe intensity; 
the probe-significance signifying this subregion. Directly beside the increased probe-significance, a restriction cleavage 
site is indicated by means of a green bar. Due to the palindrome sequence, these sites are indicated at the same genomic 
position on both DNA strands. Panel B shows the detected statistically significant regions among the different thresholds, 
and window sizes with various colors. A schematic representation of the amplified genomic region, with the virus- and 
the murine contribution, is shown in Panel C.
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Extended applications of HAT
The scope of this method is not limited to the presented studies (i.e., detecting transcription 
factor binding sites and DNA methylated regions). Moreover, we have successfully applied 
HAT for the detection of regions enriched for histone modifications such as, trimethylation 
of histone 3 at lysine 4 or lysine 27 (H3K4 me3 and H3K27 me3) (data not shown). Some of 
the detected regions-of-interest were selected for further validation and confirmed by qPCR. 
Regarding tiling-array data spanning the entire genome87 (e.g., RNA transcript mapping data67), 
we do not expect changes in algorithm performance (detection of regions-of-interest) due to an 
increased variability in hybridization consistency because the applied normalization method74,88 
corrects for two major causes of differences in hybridization consistency, i.e., probe sequence 
and presence of repeats within the genome. Furthermore, in addition to one-color arrays (e.g., 
Affymetrix tiling-arrays) we envision that HAT can also be applied on data stemming from two-
color arrays (e.g., Nimblegen tiling-arrays), because data structure remains similar. We stress 
however that the normalization procedure is an important step and strongly depends on the 
type of tiling-array dataset.
CONCLUSIONS
Here we propose a statistical framework; HAT (Hypergeometric Analysis of Tiling-arrays) to 
analyze tiling-array data. We showed that the method is robust and has increased specificity 
in the detection of regions-of-interest in comparison with two alternative methods. This is 
achieved by computing the Hypergeometric probability for every detected region-of-interest, 
among different threshold levels of probe intensities and window sizes, while keeping control 
of the Family Wise Error (FWE) by employing Bonferroni correction. Besides the detection 
of regions-of-interest, HAT also determines sequences-of-interest, flanking genes and the 
distances to 5’ transcriptional-start-sites on both DNA strands. We describe the performance 
of HAT, when applied to different experimental tiling-array datasets. For each experimental 
dataset, the selected downstream genes flanking the detected regions-of-interest were 
successfully confirmed by (q)PCR. We compared the detected regions-of-interest of HAT with 
two other methods (MAT74 and Starr77), and showed that HAT resulted in a reduced number 
of detected regions-of-interest using the same significance for both MAT and Starr. However, 
using motif enrichment analysis we showed that the regions-of-interest detected by HAT were 
more enriched for the expected binding motifs of CEBP compared to MAT and showed similar 
enrichment for Starr, illustrating increased specificity using HAT.
Besides analyzing ChIP-on-chip data, HAT is also suitable for the analysis of other types of 
tiling-array data. Applying HAT to the data from the MeDIP inverse PCR and promoter-GeneChip 
hybridization experiment, we discovered mVISs and cmVIS that are subject to DNA-methylation 
and identified the genes (unpublished data) that flank these methylated viral integration sites 
(Figure 4 and 5).
HAT is applicable to detect regions-of-interest among the different applications of tiling-arrays, 
and has the advantage of being independent for thresholds, number of probes in a region and 
probe-resolution. It does not depend on setting various user defined parameters, except for the 
significance level and an optional maximum fragment size.
METHODS
Extracting candidate gene-regions based on high throughput data using tiling-arrays is a multi-
step process (Figure 1). The first step is to normalize the probe intensity data from the chip 
(Figure 1A). For this purpose, we utilize the normalization from Model-based analysis of tiling-
arrays for ChIP-on-chip (MAT)74,88, but other normalization procedures can also be applied. The 
normalization procedure prevents systematic variation between experimental conditions, which 
are unrelated to biological differences. As a result of this normalization, the probe intensity 
values follow a normal distribution with a negative mean; hence the majority of probes have 
values below zero, and are ignored in all subsequent analyses. Probe intensities that may be the 
result of hybridization of labeled DNA on the chip (e.g., were present in the immunoprecipitated 
chromatin sample), have values greater than zero and are used to determine candidate regions-
of-interest. After normalization, probe intensities are discretized using a varying threshold 
and the significance of the probes within a varying window is determined. Significant window 
positions are then merged into the final regions-of-interest. We illustrate this approach in the 
simplified schematic representation shown in Figure 6. In Figure 6A, eight probes are shown at 
an arbitrary genomic location. Their intensities are represented by vertical lollipops. The positive 
probes (six in this example) are assumed to be part of a possible candidate region. Probes with 
higher intensity levels are more likely to be the results of hybridization on chip, but the exact 
level of intensity for which this is the case is unknown. Therefore, multiple probe intensity levels 
are taken into account by varying the discretization threshold t. The number of probes that 
exceed this threshold (called positive probes) is denoted by k(t). Figure 6B and 6E, illustrates the 
thresholds k(t)=2 and k(t)=4, respectively. All probes exceeding t are set to one, and those not 
exceeding the threshold t are set to zero. 
To define a region-of-interest, we determine the significance of all possible window positions g, 
for which the window contains at least one positive probe. To account for the fact that the exact 
number of probes in a region-of-interest is undefined, and may differ greatly between different 
regions-of-interest due to differences in local probe-resolution; the window width n is varied. 
To prevent evaluating many highly similar windows, thereby incurring a high multiple testing 
penalty, only those window widths for which the number of probes in the window varies are 
evaluated. Therefore, n is defined in terms of the number of probes contained in the window. 
The number of positive probes in a window of width n, at genomic position g, for threshold value 
t, is denoted by x(g, t, n). In the example presented in Figure 6, we varied n from 1 through to 
3. For the case k(t) = 2 (Panel B and C), x(g, t, n) ranges from 1 through to 2, and in case k(t)=4 
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(Panel E and F), x(g, t, n) ranges from 1 through to 4. For each window, a P-value is determined; 
defined as the probability of observing at least x positive probes in the window. For any window 
position g, threshold level t and window width n, P(g, t, n) is computed as:
 (1)
Note; that since we restrict each window to contain at least one positive probe to prevent 
evaluating useless window positions, this probability is conditioned on X ≥ 1. All probabilities are 
computed using the Hypergeometric distribution:
(2)
Where N is a fixed parameter and represents the total number of probes present on the (e.g., 
promoter) chip. To correct for the number of tests performed, we apply Bonferroni correction, 
controlling the Family Wise Error per value of the threshold level as follows:
(3)
Based on this P-value, it is possible to exclude regions that do not reach a predefined significance 
level (α):
(4)
Due to the use of various values for t and n, similar or partly overlapping regions are found. In 
order to find a single region-of-interest at the same genomic location, these overlapping regions 
are merged by joining regions with one or more overlapping probes. In our example, we assume 
for simplicity, that windows with x (g, t, n) ≥ 2 are statistically significant. These statistically 
significant regions are colored blue and green in Figure 6C and Figure 6F respectively. The 
merging procedure is illustrated in Figure 6D, where four blue regions are merged into a single 
region, and in Figure 6G where 18 green regions are merged.
Finally, regions found for different threshold levels t are also merged (Figure 6H) into the final 
region-of-interest (Figure 6I). Regions-of-interest tend to be larger than the regions detected 
at a single setting of the threshold level, or single window width due to the merging of all 
these individual regions. To determine the most important parts of the region-of-interest, we 
introduce a probe-significance score Q(g), which reports how often probes were part of the 
statistically significant region. This score is illustrated by the red curve in Figure 6I, and computed 
as follows:  
 (5)
In our example so far, regions are detected within a single sample. When multiple samples are 
available (for the same experiment), array-wise detection of regions-of-interest is examined in 
order to detect common regions-of-interest (Figure 1D). A radius, defined in base pairs, can be 
defined to set the maximum distance between regions over multiple samples (default is zero).
Po
sit
iv
e
pr
ob
e 
in
te
ns
ity
genomic position
k(t) = 2 
nmax = 3 
k(t) = 4
nmax = 3
Probe B Probe D
Probe A
Probe B
Probe C
Probe D
Probe A Probe B Probe C Probe D
A
B
C
E
F
1 3,2,1  xnA
D
1 3,2,1  xnD
21  xnD
43  xnD
32  xnD
43  xnA
32  xnA
21  xnA
1 3,2,1  xnD
11  xnD
23,2  xnD
G
Hk(t) = 4
k(t) = 2
Merged region-of-interest
Probe A
Probe B
Probe C
Probe D
I
0      0      9      14     14      9      0      00      0       0      4       0      4      0       0
Merged 
region-of-interest
0        0      9     18     14     13     0      0
0
18
Q(g) 
. . .
. .
.
..
Merged 
region-of-interest
13,2,1  xnB
23,2  xnB
11  xnB
tgx )( tgx )(
x(g)
Figure 6. Schematic depiction for the detection of regions-of-interest. Schematic depiction for the detection of regions-
of-interest, based on probe intensities. Eight probes, with their genomic location, are shown in Panel A. Four of these 
have positive probe intensities. The use of multiple thresholds, transforms continuous data into discrete data; as shown 
in Panel B and E. Various window scales N, are used to examine neighboring probes for their probe intensities in Panel C 
and F. These windows will contain different number of positive probes. The Hypergeometric probability is computed for 
every region-of-interest, and excludes a region-of-interest when the region is not statistically significant after correcting 
for a single positive probe in a region-of-interest and multiple testing. The remaining regions are merged for each k(t) 
(illustrated in Panel D, G, H) and then among all k(t) to a single region-of-interest (Panel I). To determine how often probes 
were detected in statistically significant regions, the probe-significance is computed (Panel D and E), and indicated with 
a red colored line that signifies the statistically significant probes in the detected region-of-interest.
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ADDITIONAL PROPERTIES OF HAT
The HAT method includes two additional properties beside the detection of regions-of-interest; 
i) the determination of sequences-of-interest surrounding and within the detected regions-of-
interest, e.g., the enhancer binding protein C/EBPα is known to interact with ‘CCAAT’ sequences, 
and it is therefore expected that detected regions-of-interest contain this sequence in a chromatin 
IP experiment. The presence, and positions of the sequences-of-interest can be indicated in the 
(graphical) output of HAT. In this graphical output, sequences are indicated with an upward 
facing green bar, indicating that the sequence is detected on the positive strand, or a downward 
facing green bar representing a sequence on the negative strand. ii) The determination of 
genes flanking the detected regions-of-interest. For every detected region-of-interest (for both 
upstream and downstream and forward and reverse DNA strands), the genes with the closest 
distance to the transcriptional-start-site are determined, and indicated in the (graphical) output. 
To include these regions-of-interest and genes into the HAT method, the public genome-
sequence (available for different model systems) can be utilized from the UCSC genome browser.
AVAILABILITY AND REQUIREMENTS
HAT is implemented in Matlab R2009b and is tested on UNIX and MS-Windows. It is available 
on http://www.erasmusmc.nl/hematologie/. The run time depends on the number of used 
threshold cut-offs as the computation complexity increases linear with the used number 
of probes for the detection of regions-of-interest. In addition, run time also depends on the 
different steps in the method (Figure 1B-F). On average, for the C/EBPα-study, 28 minutes were 
needed per sample for the detection of regions-of-interest, while MAT required on average a 
run time of 23 minutes per sample. Note, however, that in our algorithm the data were analyzed 
using a multitude of window sizes and thresholds. A more detailed overview of the run time for 
each step in the method can be found in Additional file 2: Supplemental Figure S1.
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SUPPORTING MATERIAL
Loading data
0 8 16 24 32 40 48 56 64
time (min)
Ta
sk
Step E: Gene mapping
Step D: Detection of common regions-of-interest
Step C: Merging and computing probe significance
Step B:
Detection of regions over 
an decreasing threshold
3 25 28 5
lowest
highest
1
Figure S1. HAT Computation performance. Run time of the various steps in the method. The C/EBPα-study is used to 
analyze the run time for the different steps in the method; Step B: loading data and detection of regions-of-interest, 
Step C: Merging of regions-of-interest and computation of the probe-significance, Step D: detection of common regions-
of-interest and Step E: gene mapping. Per sample, 62 minutes were needed on average to process all the steps in the 
method.
Table S1. Starr: Motif enrichment analysis. 
Nr Motif Hits Fold-change P-value
1 M00117.CEBPbeta 1992 2.153 2.74E-203
2 M00912.C-EBP 4084 1.643 9.46E-190
3 cEBP 2570 1.866 2.94E-181
4 M00770.CEBP 3980 1.627 1.90E-178
5 M00116.CEBPalpha 3523 1.607 7.15E-151
6 M00109.CEBPbeta 1670 2.011 5.44E-145
7 M00190.CEBP 3138 1.599 3.13E-132
8 HLF 666 2.023 3.80E-60
9 M00260.HLF 608 2.017 9.94E-55
10 M00771.ETS 845 1.731 6.80E-49
The top 10 motifs enriched in the 1664 detected regions-of-interest using Starr (fragment size = 600bp, minimum num-
ber of probes in a region = 8, α = 1×10-5) in the C/EBPα-study. There is a high enrichment for binding motif CEBP. For 
each reported motif, the number of hits within the regions-of-interest are counted, their fold change computed, and the 
P-value derived using the binomial test.
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BACKGROUND
Protein-DNA-interactions, such as transcription factor-DNA-binding, DNA-methylation or 
methylation/acetylation of histone tails, can nowadays be identified with high sensitivity and 
specificity, using next-generation sequencing (NGS) technology. NGS rapidly replaces tiling-arrays 
technology because of the increased resolution with which the interactions can be measured. 
Both technologies generate a signal along the genome that for instance represents the interaction 
of regions with transcription factors. Typically one is interested in finding those regions in the 
genome where a signal significantly deviates from the overall genome wide background signals. 
Previously, for tiling-array data, we developed a method called “Hypergeometric Analysis 
of tiling-arrays” (HAT), to detect regions-of-interest (ROIs). In short, HAT sets a threshold to 
decide whether the signal of a probe is excessive, and then uses a sliding window approach 
to analyze whether a significant number of marked probes are found within that window. The 
signal is analyzed at different scales by considering a range of different thresholds and window 
sizes, and the detected regions at individual scales are integrated. The detected ROIs are over 
all scales under control of a Familywise error (FWE), specified by a significance level α. HAT 
has been successfully applied on a range of different DNA-interaction sources, such as ChIP-on-
chip89, MeDIP-on-chip56, H3K4me3, H3K27me389 and 3’-Tiling-135-K-Oryza-sativa-microarray.57 
Here, we introduce HATSEQ, which is an improved version of HAT that can work on nucleotide 
resolution. As with HAT, HATSEQ is nonparametric, and independent of the coverage and 
resolution across the genome. Various methods with varying algorithmic complexity have 
been developed to detect ROIs in ChIP-Seq data such as, MACS90, FindPeaks91, CisGenome92, 
QuEST93, PeakSeq.94 MACS (Model-based Analysis for ChIP-Seq) is one of the most cited methods 
for analyzing ChIP-Seq data. Although the variety of ChIP-Seq methods, the majority can only 
be run from the command line and require variable degrees of data formatting and expertise 
to implement.95 CisGenome however does provides a graphical user interface (GUI) but is 
restricted to the windows platform. With HATSEQ, we aim at the researcher that can experience 
difficulties with the use of the command line and in the downstream analysis. After finding the 
ROIs with HATSEQ, one is generally interested in a functional analysis of the regions. Typically 
this is done by relating the regions to information present in databases, such as gene-ontology, 
pathway information, or enrichment of certain genomic content. HATSEQ supports, through a 
GUI, a number of such functional analyses of the ROIs: e.g., gene mapping, motif analysis and 
pathway analysis. It also outputs for the detected ROIs, fasta files, UCSC genome browser tracks 
to enable visualization of the ROIs together with any other genomic data, and a single circular 
graph (Circos96) that illustrates all the detected genes and their chromosomal locations. 
ABSTRACT
Probing protein-DNA is gaining popularity as it sheds light on molecular mechanisms that 
regulate the expression of genes. Currently, tiling-arrays and next-generation sequencing 
technology can be used to measure these interactions. Both methods generate a signal over 
the genome in which contiguous regions of peaks on the genome represent the presence of an 
interacting molecule. Many methods do exist to identify functional regions-of-interest (ROIs) on 
the genome. However the detection of ROIs are often not an end-point in research questions 
and it therefore requires data dragging between tools to relate the ROIs to information present 
in databases, such as gene-ontology, pathway information, or enrichment of certain genomic 
content.
We introduce HATSEQ (Hypergeometric Analysis of Tiling-array and Sequence data), a powerful 
tool that accurately identifies functional ROIs on the genome where a genomic signal significantly 
deviates from the general genome wide behavior. HATSEQ also includes a number of built-in 
post-analyses with which biological meaning can be attached to the detected ROIs in terms of 
gene pathways and dé-novo motif analysis, and provides different visualizations and statistical 
summaries for the detected ROIs. On top of that, HATSEQ has an intuitive graphic user interface 
that lowers the barrier for researchers to analyze their data without the need of scripting 
languages. We compared the results of HATSEQ against two other popular ChIP-Seq methods 
and observed overlap in the detected ROIs but HATSEQ is more specific in delineating the peak 
boundaries. We also discuss the versatility of HATSEQ by using a STAT1 ChIP-Seq data set, and 
show that the detected ROIs are highly specific for the expected STAT1 binding motif. HATSEQ is 
freely available at: http://hema13.erasmusmc.nl/index.php/HATSEQ.
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IMPLEMENTATION
HASTSEQ: a statistical framework to detect regions-of-interest in genomic signals
HATSEQ detects ROIs in NGS data using the statistical framework as described in HAT89, but with 
read depth at genomic positions as an input. It is supposed that genomic positions with read 
depth greater than zero may be the result of sequenced DNA pieces that were, e.g., present in 
the immunoprecipitated chromatin sample, indicating the presence of protein-DNA-binding at 
that particular position. To decide whether the read depth at a genomic location is excessive, 
HATSEQ varies the threshold at which it considers the read depth to be indicative for a genomic 
event. A sliding window approach is then used to analyze whether a significant number of 
excessive sequence-reads are found within the window for every threshold setting and for 
varying widths of the window (as the size of the event is not known a priori). For each window, 
a P-value is determined, defined as the probability of observing at least the number of observed 
reads, x, in the window (given a random distribution of reads over the genome). For any window 
position g, threshold level t and window width n, P(g, t, n) is computed as:
 (1)
Where P(X ≥ x | g, t, n) is based on the Hypergeometric distribution of drawing, on genomic 
position g, at least x reads that exceed the threshold t in a window of size n, and where N is 
a fixed parameter that represents the total number of reads that are sequenced, and K the 
number of reads that exceed the threshold. For each window the P-value is restricted such that 
each window should contain at least c reads to prevent evaluating window positions that are not 
of interest.
We apply Bonferroni to correct for the number of tests performed at each threshold level, which 
is defined by the number of reads (K) that exceed the threshold (t) and window size n. The 
corrected P-values are subsequently defined by: P*(g, t, n). Due to the use of various threshold 
values (t) and window sizes (n), similar or partly overlapping regions are found. In order to find a 
single region-of-interest at the same genomic location, these overlapping regions are integrated 
by joining regions with one or more overlapping reads. To determine the most important part 
of the region-of-interest, we introduce a read depth significance score Q(g), which reports how 
often reads were part of a region for a predefined significance level (α). This score is computed 
as follows:
(2)
Thus, the final candidate regions-of-interest are determined by integrating the significant window 
positions over all thresholds. HATSEQ is optimized for NGS data analysis by: (1) incorporating a 
minimum allowed read depth to prevent the detection of systematic variation; (2) incorporating 
a minimum allowed region length to prevent the detection of regions that are the result of highly 
correlated reads; (3) normalization of the read depth per sample such that sum of the read 
depth is 1, which makes the depth of the sequenced reads comparable between experiments; 
(4) normalization of the read depth by using a set of reference samples; and (5) the use of multi-
threaded computations (each chromosome is separately analyzed and HATSEQ exploits the use 
of memory mapped files that allows the analysis of any read depth).
HATSEQ can be applied in three types of study-designs, namely; (1) one sample analysis where 
only one sample is available and sequenced; (2) multi-sample analysis, where the sequenced 
reads of the experimental samples can be analyzed compared to the reads of one or more 
negative control samples; and (3) combined ChIP-Seq and ChIP-on-chip analysis where an 
overlap of candidate ROI between the experimental replicates can be marked.
FUNCTIONALITIES OF HATSEQ
Data processing and region identification. HATSEQ detects ROIs from mapped sequenced 
reads or normalized probe intensities. For the analysis of NGS data, it processes Bam or Pileup 
files to detect ROIs using the read depth at base pair position. For ChIP-on-chip data it uses 
preprocessed files, e.g., by MAT.74 As an example, both NGS data and ChIP-on-chip files can be 
loaded using the GUI and simultaneously analyzed with or without controls. 
Pathway analysis. HATSEQ integrates two pathway enrichment analyses based on the genes 
that are selected by; (1) having a selected ROI as closest ROI; or (2) having a detected ROI in their 
promoter region (the 2000bp region upstream of the transcriptional-start-site (TSS)). Pathway 
annotations (gene sets) are extracted from the Molecular Signature Database97 (MSigDB). The 
enrichment of each pathway for the selected set of genes is computed using the Hypergeometric 
distribution and is corrected for multiple testing using FDR98 or FWER.99
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Motif analysis. HATSEQ gives the opportunity to find enriched motifs in sequences derived 
from: (1) the detected ROIs; and (2) the promoter regions (2000nt upstream from TSS) 
of the genes that have a selected ROI as closest ROI. It uses the generalized extreme value 
probability method100, which detects significantly over-represented ungapped words of fixed 
length. It consequently outputs the over-represented sequences that are corrected for multiple 
testing using FDR98 or FWER.99 Finally, for each detected motif, the position weigh matrices 
(PWMs) are correlated with annotated PWMs from TRANSFAC and JASPAR and subsequently 
listed if the correlation is larger than 0.6.
Support for different species. HATSEQ supports gene-annotation (for e.g., ROI gene-associations) 
and chromosome files for the species that are available on UCSC (http://hgdownload.cse.
ucsc.edu). Species that are available on UCSC can be chosen using the GUI, which are then 
automatically downloaded, or alternatively, species can be uploaded selectively.
Statistical summaries and visualization of results. HATSEQ reports the detected ROIs, including 
the neighbouring genes and summary statistics, in tables. For example, one can extract the 
percentage of ROIs that are in close vicinity to the TSS of a gene, or the percentage of ROIs that 
contain a user defined motif. The genes for the detected ROIs can be visualized by the circular 
graph, Circos or as custom tracks in UCSC.
Equipment-Software. HATSEQ is a stand-alone application that is implemented in C++ and 
Matlab Mathworks. To run HATSEQ, an installation of Matlab or the freely available Matlab 
Compiler Runtime (MCR) is mandatory. 
Equipment-Hardware. HATSEQ runs on any x86-64 system with MS-Windows, UNIX, Linux or 
Mac OS whereas a minimum of 4GB RAM is required. The analyzed ChIP-Seq examples in this 
manuscript wererun on MS-Windows 7 with a 1.87 GHz CPU and 4GB RAM. The runtime, with 
default parameter settings, was approximately 10 minutes to detect ROIs in 1 Million reads, an 
estimate that increases with sequence coverage.
Availability. The HATSEQ program is freely available on http://hema13.erasmusmc.nl/index.
php/HATSEQ or http://www.erasmusmc.nl/hematologie/. The required Matlab Compiler 
Runtime (MCR) executable is provided.
RESULTS AND DISCUSSION
Method comparison
To evaluate the performance of HATSEQ, we used two publically available ChIP-Seq data sets 
(DNA-binding to CCAAT enhancer binding protein alpha (C/EBPα) and trimethylation of H3 
lysine 4 (H3K4me) experiment) and compared the results against to two other state-of-the-art 
methods, i.e., MACS (v1.42)90 and FindPeaks (v4).91 MACS uses a dynamic Poisson distribution 
to detect peaks and empirically estimates the false discovery rate (FDR) for each detected peak, 
whereas FindPeaks assumes a triangle based distribution in which fragments have a minimum, 
maximum and a user defined median size.
The first ChIP-Seq data set contains massively parallel sequenced DNA-fragments bound by the 
transcription factor C/EBPα (cell line U937, GEO accession: GSM722423) and is used to evaluate 
the results for one sample analysis. The sequencing data of this C/EBPα experiment is aligned 
using BWA101 (hg19). To avoid the detection of peaks that are the result of technical variation, we 
discarded genomic positions with a read depth smaller than 10. With MACS we detected 50,525 
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Figure 1. Venn diagram and an illustration of a detected ROI for HATSEQ, MACS, and FindPeaks. Detected regions-of-
interest by HATSEQ, MACS and FindPeaks are indicated in red, green and blue respectively. (A) The amount of detected 
ROIs for the C/EBPα experiment, and the overlap between the methods. (B) ROIs detected by the three methods on 
chromosome 1 (around the promoter region of IL6R). The top part of this panel illustrates the pileup or coverage that 
is determined by the sequenced reads. (C) The amount of detected ROIs for the H3K4me experiment and the overlap 
between the methods. (D) ROIs detected in the neighbourhood of SDF2L1 on chromosome 22. The top panel of this 
Figure shows a pileup of the H3K4me experiment as well as a pileup of an H3K4me background experiment (giving an 
indication of the amount of non-specific reads).
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ROIs, using default parameters (bandwidth of 300bp at the 1x10-5 significance level). 
FindPeaks detected 75,839 ROIs using the default parameters (Triangle distance low=100bp, 
median=200bp, high=300bp with minimal allowed coverage 0.001). With HATSEQ we detected 
32,735 ROIs using a bandwidth (fragment size) of 300bp, but with FWER significance level 0.05. 
Eighty-seven percent of the 32,735 HATSEQ ROIs (28,413 ROIs) were also detected by either 
of the two other methods, and 85% (27,862 ROIs) of the HATSEQ ROIs are common among all 
methods (Figure 1A). 
Although there was a high overlap of detected ROIs between the three methods, HATSEQ better 
delineates the peak boundaries in the data. This can be concluded from: (1) regions detected 
by HATSEQ showed on average higher read depth (HATSEQ: 30.1, MACS: 13.1 and FindPeaks: 5, 
Figure 2C); (2) regions detected by HATSEQ are consistently smaller in length compared to the 
other methods (average region length HATSEQ: 153bp, MACS: 350bp and FindPeaks: 1,679bp, 
Figure 2A); and (3) the read depth differences at the boundary of a region are more extreme 
for HATSEQ regions (Figure 2B). We illustrate in Figure 1B the superior behavior of HATSEQ for 
ChIP-seq data for a region on chromosome 1 of the C/EBPα experiment. It can clearly be seen 
that HATSEQ most accurately detects the three regions-of-interest, among a region close to 
the TSS of IL6R which is a known target of C/EBPα.82 Remarkably, FindPeaks detects one large 
region-of-interest, and MACS overshoots the boundaries of the three regions. Among the 4,322 
ROIs that were solely detected by HATSEQ, we detected ROIs that were in close proximity of 
known target C/EBPα genes, such as CD761 and ACSL102.
The second analysis involved sequence data from a H3K4me ChIP-Seq experiment (cell 
line K562, data available from University of Washington) in which functional loci based on 
the chromatin signatures can be identified, i.e., H3K4me peaks at the promoter of active 
genes.103 These histone marks are known to generate a bimodal distribution of the signal (read 
depth) which is caused by the spacing between the histones that interact with the DNA.104
Figure 2. ROI statistics for the C/EBPα experiment. Statistics for the detected ROIs by HATSEQ, MACS and FindPeaks (red, 
green and blue respectively) for the C/EBPα experiment. (A) Boxplot illustrating the region length of the detected regions. 
(B) Average read depth across the ROI boundaries with respect to the 5’ (left panel) and 3’end (right panel). The average 
read depths are calculated per nucleotide position after aligning the detected ROIs at their 5’ and 3’ ends, respectively. 
The solid line represents the alignment of the 32,735, 50,525 and 75,839 ROIs detected by HATSEQ, MACS and FindPeaks 
respectively. The dashed line represents the alignment of the 4,322, 7,866 and 33,359 ROIs that are uniquely detected by 
HATSEQ, MACS and FindPeaks respectively. (C) Distribution of the average read depth for all the detected regions using 
HATSEQ, MACS and FindPeaks.
We evaluated the results of HATSEQ, MACS and FindPeaks for the identification of H3K4me 
peaks by normalizing it against a control replicate. Sequence alignment was performed using 
BWA101 (hg19) with default parameter settings. HATSEQ detected 14,616 statistically significant 
regions-of-interest, MACS: 10,694 and FindPeaks: 9,471 (Figure 1C) by comparing the input 
versus the negative control. 
The regions detected by HATSEQ that overlap with either of the two other methods (9,286 ROIs, 
63.5%) again showed that HATSEQ better delineates the peaks, although less pronounced as in 
the previous experiment: (1) the HATSEQ regions have higher read depths (average read depth: 
HATSEQ: 16.1, MACS: 15.5 and FindPeaks: 10.5, Figure 3C), (2) HATSEQ regions are smaller 
in length (average region length: HATSEQ: 1,096bp, MACS: 1,751bp and FindPeaks: 4,297bp, 
Figure 3A), and (3) the difference of read depth at the border of the region are much more 
pronounced for HATSEQ regions (Figure 3B). Figure 1D illustrates a region on chromosome 22 in 
close proximity of SDF2L1. Clearly HATSEQ delineates the boundaries of the peak region best. To 
assess the validity of the detected regions by HATSEQ we tested the 14,616 ROIs for bimodality 
using the statistical dip test of unimodality.105 A significant bimodal distribution (FDR ≤ 0.05) 
was detected in 12,897 ROIs (88.2%). This illustrates that the large majority of detected ROIs 
contains the expected bimodal distribution. 
Taken together, HATSEQ showed better performance in delineating peak boundaries for the 
detected ROIs when compared to other ChIP-Seq methodologies, such as MACS and FindPeaks. 
For each method we used the default settings, although transcription factor binding and histone 
modifications can differ substantially in their properties (e.g., length of the region) yet specifying 
the optimal parameters in an unbiased way is difficult. We also tested whether HATSEQ can also 
detect ROIs in genomic areas with low read depth by re-analyzing the C/EBPα ChIP-seq data set 
without removing any genomic positions with read depth smaller then 10. We detected 42,046 
significant regions (instead of 32,735 ROIs) 
  
Figure 3. ROI statistics for the H3K4me experiment. Statistics for the detected ROIs by HATSEQ, MACS and FindPeaks 
(red, green and blue respectively) for the H3K4me experiment. (A) Boxplot illustrating the region length of the detected 
regions. (B) Average read depth across the ROI boundaries with respect to the 5’ (left panel) and 3’end (right panel). The 
average read depths are calculated per nucleotide position after aligning the detected ROIs at their 5’ and 3’ ends, 
respectively. The solid line represents the alignment of the 14,616, 10,694 and 9,471 ROIs detected by HATSEQ, MACS 
and FindPeaks respectively. The dashed line represents the alignment of the 5,330, 1,305 and 601 ROIs that are uniquely 
detected by HATSEQ, MACS and FindPeaks respectively. (C) Distribution of the average read depth for all the detected 
regions using HATSEQ, MACS and FindPeaks.
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which clearly illustrates the capability of HATSEQ to detect ROIs in low read depth genomic 
areas. Note that applications of HATSEQ are not limited to the presented NGS ChIP data but can 
be applied to other types of data, such as MeDIP-seq106, DNase-seq107 and MBD-seq.108
A case study with HATSEQ
To illustrate the functionalities of HATSEQ, we used a publicly available ChIP-Seq data set (GEO 
accession: GSE15353) where the DNA-fragments bound by the transcription factor STAT1109 were 
massively parallel sequenced. For transcription factor STAT1 it has been described that it binds to 
STAT-motifs110, and a well-known target gene is the STAT3111 gene. We compared data obtained 
from six interferon-γ (IFN-γ) stimulated HeLa S3 cells and compared those to seven unstimulated 
human HeLa S3 cells. After the alignment using BWA101, we detected in total 2502 ROIs with HATSEQ 
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Figure 4. HATSEQ results for the STAT1 case study. The HATSEQ results of the STAT1 experiments using six interferon-γ 
(IFN-γ) stimulated human HeLa S3 cells compared to seven unstimulated human HeLa S3 cells. (A) Bar graph plot that 
illustrates a ROI that is detected in the promoter of STAT3, and seen across six experiments. The blue bars depicts 
the total number of reads per base pair position, indicated by the left y-axis. The red line illustrates the read depth 
significance score Q(g), which reports how often reads were part of the statistically significant region, indicated by the 
right y-axis. The green bar illustrates the binding site of the expected STAT1 motif. (C) The top enriched motifs, among the 
511 ROIs detected across two or more replicates. (D) Circos plot illustrating the genes, for which the closest detected ROI 
is detected among 2 or more experiments. A line connects selected genes, based on the chromosomal location with the 
number of experiments that a ROI is detected in. The colors indicate the chromosomal location of the genes. (E) Pathway 
analysis illustrates the enrichment for curated gene sets, computational gene sets, gene ontology and positional gene 
sets (with a maximum of ten gene sets in each category).
(sizes between 11bp-669bp, median: 81bp) using default parameter settings (α ≤ 0.05 and 
read depth ≥ 10). These ROIs showed significant binding in the stimulated cells but not in the 
unstimulated cells, which were subsequently investigated using HATSEQs motif analysis. Thus, 
from the design of the experiment, it is expected that the detected ROIs should contain STAT-
binding sites. The detected motifs, among the sequences of the 2,502 ROIs correspond to the 
STAT1 motif according to our results (P-value < 9.1x10-6), and also according to MEME112 and 
TOMTOM.113 The 2,502 detected ROIs are annotated with 914 unique genes. These 914 genes 
included the STAT3 gene, which was associated with one of the most significantly detected 
ROI. This ROI was also strongly enriched for the STAT1 motif sequence (P-value < 2.13x10-177, 
Figure 4A and B). However, not all detected ROIs contained the STAT-binding site. Therefore 
we searched for ROIs that were detected across two or more replicates. We found 511 ROIs 
that were consistently detected, i.e., in two or more replicates (Figure 4D). The HATSEQ motif 
analyses on these 511 consistently detected ROIs showed a strong enrichment for the STAT-
binding site (Figure 4C), and was seen in 88% of these ROIs. In addition, using HATSEQ we found 
47 enriched MSigDB pathways for these 511 ROIs including a pathway that involve STAT3 and 
its targets (Figure 4E).
CONCLUSIONS
We present HATSEQ, a tool to analyze both tiling-array and NGS data. We applied HATSEQ to 
analyze a STAT1 ChIP-Sequence experiment and detected ROIs that were enriched for the STAT1 
motif. In addition, we detected unknown as well as previously reported direct target genes of 
STAT1: STAT2114, STAT3111, IRF1115, IL-27116, PTK2117 and IFNAR2.118 HATSEQ can be used for single 
sample analysis or with a set of reference samples whereas the expected regions-of-interest can 
be of any size. We showed for both the C/EBPα and H3K4me ChIP-Seq experiments that HATSEQ 
better delineates the peak boundaries. HATSEQ is a powerful tool with an intuitive graphic user 
interface that lowers the barrier for researchers to detect regions-of-interest in genomic signals, 
and integrates an analysis of these detected regions to enhance their functional role. 
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ABSTRACT
Acute myeloid leukemia (AML) results from multiple genetic and epigenetic aberrations, 
many of which remain unidentified. Frequent loss of large chromosomal regions marks haplo-
insufficiency as one of the major mechanisms contributing to leukemogenesis. However, which 
haplo-insufficient genes (HIGs) are involved in leukemogenesis is largely unknown and powerful 
experimental strategies aimed at their identification are currently lacking. Here, we present 
a new approach to discover HIGs, using retroviral integration mutagenesis in mice in which 
methylated viral integration sites and neighbouring genes were identified. In total we mapped 6 
genes which are flanked by methylated viral integration sites (mVIS). Three of these, i.e., Lrmp, 
Hcls1 and Prkrir, were upregulated and one, i.e., Ptp4a3, was downregulated in the affected 
tumor. Next, we investigated the role of PTP4A3 in human AML and we show that PTP4A3 
expression is a negative prognostic indicator, independent of other prognostic parameters. In 
conclusion, our novel strategy has identified PTP4A3 to potentially have a role in AML, on one 
hand as a candidate HIG contributing to leukemogenesis in mice and on the other hand as a 
prognostic indicator in human AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a complex disease driven by multiple cytogenetic abnormalities, 
such as inv(16), t(8;21), t(15;17), 3q abnormalities, deletions of (the q-arms) of chromosome 
5 and 7 and by aberrant expression and/or mutations of genes e.g., EVI1, FLT3, RAS, RUNX1, 
CKIT, WT1, CEBPA and NPM1119,120. The frequent occurrence of chromosomal deletions suggests 
that haplo-insufficiencies contribute to the pathogenesis of AML. However, because deleted 
regions often harbor numerous genes, it remains difficult to pin point critical haplo-insufficient 
genes (HIGs) involved in the pathogenesis of AML. Gene expression profiling (GEP) focusing 
on downregulated genes could be informative, however differences in expression levels 
may relate to differentiation status of the AML blasts, rather than to mechanisms underlying 
leukemogenesis121. In addition, mapping of minimal affected regions in combination with GEP 
to identify HIGs often is cumbersome because these regions may still contain numerous genes 
and differences in their expression level may be subtle. Even in chromosomal regions frequently 
lost upon leukemic progression, e.g., the q-arm of chromosome 7, identification of critical HIGs 
remains difficult.
Retroviral insertion mutagenesis in mouse models has been used to discover novel genes 
involved in the development of different types of cancer83,85,86. Most of these genes have been 
classified as proto-oncogenes, owing to the fact that proviral integrations preferentially occur in 
5’ promoter regions, supposedly leading to increased or sustained expression of flanking genes. 
Only a small minority of identified genes have been classified as tumor suppressor genes or 
HIGs, based on disruption of coding sequences by the proviral integration122,123. Gene therapy 
studies using murine leukemia virus (MLV)-based vectors have shown that epigenetic changes 
of long terminal repeats (LTRs) of integrated proviruses often result in silencing of therapeutic 
genes124,125, and that preventing methylation of the CpG islands within LTRs overcomes this 
problem126. Based on these observations, we hypothesized that methylation of viral sequences 
not only results in silencing of retroviral genes themselves but may also affect host genes located 
proximal to proviral integrations. Methylated LTRs located in proximity of promoter regions may 
thus identify genes that are deregulated leading to haplo-insufficiency.
To discover potential HIGs relevant for human AML, we used murine leukemia samples induced 
by Graffi 1.4 Murine Leukemia Virus (Gr1.4 MLV), classified as mixed lineage or myeloid 
leukemias by immunophenotyping83,127. By methylation specific PCR (MSP) and methylated 
DNA immunoprecipitation (MeDIP)128 we observed an extensive variation in the level of DNA 
methylated proviral integrations in these tumors. We designed a strategy to map methylated 
proviral integrations by combining MeDIP, inverse PCR (iPCR) and promoter array hybridization. 
We identified 6 genes to be flanked by methylated viral integration sites (mVIS), of which 
Lrmp, Hcls1 and Prkrir were transcriptionally upregulated and Ptp4a3 was transcriptionally 
downregulated. Further studies in human AML samples revealed a negative prognostic value of 
PTP4A3 expression levels, independent of other prognostic indicators. In conclusion, by mapping 
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DNA methylated viral integration sites in murine leukemias induced by retroviral integration 
mutagenesis followed by comparative analysis in human AML, we identified PTP4A3 not only as 
a candidate HIG contributing to leukemogenesis in mice but also as an independent prognostic 
indicator in human AML.
Figure 1. LTR methylation analysis. (A) Overview of the methylation specific PCR (MSP) approach. Depicted is a schematic 
representation of the Gr1.4 MuLV LTR, containing 23 CpGs. The MSP was performed, after bisulphite treatment, with a 
methylation neutral forward primer (MN-LTR-fw), and a methylation specific (MS-LTR-rv) or neutral (MN-LTR-rv) reverse 
primer. Amplification products were quantified using methylation neutral probe-MN. Tumor samples were divided into 4 
equal groups based on the methylation status of their LTRs (1 = highest LTR methylation level, 4 = lowest LTR methylation 
level). (B) Left panel. For H19, the LTR and ActB, average enrichment after MeDIP compared to input levels were calcu-
lated for each MSP-defined methylation category as well as for normal bone marrow, spleen and liver (N). In category 1 
to 4 respectively 18, 15, 4 and 3 samples were analysed; error bars indicate standard deviations. P-values were calculated 
using a Wilcoxon test; *significantly higher than other categories, P-value < 0.001. Right panel. Example of LTR enrich-
ment after MeDIP (I = input, + = IP with anti-5-methylcytidine, − = IP with pre-immune serum IgG, 1 and 3 = methylation 
categories, N = normal spleen).
Table 1. Multivariate survival analysis.
Risk factor Overall Survival P-value Event-Free Survival P-value
HR (95% CI) HR (95% CI)
PTP4A3 expression 1.112 (0.99–1.24) 0.061 1.131 (1.02–1.26) 0.021*
Age (decades) 1.134 (1.02–1.26) 0.016* 1.068 (0.97–1.18) 0.186
WBC ∞ 1.373 (1.06–1.77) 0.015* 1.296 (1.02–1.65) 0.034*
Favorable cytogenetic risk † 0.376 (0.26–0.55) < 0.0001* 0.469 (0.34–0.66) < 0.0001*
Unfavorable cytogenetic risk † 1.432 (1.06–1.94) 0.020* 1.507 (1.12–2.02) 0.006*
NPM1+ / FLT3ITD- ‡ 0.473 (0.32–0.71) 0.0002* 0.578 (0.39–0.84) 0.004*
CEBPA double mutant $ 0.591 (0.42–0.84) 0.003* 0.560 (0.38–0.82) 0.002*
Multivariate analysis in 454 de novo AML patients under the age of 60; ∞ WBC higher than 20×109/L versus lower than 
20×109/L; † compared to intermediate cytogenetic risk; ‡ compared to no NPM1+/FLT3ITD-; $ compared to no CEBPA 
double mutation; * Statistically significant. HR: hazard ratio, CI: confidence interval, WBC: white blood cell count.
RESULTS
Viral integrations sites of the Graffi1.4 MuLV are subject to DNA-methylation
In this study murine leukemia samples induced by Gr1.4 MLV were analysed83. First, a 
methylation specific PCR (MSP) was performed to determine the level of DNA-methylation of the 
Gr1.4 MLV LTRs. To this end, amplification products from methylated LTRs were quantified with 
quantitative PCR (qPCR) and corrected for total LTRs in these samples (Figure 1A). A considerable 
variation in LTR methylation was seen between different tumors (data not shown). Based on 
these methylation levels, leukemia samples were divided into 4 methylation categories of equal 
sample size (1 = highest LTR methylation level, 4 = lowest LTR methylation level).
Subsequently, MeDIP was used on a subset of samples to enrich for methylated LTRs and flanking 
genomic regions. As a control, genomic DNA of normal bone marrow, spleen and liver was used. 
MeDIP enrichment relative to input levels was determined for the LTR, the non-methylated actin 
B locus (ActB) and the hemi-methylated imprinting control region 1 (ICR1) of H19. As expected, 
H19 enrichment scores were high and ActB enrichment scores were low in all categories (Figure 
1B). Additionally, samples in the highest methylation category showed a significantly higher 
LTR enrichment after MeDIP compared to the samples in other categories (P-value < 0.001), 
confirming the specificity of the MSP (Figure 1B).
Ptp4a3 is flanked by a methylated viral integration site and is transcriptionally downregulated
Genes located near methylated viral integration sites (mVIS) may be downregulated due to 
the proximity of a methylated regulatory sequence, and, their transcriptional downregulation 
may contribute to murine leukemogenesis. Therefore, after showing that a proportion of viral 
integration sites are subject to DNA-methylation, we set out to identify genes flanking these viral 
integration sites. To this end, iPCR, to amplify regions flanking viral integration sites, and MeDIP, 
to enrich for DNA methylated fragments, were combined to amplify regions flanking mVIS 
(Figure 2). Amplified fragments of 6 tumor samples were hybridized to Murine 1.0 R promoter 
arrays and, using Hypergeometric analysis of tiling-arrays (HAT)89, 15 amplified regions were 
mapped in these tumors (Table S1). Eight of these integrations were validated by directed PCR 
followed by Sanger sequencing (Figure 3, Table S1). Because MLVs tend to integrate within 10 
kb around the transcriptional-start-site129, the nearest genes within 10 kb downstream of these 
8 mVIS were determined (Figure 3, Table S1).
To support that regions identified in this way were indeed flanked by methylated LTRs, we 
performed a methylation sensitive digestion followed by directed PCR. Using this approach, only 
viral integration sites flanked by methylated LTRs could be amplified (Figure 4A), as was the 
case for 6 out of 8 identified integrations (Figure 4B, Table S1). Subsequently, expression levels 
of genes flanking these mVIS were quantified by qPCR and compared to normal bone marrow 
expression levels. Unfortunately, RNA of tumor 1 was lacking, therefore this analysis could not 
be performed for Taf12 and Ranbp3. Of the other 4 genes, Ptp4a3 expression was 2-3 fold 
reduced in the respective tumor (Figure 4C, Table S1). 
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Ptp4a3 is an independent prognostic factor in human AML
The human orthologue of murine Ptp4a3, i.e., PTP4A3, was further studied in human AML. 
Transcript levels of PTP4A3 were assessed in 454 AML samples, diagnosed under the age of 
60, profiled using the HGU133 2.0 plus gene expression arrays62. PTP4A3 expression values are 
represented by 2 probesets with a high correlation (Pearson correlation coefficient = 0.90). 
Survival analysis with these probesets gave similar results; all results shown are based on 
expression levels of probeset 206574_s_at. PTP4A3 expression levels were negatively correlated 
with prognostic outcome both for overall survival (OS, P-value < 0.0001, hazard ratio = 1.269) 
and event-free survival (EFS, P-value < 0.0001, hazard ratio = 1.261). Kaplan-Meier curves are 
shown in Figure 5. A permutation test predicted a probability of 0.0036 for a random gene locus 
to be a significant prognostic indicator with a P-value < 0.0001 for both OS and EFS. Multivariate 
analysis showed that the negative correlation of PTP4A3 expression with event-free survival was 
independent of other prognostic parameters, i.e., age, white blood cell count, cytogenetic risk, 
CEBPA mutation status and NPM1+FLT3ITD− status (Table 1).
Figure 2. Identification of mVIS. Strategy outline for identification of regions flanking DNA methylated viral integration 
sites (mVIS) within murine leukemias. Genomic DNA was digested with DpnII (step 1), followed by methylated DNA 
immunoprecipitation (MeDIP, step 2). MeDIP enriched fragments were ligated (step 3) and amplified using primers within 
the LTR (step 4). These fragments were hybridized on a DNA promoter array (step 5). Hypergeometric Analysis of Tiling-
arrays (HAT) was used to identify regions flanking mVIS (step 6).
Figure 3. Identified viral integration sites. Eight viral integrations identified with HAT could be confirmed with directed 
PCR and Sanger sequencing (see Table S1 for further details). The graphical output of HAT is represented in graph A–H. 
Above each graph, the tumor in which the integration was identified as well as the nearby located gene are indicated. 
The upper panel of each graph shows normalized intensities of the different probes (blue lollipops) on the mouse pro-
moter 1.0R arrays and their significance (in red) as calculated with HAT. The black arrowhead indicates the exact position 
of the proviral integration, as determined by directed PCR followed by Sanger sequencing. In the lower panel the low-
est and highest probe intensity threshold with a significant outcome are given on the left. The stripes indicate signifi-
cantly enriched regions at different probe intensity thresholds, calculated with HAT, which are merged into the final viral 
integration site. Below each graph, the genomic position is indicated (assembly mm8, February 2006).expression may 
lead to downregulation of p53131 and it is variably induced by γ-irradiation132. Finally, high PTP4A3 expression has been 
linked to increased tumor aggressiveness in different types of solid tumors, e.g., melanoma, gastric cancer, colon cancer, 
hepatocellular carcinoma and breast cancer133-138, possibly because high PTP4A3 expression leads to increased epithelial-
mesenchymal transition138.
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DISCUSSION
We designed a strategy to identify candidate HIGs in AML using retroviral integration 
mutagenesis, by mapping DNA methylated proviral integrations. By using HAT89, we deliberately 
aimed at detecting integrations present in the majority of the leukemic cells, which are most 
likely involved in the early phase of leukemogenesis. At the same time, integrations present 
in subclones that contribute to later stages of leukemic progression will be missed using this 
approach. We identified 6 genes that are flanked by methylated viral integrations. Expression 
analysis showed that Lrmp (lymphoid-restricted membrane protein), Hcls1 (hematopoietic 
cell specific Lyn substrate 1) and Prkrir (protein-kinase, interferon-inducible double stranded 
RNA dependent inhibitor, repressor of (P58 repressor)) were upregulated and Ptp4a3 (protein 
tyrosine phosphatase type IVA), a phosphatase also known as Prl3 (phosphatase of regenerating 
liver 3) was downregulated in the respective murine tumor. These results indicate that a flanking 
methylated viral integration site does not necessarily lead to transcriptional repression. As 1 
out of 4 genes flanked by a mVIS was transcriptionally downregulated and expression of the 2 
other genes could not be investigated, the efficiency to detect potential HIGs by identifying mVIS 
would approximately be 17–25%. However, the number of analysed tumors is too small to allow 
an accurate estimation of the efficiency.
Ptp4a3 expression is controlled by p53 induced after DNA damage in mouse embryonic 
fibroblasts (MEFs) and its activity is involved in inducing a G1 cell cycle arrest in these cells130. 
Surprisingly however, the same study also demonstrated a cell cycle arrest upon reduction of 
PTP4A3 expression130. Apparently, depending on expression level dosage, PTP4A3 may have both 
positive and negative effects on cell cycle regulation. Hence, PTP4A3 haplo-insufficiency, but not 
its complete loss, may lead to an impairment of cell cycle arrest after DNA damage. Dosage effects 
of PTP4A3 expression in relation to cellular responses may be more complex, particularly in 
cancer cells. For example, in carcinoma cell lines PTP4A3 expression may lead to downregulation 
of p53131 and it is variably induced by γ-irradiation132. Finally, high PTP4A3 expression has been 
linked to increased tumor aggressiveness in different types of solid tumors, e.g., melanoma, 
gastric cancer, colon cancer, hepatocellular carcinoma and breast cancer133-138, possibly because 
high PTP4A3 expression leads to increased epithelial-mesenchymal transition138.
The role of PTP4A3 in hematopoietic malignancies has not been studied as extensively as in 
carcinoma. Only a few studies report differences in expression levels of PTP4A3 in ALL and 
myeloma subgroups, based on gene expression profiling139-141. Interestingly however, in a recent 
study, PTP4A3 has been proposed to have a role in drug-resistance in AMLs with internal tandem 
duplication of FLT3 (FLT3ITD)142. This finding, together with the observation that high PTP4A3 
expression negatively correlates with prognostic outcome, indicates that PTP4A3 might be a 
potential therapeutic target in AML.
In conclusion, using a retroviral mutagenesis screen in which we enriched for DNA methylated 
viral integration sites we identified PTP4A3 as a potential haplo-insufficient gene with an 
independent prognostic value in human de novo AML. Challenges for the future are to determine 
the dose-effect of PTP4A3 expression in myeloid development and to extend the screens to 
additional myeloid neoplasms, e.g., myelodysplasia, therapy-related AML, AML secondary to 
bone marrow failure and myeloproliferative disorders.
 MATERIALS AND METHODS
Ethics statement
For this study no novel murine leukemias were generated, all experiments described were 
performed on material generated in a previous study83. All animal procedures for the use of 
control bone marrow fractions were approved by the animal care and use committee of the 
Erasmus MC (approval # 119-10-05).
All human cell samples were obtained after written informed consent and stored anonymously 
in a biobank. The study was performed under the permission of the Institutional Review Board 
of the Erasmus MC, registration number MEC-2008-387.
Mouse leukemia and normal cell samples
DNA and RNA samples from a previously generated panel of Gr1.4-induced leukemias83, and 
control samples (bone marrow, spleen, liver) from normal FVB/N mice were used.
Methylation specific PCR
Primer and probe sequences are shown in Table S2. Two µg of genomic DNA was treated with 
bisulphite using the EZ DNA-methylation kit according to the manufacturers protocol (Zymo 
research, Orange, CA, USA). LTRs were amplified with bsLTRfw and bsLTRrv using 1 µL out of 10 
µL of bisulphite-treated DNA. Cycling conditions were 30” at 94°C, 30” at 50°C and 1’ at 72°C 
for 10 cycles in a total volume of 50 µL. Two µL was used in a nested qPCR (Figure 1A) using 
MN-LTR-fw × MS-LTR-rv/MN-LTR-rv (MN = methylation neutral, MS = methylation specific). 
Cycling conditions were 15” at 94°C, 30” at 57°C and 30” at 60°C for 45 cycles. Amplified LTRs, 
methylated and unmethylated, were quantified using a methylation neutral probe (probe-MN, 
Sigma-Aldrich, Zwijndrecht, The Netherlands). Delta cycle threshold values (dCt), representing 
the number of methylated LTRs as a fraction of total LTRs, were calculated as follows: dCt = 
Ct(Methylated LTRs)-Ct(All LTRs) = Ct(MN-LTR-fw × MS-LTR-rv) – Ct(MN-LTR-fw × MN-LTR-rv). 
PCRs were performed in duplicate and mean dCt values were calculated.
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Figure 4. Methylation sensitive restriction analysis of viral integration sites and expression of nearby located genes. 
(A) Schematic overview of the methylation specific restriction approach. Genomic DNA was digested with BstU1 (CGCG, 
blocked by DNA-methylation), followed by mVIS amplification with primers as indicated by arrows. If the flanking LTR is 
methylated, mVIS amplification is unaffected upon BstU1 digestion. (B) All 8 identified viral integration sites, identified in 
tumor 1, 2 and 4, were amplified before (−) and after (+) BstU1 digestion. As controls, H19 (hemi-methylated) and ActB 
(unmethylated), both containing 2 BstU1 digestion sites, were analysed in each tumor. (C) Expression levels of 4 genes 
flanked by methylated viral integration sites were determined by qPCR in the respective tumors. Expression levels relative 
to housekeeping gene Tbp are shown; error bars indicate standard deviations. NBM=normal bone marrow.
Figure 5. Survival analysis. A cohort of 454 de novo AML cases diagnosed under the age of 60 was divided into 2 groups 
of equal size based on MAS5 normalised expression of PTP4A3 (probe 206574_s_at). Overall survival (A) and event-free 
survival (B) were analysed. P-values were calculated with a log rank test.
MeDIP
Ten µg genomic DNA was digested overnight with 100 U of DpnII (New England Biolabs, Ipswich, 
MA, USA). Four µg digested DNA was denatured for 10’ at 95°C and incubated with either 2.5 
µg anti-5-methylcytidine (BI-MECY-1000, Eurogentec, Liège, Belgium) or mouse pre-immune IgG 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) in 500 µL IP-buffer (PBS with 0.05% Triton X-100) 
for 2 hrs at 4°C, followed by incubation with 30 µL of washed beads (M-280 sheep-anti-mouse 
IgG, Invitrogen, San Diego, CA, USA) for 2 hrs at 4°C. Beads were washed 3 times with 700 µL 
IP-buffer. As a 10% input reference, 400 ng digested DNA not subjected to MeDIP was used. 
Beads and the 10% input reference DNA were resuspended in 100 µL IP-buffer and incubated 
for 3 hrs at 50°C after adding 20 µg proteinase K (Roche, Basel, Switzerland). Supernatants, 
containing immunoprecipitated DNA, and the input DNA were purified using the MinElute 
Reaction Cleanup Kit (Qiagen, Hilden, Germany) and were eluted in 40 µL elution buffer. Two µL 
immunoprecipitated DNA was used to amplify the imprinting control region 1 (ICR1) of H19 with 
H19ICR1fw × H19ICR1rv, ActB with ActBfw × ActBrv and the LTR with LTRfw × LTRrv using (q)PCR. 
Primer sequences are shown in Table S2. Cycling conditions were 30” at 95°C, 30” at 58°C and 
45” at 72°C for 30 cycles (PCR) or 15” at 94°C, 30” at 59°C and 30” at 60°C for 45 cycles (qPCR). 
Amplification products were analysed using gel electrophoresis (PCR) or quantified (qPCR) using 
SYBRgreen Master mix (Applied Biosystems, Foster City, CA, USA).
Inverse PCR
Primer sequences are shown in Table S2. Six murine leukemias with high LTR enrichment (more 
than 10% of input) and low ActB enrichment (less than 10% of input) were selected for inverse 
PCR. Eight µL MeDIP-DNA was denatured for 3’ at 95°C, renatured by a temperature decrease of 
0.1°C/sec to 20°C, and ligated for 45’ at room temperature using a rapid DNA ligation kit (Roche, 
Basel, Schwitzerland). Two µL out of 20 µl ligated product was amplified with primers mL1 and 
mL2, followed by a nested PCR with primers mL1N and mL2N using 2 µL of the first PCR product. 
Cycling conditions were 30” at 95°C, 30” at 60°C (first PCR) or 56°C (nested PCR) and 3’ at 72°C 
for 30 cycles. In the nested PCR 10 mM dCTP, dATP, dGTP, 8 mM dTTP and 2 mM dUTPs were 
used.
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Promoter array hybridization
PCR products of 10 nested PCR reactions were purified with a PCR purification kit (Qiagen, 
Hilden, Germany) and pooled. A total of 7.5 µg of these amplified fragments was fragmented 
and labeled using the GeneChip WT Double stranded DNA terminal labeling kit (Affymetrix, Santa 
Clara, CA, USA). Fragmentation to 66 bp was checked on a Bioanalyser (Agilent, Santa Clara, CA). 
Labeled DNA was hybridized to mouse promoter 1.0R arrays (Affymetrix, Santa Clara, CA, USA) 
for 16 hrs at 45°C. Arrays were washed with the FS_450_0001 protocol using the Fluidics Station 
450 (Affymetrix, Santa Clara, CA, USA), followed by scanning. Probe values were normalized with 
model-based analysis of tiling-arrays (MAT)74 and mVIS were determined using hypergeometric 
analysis of tiling-arrays (HAT)89, both for HAT and MAT default settings were used. Genes located 
nearby amplified regions were identified using UCSC (assembly mm8, Feb. 2006).
Directed PCR and Sanger sequencing
Primers are shown in Table S2; amplification of the integration site was performed with 
VIS(corresponding gene) × LTRfw2, for Lrmp a nested PCR was performed with VIS(Lrmp_nested) 
× LTRfw. As input, 200 ng of the corresponding tumor DNA was used; cycling conditions were 30” 
at 95°C, 30” at 58°C and 45” at 72°C for 30 cycles. Products were purified using the Multiscreen 
HTS 66-well filtration system (Millipore, Billerica, MA, USA). Sanger sequencing was performed 
with primer LTRfw according to the manufacturers protocol (Applied Biosystems, Foster City, 
CA, USA).
Methylation sensitive restriction analysis
Primers are shown in Table S2. Two and a half µg of tumor DNA was digested with 25 U of 
BstU1 (New England Biolabs, Ipswich, MA, USA) o/n at 60°C, purified using the Multiscreen HTS 
66-well filtration system (Millipore, Billerica, MA, USA), eluted in 30 µl and diluted to 50 ng/
µl. Amplification of the integration site was performed as described under directed PCR and 
Sanger sequencing, with 100 instead of 200 ng input of DNA. As controls H19 ICR1 (H19ICR1fw 
× H19ICR1rv) and ActB (ActBfw × ActBrv) were amplified. Cycling conditions were 30” at 95°C, 
30” at 58°C and 45” at 72°C for 30 cycles. Amplification products were analysed using gel 
electrophoresis.
RNA isolation, cDNA preparation and qPCR
RNA of murine samples was isolated using Trizol (Invitrogen, San Diego, CA) according to the 
manufacturers protocol. One µg of RNA was used for cDNA preparation, using SuperScript II 
Reverse Transcriptase (Invitrogen, San Diego, CA) according to the manufacturers protocol. One 
µl cDNA was used as input for the qPCR. Genes of interest were amplified with their respective 
forward and reverse primers (Table S2), as an input control, TATA box binding protein (Tbp) 
was analysed. Cycling conditions were 3” at 95°C and 30” at 60°C for 45 cycles. Amplification 
products were quantified using Fast SYBRgreen Master mix (Applied Biosystems, Foster City, CA, 
USA). Expression levels relative to Tbp were calculated.
Survival analysis human AML samples
Purified AML blasts were obtained following informed consent as described18. Gene expression 
profiles of 454 de novo AML patients under the age of 60 were used for this analysis62. Expression 
levels were MAS5 normalised (Scaling factor 100), values < 30 were set at 30, followed by log2 
transformation.
For Ptp4a3, univariate and multivariate survival analyses were performed using expression levels 
of probesets 206574_s_at or 209695_at in a Cox regression model. In the multivariate analysis 
age, white blood cell count, cytogenetic risk group, NPM1+FLT3ITD− status and CEBPA mutation 
status were used as additional prognostic parameters. We recognised the following cytogenetic 
risk groups: favorable = t(15;17), inv(16) and t(8;21), unfavorable = t(3;3), inv(3), −7/7q-, −5/5q-, 
complex karyotype, t(11q23) except t(9;11), t(9;22) and t(6;9), intermediate = all other cases 
with known cytogenetics. Kaplan-meier graphs were generated by dividing the AML cohort in 2 
groups of equal sample size based on PTP4A3 expression of probe 206574_s_at. Analyses were 
performed in SPSS (version 17, SPPS Inc, Chicago, IL).
For the permutation test, all probesets with an annotated gene symbol (based on HG-U133_
Plus_2.na32.annot.csv, Affymetrix, Santa Clara, CA, USA) were selected. Next probesets with 
expression levels < 30 in all 454 patients were discarded, leaving a total of 40720 probesets. 
The permutation test was performed by randomly selecting 6 probesets (representing 6 mVIS), 
followed by randomly selecting 1 out of these 6 probesets (representing 1 downregulated gene). 
For this probeset a univariate Cox regression analysis was performed for overall survival (OS) 
and event-free survival (EFS). A P-value of < 0.0001 (as observed for PTP4A3) was considered 
significant. This analysis was repeated 100,000 times, followed by calculating the frequency, i.e., 
probability, of observing a significant P-value for both OS and EFS. Analyses were performed in 
Matlab (version 2008b, Mathworks).
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Table S2. Primers and probes.
Name Sequence
bsLTRfw GAGAAATAGGGAAGTTTAGATTAA
bsLTRrv CCCAAAATAAACAATCAATCAATC
MN-LTR-fw GGTTAAATAGGATATTTGTGGTGAGTAG
MN-LTR-rv AACGAACTAATTAATTAATTCAAATAAAAC
MS-LTR-rv CGAACAAAAACGAAAAACGAA
Probe-MN FAM-AAACCATATCTAAAAACCATCTATTCTTACCCCC-TAMRA
H19ICR1fw ACATTCACACGAGCATCCAGG
H19ICR1rv GCTCTTTAGGTTTGGCGCAAT
ActBfw AGCCAACTTTACGCCTAGCGT
ActBrv TCTCAAGATGGACCTAATACG
LTRfw AAAGACCTGAAACGACCTTGC
LTRrv AAGGACCAGCGAGACCACG
mL1 CAACCTGGAAACATCTGATGG
mL2 CCCAAGAACCCTTACTCGGC
mL1N CTTGAAACTGCTGAGGGTTA
mL2N AGTCCTCCGATAGACTGTGTC
LTRfw2 CCAGGTTGCCCCAAAGACCTG
VIS(Taf12) CAAGATCCGGGCTTTCAGAC
VIS(Ranbp3) GACCAGGCTGCTCTCAAACG
VIS(Lrmp) GGACACTACACTCATATTTG
VIS(Lrmp_nested) GTGTGCTATGGGTAATTCAG
VIS(Hcls1) TTCTCCTCCTTGCTTTCTGC
VIS(Lta) CTAGGAGTCTTGTGCATCGTC
VIS(Blnk) GAGGACAAGCCTAGTGATTTC
VIS(Prkrir) CTGCTTGTTCACACAAAGTC
VIS(Ptp4a3) CAGCCTCCTCTAGCAGTATC
Tbp fw GCTGACCCACCAGCAGTTCAGTA
Tbp rv AAGGAGAACAATTCTGGGTTTGA
Lrmp fw CACAAGGCGAAGAGGCAGTG
Lrmp rv GTGCTCTGTTGGCTCTTCTG
Hcls1 fw CCCTTCTCTGTCCTACCAAG
Hcls1 rv CCTTCATCCACCATCTCAAT
Prkrir fw CTTACCAGTCATTTGAACAAC
Prkrir rv CTTCAAGGGTTAAAGGCAGC
Ptp4a3 fw CCATCCAGTTCATCCGACAG
Ptp4a3 rv GACACAGATGTAATGAGGTAC
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ABSTRACT 
Tiling-arrays are useful for exploring local functions of regions of the genome in an unbiased 
fashion. The exact determination of those genomic regions based on tiling-array data, e.g., 
generated by means of hybridization with immunoprecipitated DNA-fragments to the arrays 
is a challenge. Many different statistical methodologies have been developed to find biological 
relevant regions-of-interest (ROI) by using the quantitative signal intensity of each probe. We 
previously developed a method called Hypergeometric Analysis of Tiling-arrays (HAT) for the 
analysis of tiling-array data, but it is developed such that it can also be used to study data derived 
by genome wide deep sequencing approaches. Here we applied HAT to analyze two publicly 
available Tiling-array data sets. After the detection of statistically significant ROI, these are often 
used in additional analysis for hypothesis testing. We therefore discuss, by using the results of 
the tiling-array experiment, pathway and motif analyses.
INTRODUCTION
Tiling-arrays are a subtype of microarrays which are designed with probes that cover contiguous 
regions of a genome. The locations of probes do not necessarily cover genomic regions that are 
known to be functional, as is the case for gene expression or promoter arrays. Therefore tiling-
arrays differ from these microarrays as they are not by definition designed to cover known or 
predicted genes in the genome. Moreover, the coverage of probes in unknown genomic regions 
has been useful for exploring the genome in an unbiased fashion. Examples of applications for 
tiling-arrays are: 1) protein-DNA-interaction by conducting chromatin immunoprecipitation (ChIP-
on-chip) experiments143, 2) epigenetic modifications by Methyl-DNA immunopreciptitation56 
(MeDIP-on-chip) or 3) identification of DNAse hypersensitive sites, which can be used to predict 
regulatory elements such as promoter regions, enhancers and silencers144. Although tiling-arrays 
are useful for genome wide studies, the coverage of the genome on the arrays depends on the 
species that is being studied. As an example, probes can cover the majority of a small genome 
such as for Arabidopsis 145 whereas probes will cover only contigs in a large genome, such as for 
human. Thus for larger genomes, as is the case for mouse or humans, the choice of the content 
depends on the questions one wishes to address using a particular tiling-array. 
Each tiling-array produces quantitative signal intensity for each probe by the hybridization of 
labeled DNA. Normalized probe intensities are illustrated by the different peaks in Figure 1, 
where the colors indicate the probe signals at different chromosomes. Although single probe-
hybridization with high signal intensity suggest strong hybridization, it is not necessarily the result 
of specific hybridization of labeled DNA (illustrated by the probes above threshold 1 in Figure 
1A and 1B). Multiple contiguous probes that show increased signal intensity upon hybridization 
across a particular genomic region are more likely to be the result of true hybridization in a 
biological experiment. These genomic regions are denoted as a putative region-of-interest (ROI). 
In order to find such ROI, a low threshold must be employed which may compromise the results 
by introducing false positives ROI (Figure 1A and 1B, threshold 2). To detect biological relevant 
ROI, probe intensity signals should be discriminated from non-specific signals. A challenge in 
the analysis of tiling-array data is the detection of true ROI, and to minimize the number of 
false positives. A straightforward approach is to choose a fixed number of consecutive probes 
above a certain threshold and indicate it as a ROI. Nevertheless, this definition of ROI may be 
inadequate because of the required number of consecutive probes and the optimal threshold 
may be difficult to establish. In addition, the probe-resolution varies across the genome, and 
across different tiling-array platforms.
Multiple methods have been developed to analyze tiling-array data which all serve one goal, 
i.e., the detection of true ROI and thereby discriminating positive probe intensity from the 
background. The developed methods differ in their statistical approaches: methods incorporate 
the Hypergeometric distribution89, hidden Markov models146-148, correlation structures149, 
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Figure 1. Graphical representation of probe intensities in a ChIP-on-chip tiling-array experiment. (A) Normalized probe 
intensity of 4.6 million probes among 22 chromosomes. Colours illustrate the different chromosomes whereas the length 
of a lollipop represents the probe intensity. (B) Distribution of the probe intensity values. The probe intensity values are 
normalized against a reference file. Threshold 1 indicates a high threshold cut-off whereas threshold 2 indicates a low 
intensity cut-off. HAT uses many different threshold cut-offs to determine significantly enriched ROI.
heuristics150, mixture models151, Bayesian modeling152,153, wavelets154, or by using other 
methodologies55,74,155-160. All methods have shown to be useful in filtering large data sets for 
candidate gene discovery. It is of importance to note, that biological experiments are always a 
necessity to validate particular findings.
Here we discuss the previously developed method, Hypergeometric Analysis of Tiling-arrays 
(HAT)89, that uses the Hypergeometric distribution to assess the probability of a consecutive 
number of probes in a particular genomic region while controlling multiple testing (Family 
Wise Error: FWE). Furthermore, HAT uses multiple threshold cut-offs, it does not necessarily 
requireexperimental replicates, and can be normalized against reference files. It furthermore 
employs a single user defined parameter: the significance level alpha. Note that alpha is not used 
to determine the threshold cut-off using the data distribution (Figure 1B), instead it computes 
the probability to observe a specific number of probes for a particular genomic region (window) 
over multiple threshold cut-offs. Furthermore, specifying parameters such as fragment size 
may improve the detection of ROI, whereas parameters for gene mapping and sequence of 
interest are required for additional analysis (Figure 2). HAT is generically built and therefore 
HAT
Alpha
Fragment size
UCSC browser track
Motif analysis
Pathway analysis
Gene mapping UCSC
genomeSequence of interest
Normalized 
tiling-array data
Optional settings
Mandatory setting
Results
FASTA files
Additional analysis
ROI < alpha
Flanking genes
Figure 2. Schematic overview of tiling-array data analysis. Stepwise illustration of normalized tiling-array data towards 
the detection of significantly enriched ROI, the flanking genes, sequences files (FASTA), motif analysis, pathway analysis 
and the UCSC-browser. 
independent of probe intensity distribution, probesets coverage and probesets resolution 
across the genome and tiling-array platform. It is successfully applied in multiple types of 
biological research questions, i.e., the detection of protein-DNA-interactions (ChIP-on-chip89), 
identification of genomic locations that are involved in viral integration and potentially harbor 
tumor suppressor genes (MeDIP-on-chip)56, the identification of regions enriched for histone 
modifications such as, trimethylation of histone 3 at lysine 4 or lysine 27 (H3K4 me3, H3K27 
me3)89, and for the identification of anthocyanin-specific genes that flank enriched genomic DNA 
in black rice using 3’-TILLING 135 K Oryza sativa microarray57. Many detected ROI among these 
different studies were confirmed by quantitative polymerase chain reaction (qPCR). 
Although tiling-arrays have been applied successfully for genome wide applications, high 
throughput sequencing of for instance chromatin immunoprecipitated DNA-fragments (ChIP-
Seq), show genome wide associations in higher resolutions and will therefore be superior to 
chip technology. Even though ChIP-Seq is becoming the standard for genome wide applications, 
numerous high quality tiling-array data sets are publicly available at the the gene expression 
omnibus website (GEO: http://www.ncbi.nlm.nih.gov/geo/). These can be of value to address 
particular research questions raised by investigators and to which HAT may be very useful. 
Furthermore, although HAT was initially developed for the analysis of tiling-array data, the 
application is not limited to the studies discussed in this chapter, but can be applied for the 
analysis of ChIP-Seq data as well. 
Here we stepwise discuss how to apply HAT to analyze tiling-array data. As case examples we 
used two publicly available ChIP-on-chip data sets. In addition we discuss two types of analysis 
that frequently follow-upon the detection of ROI, namely motif and pathway analysis. 
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MATERIALS
We previously reported the successful usage of HAT on two novel data sets89. Here we 
demonstrate HAT on previously reported STAT4-chromatin immunoprecipitation (ChIP-on-chip) 
experiments (n=2), compared to controls (n=2). Secondly, we use HAT to analyze the DNA-binding 
capacity of a C-terminal mutant C/EBPα (n=2), compared to controls (ER) (n=2). Both data sets 
are available on the gene expression omnibus (GEO), GSE19321 and GSE16845 respectively. Data 
were generated using the Affymetrix GeneChip Mouse Promoter 1.0 Array. This chip generates 
4.6 million perfect match probes over 28000 mouse promoter regions. Promoter regions cover 
6kb upstream to 2.5kb downstream of 5’ transcription start sites. Each probe has a size of 25 
basepairs (bp). RAW probe intensity values are normalized by utilizing Model-based analysis of 
tiling-arrays for ChIP-on-chip (MAT) 74,88.
ANALYZING TILING-ARRAY DATA SETS
In this paragraph we demonstrate the usage of HAT for the identification of significant ROI 
and define the parameters for ChIP-on-chip experiments. Before starting the peak-detection 
algorithm (HAT), pre-knowledge about the experimental setup is highly recommended. The 
experimental protocol requires shearing of the DNA by using a sonication process which results 
in DNA-fragments of approximately 600 base pairs (bp). Subsequently, chromatin fragments are
Table 1. Motif enrichment analysis on the detected regions-of-interest in the STAT4 experiment.
Transcription Factor Recognized factors Fold-increase P-value
STAT1_01 STAT1, STAT1alpha, STAT1beta 8.059 5.53E-29
STAT5B_01 STAT5A, STAT5B 4.092 1.05E-26
STAT1_05 STAT1 5.611 2.15E-26
STAT_01
STAT1, STAT1alpha, STAT1beta, STAT2, STAT3, STAT3-
isoform1, STAT4, STAT5A, STAT5B, STAT6
3.542 5.45E-22
STAT3_01 STAT3, STAT3-isoform1 5.963 1.34E-19
STAT1STAT1_Q3 CBF3, STAT1:STAT1, ehf 4.046 1.11E-18
IRF_Q6
IRF-10, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, IRF-7A, IRF-
7B, IRF-7H, IRF-8, IRF4-1, irf1
3.603 1.08E-11
AP1_Q6_01
AP-1, FOSB, FosB, Fra-1, Fra-2, JunB, JunB:Fra-1, 
JunB:Fra-2, JunD, JunD:Fra-2, JunD:deltaFosB, c-Fos, 
c-Jun, c-Jun:FosB, c-Jun:JunD, c-Jun:c-Fos, deltaFosB
2.703 2.04E-11
STAT5A_01 STAT5A 4.080 3.81E-11
BACH1_01 Bach1, Bach1t 3.121 3.35E-09
The top 10 enriched TFBS among the detected binding regions using HAT for the STAT4-study (ChIP-on-chip). A TFBS is 
called when the position weight matrices (PWM) are enriched at P ≤ 0.001. Recognized factors: the transcription factors 
that are recognized by the TFBS. Fold-increase: the frequency that a TFBS is detected among the binding regions com-
pared to the reference set (5000 randomly chosen genes).
immunoprecipitated using antibodies directed to the protein-of-interest, known to interact with 
DNA. The consecutive probes can therefore cover up to 600bp after the hybridization process 
per fragment. This information can be used in the model for the detection of ROI. Note that 
significant ROI can be detected that are larger or smaller in width than 600bp. In addition, we 
set the significance level on 0.05. 
The first ChIP-on-chip data set to which we applied HAT is a study that was previously reported 
and in which STAT4-mediated transcriptional regulatory networks in Th1 cell development were 
investigated143. STAT4 is a critical component in the development of inflammatory adaptive immune 
responses. Although STAT4 was subject in various other studies161,162, it was claimed that the genetic 
program, activated by STAT4 that results in an inflammatory cell type, is not well characterized. A 
ChIP-on-chip experiment was therefore conducted as previously reported143. Here, we analyzed 
both experimental replicates by choosing a fragment size of 600nt and α: 0.05, and detected 
n=2903 and n=3106 ROI. Moreover, 84% (n=2499) overlapped in both replicates compared to 
the controls (sized between 215bp-4543bp, median: 1002bp). It was previously demonstrated 
that the analysis method, GenPathway, identified 4669 genes that were seen in both replicates143. 
This list is subsequently filtered for genes with binding intensity > 4 and thereby resulted in 1540 
genes. This indicates that using the unfiltered list, GenPathway detects almost twice the number 
of ROI when compared to HAT. To investigate the validity of the ROI that were detected by HAT, 
a motif enrichment analysis was conducted on the 2499 common ROI by using F-MATCH163,164.
We hypothesize that the detected ROI should contain a STAT-binding site. We detected a total of 
38 transcription factor binding sites of which the STAT-motifs were highly enriched (P < 0.001). 
Table 2. Motif enrichment analysis on the detected regions-of-interest that are exclusively detected using HAT in the 
STAT4 experiment.
Transcription Factor Recognized factors Fold-increase P-value
STAT1_01 STAT1, STAT1alpha, STAT1beta, STAT2, STAT3, STAT3-
isoform1, STAT4, STAT5A, STAT5B, STAT6
7.235 4.96E-16
STAT3_01 STAT3, STAT3-isoform1 5.862 7.36E-12
STAT5B_01 STAT5A, STAT5B 3.633 2.16E-11
STAT1_05 STAT1 4.658 2.45E-9
STAT_01 STAT1, STAT1alpha, STAT1beta 3.405 4.05E-9
GADP_01 GABP 4.416 1.88E-8
SAP1A_01 SAP-1a 4.106 5.32E-8
STAT1STAT1_Q3 CBF3, STAT1:STAT1, ehf 3.507 5.26E-7
ELK1_02 Elk-1, Elk1-isoform1 4.025 7.68E-7
CETS1P54_01 Ets-1, Ets-1 deltaVII, c-Ets-1, c-Ets-1 54, c-Ets-1A, c-Ets-1B 3.981 8.78E-7
The top 10 enriched TFBS among the exclusively detected binding regions of HAT for the STAT4-study (ChIP-on-chip). A 
TFBS is called when the position weight matrices (PWM) is enriched at P ≤ 0.001. Recognized factors: the transcription 
factors that are recognized by the TFBS. Fold-increase: the frequency that a TFBS is detected among the binding regions 
compared to the reference set (5000 randomly chosen genes).
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Moreover, 7 STAT-motifs were detected in the top 10 after ranking the TFBS on significance 
(Table 1). This suggests high specificity of the detected ROI. Note that the STAT-motif is also 
highly enriched in the genes detected by GenPathway143. Although both methods detected 
high enrichment for the STAT-motifs, the overlap of genes between both methods was 897 
genes. In other words, 1211 genes were solely detected by HAT and not by GenPathway. To 
assess the validity of these ROI, we conducted a motif analysis for only those 1211 ROI and 
detected again high enrichment for the STAT-motifs, i.e., 6 STAT-TFBS are detected in the top 
ten ranked list (Table 2). We hypothesize that the 1211 genes may be present in the initial 4669 
genes detected by GenPathway, but are excluded from the list as these did not comply the 
above mentioned criteria. This is supported by the notion that significantly lower probe intensity 
levels are observed (P < 0.0001) in the 1211 ROI compared to the 897 ROI. Note that the probe 
intensity levels, of all the detected ROI, are significantly higher compared to the background. 
Unfortunately, we were not able to analyze the motifs among the exclusively detected genes by 
GenPathway, as the exact genomic positions of the ROI were not specified. These differences 
may occur due to alternatively defined gene mapping procedures Figure 3) and the differences 
in statistical methodologies. In conclusion, we identified another set of genes that were highly 
enriched for the STAT-motif. 
The second ChIP-on-chip data set is used to study the DNA-binding capacity of a variant of 
CCAAT enhancer binding protein alpha (C/EBPα) that carries a C-terminal-mutation. C/EBPα 
is a transcription factor and master regulator of myeloid differentiation 165,166. It is frequently 
mutated in patients with acute myeloid leukemia (AML) (5%-14%)44. Abnormalities in CEBPA 
may contribute to a block in differentiation of progenitor cells of granulocytes, which can result 
in leukemogenesis. Mutations in CEBPA are associated with a particular prognosis of patients
gene iii gene iv
gene i
5’ 3’
strand
downstreamupstream
TSS
gene ii
TSS
3’ 5’
strand
upstreamdownstream
TSS TSS
ROI
Figure 3. Mapping of detected regions-of-interest to genes located in close vicinity. A single ROI is illustrated with four 
neighbouring genes: two on the positive-strand (upstream and downstream) and two on the negative-strand (upstream 
and downstream). Mapping of ROI to genes is crucial for additional analysis (e.g., pathway analysis). Abbreviations, ROI: 
Region-of-interest, TSS: Transcriptional-start-site, 3’: Three prime UTR, 5’: Five prime UTR.
with AML 44. In AML patients, two types of CEBPA mutations are known to exist: mutations in 
the N-terminus and C-terminus. C-terminal mutations are found in the DNA-binding domain. 
chr 3
ch
r
8
chr 14
Figure 4. Graphical representation of the genes that are bound by the C-terminal mutant C/EBPα. One hundred and 
forty mapped genes from the detected ROI of the C-terminal mutant C/EBPα experiments are illustrated. Candidate 
genes in experiment 1 are indicated by the red box whereas the candidate genes from experiment 2 are indicated by the 
blue box. Forty-six genes (mapped from 48 ROI) that overlap between experiment 1 and 2 are indicated with a red text-
color. Line-colors are colored similar as the chromosomes which are numbered from 1-19 and X, and show the relative 
location of the genes using mouse genome build 8 (mm8).
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Since the mutant protein can still interact with other proteins that may interact with DNA, we 
propose that mutant C/EBPα may indirectly interact with DNA. We wondered to which loci 
mutant C/EBPα might interact in an indirect manner. We created a similar C-terminal-mutation 
as found in one particular human AML patient36, with an insertion of 6 amino acids in the 
C-terminal bZIP domain. We used it in the ChIP-on-chip experiment to identify genes that may 
play a role in leukemogenesis. Promoter array hybridizations were conducted from a myeloid 
cell line model (32D), that expresses either beta-estradiol inducible C-terminal mutant C/EBPα 
(2 clones) or control-ER (2 clones). The question that we wished to address is whether mutated 
C/EBPα can bind to the DNA, thereby identifying the associated genes. Using a fragment size of 
600bp and an alpha of 0.05, we detected in total n=89 and n=109 significant binding regions 
in the two clones with C-terminal mutant C/EBPα that was not seen in the controls Figure 4). 
The ROI are sized between 154 and 2481 nucleotides (median 717bp) and forty-eight were 
commonly detected in both clones.
We next searched for binding motifs among the detected ROI of the C-terminal mutant C/EBPα. 
Although it is known that the C-terminal mutant C/EBPα lacks binding capacity, we identified 
three enriched motifs namely, core-binding factor (CBF), ETS and ESE-1 (P-value < 0.001). Core-
binding factors have been shown to fulfil an important role in haematopoiesis167 and ETS family 
members, such as ESE-1, fulfil an important role in several signal transduction pathways168-170. 
As expected, we did not find the consensus binding motif CEBP as we showed previously for 
wild-type C/EBPα using the same model system 89. The detection of these three enriched motifs 
and the absence of the CEBP motif suggest that DNA-binding by mutant C/EBPα had occurred 
indirectly. We hypothesized that other factors may influence the DNA-binding capacity and 
therefore analyzed the 2kb upstream regions, from the transcriptional-start-site (TSS) of the 
detected genes (Figure 4). This resulted in the detection of 71 enriched TFBS with P ≤ 0.001 
and 1.5 times more frequently observed than in the reference set (fold-increase ≥ 1.5). As a 
reference set we selected 2kb upstream sequences (starting from the transcription start site) 
of 5000 randomly selected genes. The 2kb upstream sequences are gathered using the UCSC 
database (http://hgdownload.cse.ucsc.edu). The top 15 TFBSs are depicted in Table 3.
DETECTED REGIONS-OF-INTEREST CAN BE MAPPED TO GENES THAT ARE 
LOCATED IN CLOSE VICINITY 
Although the goal is to detect ROI by using ChIP-on-chip tiling-arrays, it often requires additional 
analysis, such as pathway analysis, to test a particular hypothesis. This requires the mapping of 
ROI to genes. Each ROI can, theoretically, be mapped to four genes that are located on: 1. the 
positive strand and upstream, 2. the positive strand and downstream, 3. the negative strand 
and upstream, and 4. the negative strand and downstream (Figure 3). From these four genes, 
only one gene may be targeted (or two genes in a bi-directional promoter region). For promoter 
tiling-arrays, where only the promoter regions are present on chip, it is straightforward to map 
Table 3. Motif enrichment analysis on the 2kb upstream regions-of-interest of the C-terminal mutant C/EBPα target 
genes.
Transcription Factor Recognized factors Fold-increase P-value
POU3F2_02 POU3F2, POU3F2 (N-Oct-5a), POU3F2 (N-Oct-5b) 1.948 6.81E-12
CDP_02 CDP, CDP-isoform1, CDP2 2.072 9.86E-9
FOXP3_Q4 FOXP3 4.753 5.98E-8
OCT1_01 Oct-1, POU2F1, POU2F1a 1.713 6.24E-8
IPF1_Q6 PDX1, ipf1 1.605 1.37E-7
CLOX_01 Cutl 1.756 8.19E-7
SATB1_01 CBF-C 1.587 8.48E-7
OTX_Q1 Otx1, Otx2 1.903 9.09E-7
HMGIY_Q3 HMGI-C, HMGIY, HMGIY-isoform1, HMGIY-isoform2 1.546 1.72E-6
FOXO1_01 FOXO1A 1.714 1.93E-6
DMRT4_01 DMRT4 1.581 2.29E-6
NFAT_Q6
NF-AT, NF-AT1, NF-AT1C, NF-AT2, NF-AT3, NF-AT4, NFAT1, 
NFAT1-isoformD
3.009 2.74E-6
TEF_Q6
TEF-xbb1, Thyrotroph embryonic factor, Thyrotroph 
embryonic factor-isoform1, Thyrotroph embryonic factor-
isoform2, Thyrotroph embryonic factor-isoform3, VBP
1.955 5.14E-6
SRF_C SRF, SRF-I, SRF-L, SRF-M, SRF-S 2.111 5.91E-6
CEBP-GAMMA_Q6 C/EBPgamma 1.828 6.50E-6
The top 15 enriched TFBS among the 2kb upstream genes of the C-terminal mutant ROI. A TFBS is called when the posi-
tion weight matrices (PWM) are enriched at P ≤ 0.001 and with fold-increase > 1.5. Recognized factors: the transcription 
factors that are recognized by the TFBS. Fold-increase: the frequency that a TFBS is detected among the binding regions 
compared to the reference set (5000 randomly chosen genes).
the detected ROI to the nearest located transcriptional-start-site (TSS) of a gene. To prevent 
incorrect gene mapping, due to differences in genomic locations of TSS between species 
and/or genomic-build (hg18, hg19 for human and mm8, mm9 for mus musculus, it is highly 
recommended to use the same species and genomic-build for both the gene mapping file as the 
one used in the normalization process. These gene mapping files can be downloaded from the 
UCSC: http://hgdownload.cse.ucsc.edu. 
Manually curating each detected ROI to a particular gene is possible using the UCSC genome 
browser track (generated using HAT, Figure 2) but can be time consuming. Alternatively, by 
specifying the species and genome build in HAT, each ROI can automatically be mapped to the 
TSS of a gene in closest vicinity. We specified in both ChIP-on-chip experiments “mm8” because 
the experimental samples were derived from mus musculus and normalized with genomic-build 
8. Because both analyzed data sets have been generated using promoter tiling-arrays, it allowed 
the mapping of the ROI to genes in close vicinity. For the STAT-study, the 2499 detected ROI 
were mapped to 2108 unique genes. For the C/EBPα-study, it resulted in the detection of 140 
unique genes. These are graphically illustrated using a circos-plot96 (Figure 4). Such graphical 
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representation indicates the chromosomal location of the genes, and whether genes are 
commonly detected in the independent experiments using different clones. 
MOTIF AND PATHWAY ANALYSIS ON THE DETECTED REGIONS-OF- 
INTEREST AND THEIR FLANKING GENES
Analysis on the detected ROI or the genes that are located in close vicinity of the ROI, is an 
important next step for hypothesis testing. Both motif and pathway analysis are therefore useful 
in tiling-array studies (Figure 2). 
Motif analysis detects specific sequences involved directly in protein-DNA-binding interactions, 
or alternatively whether the promoter regions of the flanking genes include overrepresented 
sequences of transcription factors. These so called transcription factor binding sites (TFBS) may 
suggest that the protein-of-interest interacts synergistically with other proteins or is involved in 
the formation of protein-complexes. In general, two types of motif analysis exist: by using known 
TFBS that are derived from published collections (e.g., JASPAR or TRANSFAC databases). These 
databases should be used when seeking specific factors or structural classes. Secondly, dé-novo 
motif analysis can be used to analyze similarities among the sequences to produce a description 
for each pattern it discovers. F-MATCH163,164 and MEME112 are two algorithms which can be used 
for the detection of known TFBSs and/or dé-novo motifs. These methods are online accessible 
and require FASTA files as an input, which contain sequences of the ROI (generated by HAT).
Besides motif analysis, it can be useful to analyze the detected genes for enriched pathways. 
Pathway analysis is the process of identifying interactions and associated annotations171. For 
the detected flanking genes it may provide insight how genes are regulated and which processes, 
functions or networks were involved. Both commercial and noncommercial entities provide 
pathway analysis. A commercial tool is Ingenuity Pathway Analysis (Ingenuity® Systems, http://
www.ingenuity.com, IPA 8.8). Networks in IPA are created using literature-based records that 
are maintained in the Ingenuity Pathway Knowledge Base. It computes a network-score for the 
overlap of the focus genes with a global molecular network. Alternatively, Gene Set Enrichment 
Analysis (GSEA)97 provides both software and a collection of annotated gene sets (MSigDB: 
Molecular Signature Database) that can be used for the detection of pathways and/or gene 
sets (noncommercial). Depending on the research question, different gene sets can be used: 1. 
BioCarta pathways, describing the molecular relationships derived from active research areas, 
2. KEGG pathways, describing the molecular interactions and reaction networks, 3. Reactome 
pathways, manually curated and peer-reviewed pathways, 4. GO biological processes, gene 
sets describing the biological process ontology, 5. Transcription factor targets (TFT), gene sets 
contain genes that share a transcription factor binding site (TFBS), and 6. MicroRNA targets, 
Gene sets that contain genes that share a 3’ UTR microRNA-binding motif.
NOTES
Different methodologies come to different results, what is the correct one to choose?
All previously described methods have been reported to validate some of the detected ROI as 
described in the first section, “Introduction”. Nevertheless, different statistical methodologies 
lead to differences in the detected ROI. We hypothesize that various methodologies may results 
in similar detected ROI which are most likely the genomic regions that contain a contiguous 
number of probes with high probe intensity levels (the results of two methods are shown in 
section 3 “Analyzing tiling-array data sets”). In addition, the differences between detected 
ROI among various methodologies are likely the genomic regions with subtle changes in probe 
intensity levels. Note that some developed methodologies are designed for the analysis of one 
type of tiling-array application. Others may require various parameters to set before starting 
the analysis, e.g., by defining the ROI using the maximum and/or minimum number of probes 
in a genomic region, maximum gap size between two probes and threshold. Changing one of 
the parameters will affect the final results. It is therefore always recommended to perform 
additional analysis after the detection of ROI to ensure confidence about the gained results. 
We demonstrated this in section 3 “Analyzing tiling-array data sets”, where we detected 1211 
ROI that were exclusively found for HAT. A motif analysis showed significant enrichment for 
the STAT-consensus binding site. Such findings may help deciding which method to use. It is 
important to note that in the end laboratory experiments are indispensable to demonstrate the 
biological significance of particular that ROI, identified by means of tiling-array analysis.
How to continue if no significant regions-of-interest are detected?
The analysis of tiling-array data (section 3 “Analyzing tiling-array data sets”) can result in 
the absence of significantly enriched ROI. This indicates that probe intensity values, by the 
hybridization of DNA-fragments on chip, showed no significant differences compared to the 
background data-file. In case the hybridization process on chip is successfully performed (i.e., 
DNA-fragments are immunoprecipitated) and the background data-file is correctly provided into 
the model, it still may result in the absence of significantly enriched ROI. Note that analysing 
experimental data-files without the usage or incorrect usage of a background data-file can lead to 
the absence of significantly enriched ROI or the detection of false positive ROI. If no significantly 
enriched ROI are detected, it should be considered that no DNA-binding did take place and 
therefore no ROI were detected. Alternatively, one could decide to increase the significance 
level alpha and rerun the analysis. Note that the false positive rate increases by using alpha 
> 0.05. It is therefore highly recommended to validate the ROI by qPCR. As an example, it is 
demonstrated that a MeDIP-on-chip experiment resulted in the detection of 15 ROI56. These are 
detected without using a background56. Although there was supporting evidence that all 15 ROI 
may be valid (additional analysis showed that all ROI contained a nearby restriction site), only 
eight viral integration sites could be validated by directed PCR followed by Sanger sequencing56. 
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The remaining seven ROI may therefore be the result of technical variation which may have been 
prevented by using a background file.
How to determine the best flanking gene for a detected regions-of-interest?
The usage of tiling-array data does not provide information regarding the strand (positive or 
negative) or genes affected by the putative promoter. It only indicates the probe intensity 
values and their genomic positions. If a particular genomic region is marked as a potential ROI, 
the responsible immunoprecipitated DNA-fragment is suggested to show binding, e.g., via an 
immunoprecipitated transcription factor, that could bind to the DNA strand. The ROI is then 
linked to the gene in close vicinity (Figure 3). The use of an UCSC-browser track may help 
manually curating the ROI to a gene. Alternatively, it requires biological experiments to validate 
whether the binding had an effect on the regulation of a gene. Note that promoter tiling-arrays 
(as described in section 2 “materials”) only contain probes of which the genomic locations are in 
the promoter regions of genes and therefore simplifies the gene mapping procedure. 
How to run HAT with RAW cell files?
HAT is built generically to analyze different applications and platforms of tiling-array data (as 
described in section “Introduction”). On the contrary, normalization may differ between different 
applications and platforms of tiling-arrays, e.g., one-color arrays of Affymetrix versus two-color 
arrays of Nimblegen. Including a normalization step into the model would therefore limit the 
model to one type of tiling-array. RAW cell files need to be normalized based on the type of 
tiling-array88, and then used as an input into the model (Figure 2). 
How to install HAT in Windows or an UNIX environment?
The installation of HAT requires an x86-64 Windows or UNIX-based system and 4GB memory or 
more is highly recommended. Both platforms require the installation of MATLAB or the freely 
available MATLAB Compiler Runtime (MCR) which is a standalone set of shared libraries that 
enable full functioning of HAT. Documentation regarding the installation procedure can be 
found on: http://www.erasmusmc.nl/hematologie/ or http://hema13.erasmusmc.nl/index.php/
HATSEQ.
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ABSTRACT
C/EBPα is a transcription regulator that is essential for normal neutrophil development. We 
hypothesize that methylation and consequent silencing of the gene encoding C/EBPα is an 
abnormal event that occurs in a subset of human acute leukemias. This recently identified 
CEBPAsilenced group subtype has a unique epigenetic feature, i.e. silencing of the gene that encodes 
CCAAT-enhancer binding protein alpha (C/EBPα) by DNA hypermethylation. The leukemic 
blast cells of these patients express myeloid as well as T-lymphoid markers. Moreover, gene 
expression and DNA-methylation profiling stratifies these leukemias in between Acute Myeloid 
Leukemia (AML) and T-lymphoid Acute Lymphoblastic Leukemia (T-ALL). We carried out gene 
expression profiling of the CEBPAsilenced group and identified the genes that were differentially 
expressed in this AML subtype compared to other AMLs and normal marrow blast cells. To 
assess whether these genes are C/EBPα targets and whether expression has been altered as 
the result of CEBPA loss of expression, we transduced an estrogen-inducible C/EBPα construct 
in 32D cells and carried out ChIP-on-chip using ER specific antibodies. We detected 529 
C/EBPα target genes that were subsequently overlaid with the differentially expressed genes in 
the CEBPAsilenced group. This resulted in 49 overlapping genes (P = 1x10-7) that are indicative as 
putative direct targets. We hypothesized that the downregulated genes, that overlap with the 
C/EBPα target genes (n=25, P = 1.2x10-3) represent targets that are normally activated by 
wild-type C/EBPα. The upregulated genes, that overlap with the C/EBPα target genes (n=24, 
P = 1.6x10-5) are assumed to be repressed in wild-type C/EBPα expressing cells and activated 
when CEBPA is silenced. A selection of the latter group of genes appeared to be upregulated 
in hematopoietic stem cells of Cebpa knock-out mice as well, emphasizing a putative repressor 
function of this transcription factor for certain genes. We hypothesize that CEBPA silencing is 
a transforming event that allows the expression of lymphoid genes to take place in a subset 
of leukemias with myeloid/T-lymphoid features. These genes are predicted to be repressed by 
direct promoter interaction with C/EBPα in normal myeloid progenitors and in other AMLs. 
INTRODUCTION
Myeloid committed progenitors are under tight control of combinations of transcription factors 
that modulate gene expression in order to maintain a balance between differentiation and 
proliferation. Transcription factor CCAAT/enhancer binding protein alpha (C/EBPα) is one of the 
master regulators of myeloid differentiation165,166. C/EBPα mRNA encodes a 42kDa (p42) protein, 
and a shorter isoform of 30kDa (p30)53,172-174. Both isoforms share a highly conserved C-Terminal 
domain that contains a basic region required for DNA-binding and a leucine zipper (bZIP) essential 
for homo or heterodimerization. The N-terminal domain is less conserved and consists of two 
transcription activation domains (TADs) that contribute to cell growth inhibition. Both isoforms 
appear to be expressed at a constant ratio which is possibly required to maintain the function 
of C/EBPα and regulate normal differentiation. Deregulation of CEBPA expression causes an 
imbalance in myeloid differentiation175. In Cebpa knock-out mice, neutrophil development is 
disrupted and consequently only myeloblasts are detectable in the marrow of these mice175. 
The functional importance of CEBPA in myel opoeisis is further supported by its deregulation in 
various subsets of AML patients18. In AML with recurrent translocations t(8;21), expressing the 
translocation specific AML1-ETO fusion gene, CEBPA has been reported to be downregulated 
by the oncogenic fusion protein176. Mutations in CEBPA, the gene encoding C/EBPα, have been 
demonstrated in multiple studies52,53,177. These mutations have been found in the N-terminus or 
in the C-terminus of the protein, and can either occur in a monoallelic or biallelic fashion178,179. As 
a consequence, these mutations impair differentiation of hematopoietic progenitors40,180. 
A subset of AML patients, previously characterized as CEBPAsilenced AMLs, lack CEBPA expression 
due to an aberrant DNA hypermethylation pattern. This subset of patients have a distinct 
phenotype when compared to other AMLs; their leukemic cells express myeloid surface antigens 
CD13 and CD33 as well as T-lymphoid markers. The most consistently expressed surface protein 
is CD7, while other T-cell related genes are also expressed such as LCK, TRIB2, CD3D, CD3G, 
TRD@ and NOTCH161. We recently demonstrated a similar reverse correlation between CEBPA 
and lymphoid genes in myeloblasts from Cebpa knock-out mice175 61. These findings made us 
hypothesize that there is a negative regulatory control of a set of genes by C/EBPα and that these 
genes, of which many are T-cell related, are transcriptionally activated in case the expression of 
CEBPA is turned down. The data that we provide in this study are in support of a hypothesis of a 
direct negative regulatory control of a set of genes by C/EBPα. 
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MATERIAL AND METHODS
Data
Two Large scale datasets were used in this study: ChIP-on-chip data using Affymetrix GeneChip 
Mouse Promoter 1.0 array, derived from an inducible CEBPA expressing myeloid cell line 
model of three wild-type C/EBPα-ER clones and two control clones (C/EBPα-mutant-ER) and 
three control clones expressing a construct that only contains ER. Data is available at the NCBI 
Gene Expression Omnibus (GEO), accession number GSE19321. Secondly, genome wide gene 
expression profiles were generated for 506 de novo AMLs and 11 normal CD34+, using Affymetrix 
U133 Plus 2 microarray (Santa Clara, CA, USA) previously18. GEP data are available at the 
Gene Expression Omnibus (National Center for Biotechnology Information; accession number 
GSE14468 (HOVON-SAKK cohort). Sample processing and quality control were carried out as 
described previously18,181. Normalization of raw data was processed with Affymetrix Microarray 
Suite 5 (MAS5) to target intensity values at 100. Intensity values were log2 transformed and 
mean centered per probeset. 
Chromatin immunoprecipitation on DNA promoter microarrays
Chromatin immunoprecipitation (ChIP) was carried out according to a protocol from Affymetrix 
(Santa Clara, CA, USA). Genome wide discovery of C/EBPα targets was conducted using ChIP from 
a beta-estradiol induced C/EBPα in a myeloid cell line model (32D) followed by promoter array 
hybridizations (for details see supplementary material, section: C/EBPα-ER cells differentiate upon 
E2 treatment while C/EBPα-mutant-ER cells show impaired differentiation). This chip contains 
4.6 million perfect match probes over 28000 mouse promoter-regions. Promoter-regions have 
10Kb coverage for each promoter-region and each probe has a size of 25 nucleotides. Clones 
express either beta-estradiol inducible C/EBPα-ER or beta-estradiol inducible C/EBPα-mutant-
ER. The mutant has an insertion of 6 amino acids in the bZIP domain and previously found in 
a human AML patient36 (for details see supplementary material, section: Plasmids). It showed 
less pronounced inhibition of proliferation upon treatment with E
2
 in the presence of IL3. In 
the presence of G-CSF, C/EBPα-mutant-ER cells also demonstrated delayed differentiation with 
the suggestion of a partial block. Chromatin immunoprecipitations were carried out using an 
antibody directed against ER in the beta-estradiol treated cells (E
2
 for 4 hours) and the DNA 
obtained from these cells, after immunoprecipitation, was hybridized to Affymetrix promoter 
chips.
METHODS
Aberrant genes that are specific for the CEBPAsilenced group in human AML are derived by 
comparing the gene expression data of the CEBPAsilenced patients (n=10) against CD34+ samples 
(n=11) and against the remaining AML group (n=496) using a three-way ANOVA and a post-
hoc test. The post-hoc test is based on the tukey-kramer method which is used to select genes 
that significantly differed between: 1) CEBPAsilenced group versus CD34+ group and, 2) CEBPAsilenced 
group versus the other AMLs. Genes are considered to be differentially expressed when mRNA 
levels differed with P ≤ 0.05 after multiple testing (using the family wise error rate, FWER). 
Binding of C/EBPα in 32D cells was determined by utilizing Hypergeometric Analysis of Tiling-arrays 
(HAT182) after normalization of the raw probe intensity data74. As a result of this normalization, 
probe intensity values follow a normal distribution with a negative mean. Probe intensities that 
may be the result of hybridization of labeled DNA on the chip, have values greater than zero and 
are processed to determine candidate C/EBPα binding regions. A binding event was called when 
fragments are enriched with significance level < 0.05 and, maximum fragment size of 600bp. This 
fragment size correlates with the average sonicated fragment sizes, being 600bp. Furthermore, 
we considered only genes from which the enriched binding region to the transcriptional-start-
site (TSS) was located within 2Kb and, binding of C/EBPα in the promoter-region was detected in 
two or more clones. Gene-symbols are annotated using HAT182 and mapped using NCBI murine 
Genome Build 36 (February 2006). This resulted in the identification of 529 unique genes, by 
comparing C/EBPα-ER clones (n=3) versus C/EBPα-mutant-ER clones (n=2). It is expected that the 
mutations inserted in the bZIP domain of C/EBPα-mutant-ER clones disrupt the physical binding 
of C/EBPα with DNA motif sequences of downstream target genes. More detailed information 
about the detected binding regions and enriched motifs can be found in supplementary material 
(candidate C/EBPα targets: ChIP-on-chip promoter arrays).
Transcription Factor Binding Site analysis - For the identification of transcription factor binding 
sites (TFBSs), we used F-MATCH163 to scan the 2Kb upstream regions, from the TSS, for occurrence 
of one or more of the 656 highly specific position weight matrices (high-PWMs) gathered from 
the TRANSFAC Pro database. A TFBS was called when its PWM is enriched at P ≤ 0.001. As a 
background set we selected 2Kb upstream sequences (starting from the transcription start site) 
of 5000 randomly selected genes that are not associated with C/EBPα in terms of binding, using 
the 32D model-system or identified as differential expressed for the CEBPAsilenced group. The 2Kb 
upstream sequences for each gene were retrieved from the UCSC database (http://hgdownload.
cse.ucsc.edu/goldenPath/).
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RESULTS
Genes involved in T-cell development are differentially upregulated in CEBPAsilenced leukemias
To identify genes differentially expressed in CEBPAsilenced AMLs (n=10), we compared their 
gene expression profiles with those of CD34+ normal bone marrow (n=11) and of the other 
AML cases18 (n=496). Six hundred eighty-nine differentially expressed genes were identified 
in CEBPAsilenced leukemias, of which 286 (blue circle in Figure 1A) were upregulated and 403 
downregulated (green circle in Figure 1A). Twenty pathways were significantly represented by 
Ingenuity pathway analysis (IPA) using both up and downregulated genes (Figure 1B). Genes 
involved in T-cell development appeared to be highly enriched. Notably, the genes upregulated 
in CEBPAsilenced leukemias were more frequently annotated with T-cell functions than the 
downregulated genes. Therefore we carried out pathway analysis of the 286 upregulated or 
403 downregulated genes separately and identified 42 and 80 unique pathways (P < 0.001) 
respectively. We indeed observed associations with (T-) lymphocytes for the enriched pathways 
specific for the upregulated genes in CEBPAsilenced leukemias (Figure S1A). Pathways specific for 
the downregulated genes (Figure S1B) included myeloid associations, such as pathways that 
are involved with macrophage, neutrophil or dendritic cell development. Besides analysing the 
pathways associated with molecular, cellular and developmental functions we also analysed 
the canonical pathways and detected a strong relation with T-cell development/function for 
the upregulated genes, in contrast to the downregulated genes in leukemias with CEBPA being 
switched off (Figure S2 and Table S1). These data suggest a relation between the absence of 
CEBPA and activation of T-cell related genes. 
We next investigated the presence of transcription factor binding sites (TFBSs) in the promoter 
regions (2Kb upstream region of the TSS) for the 286 upregulated and 403 downregulated genes. 
We detected 13 and 4 unique significantly enriched TFBSs with fold-increase > 1.5 respectively 
(Table S2). Among the upregulated or downregulated genes we did not detect C/EBPα consensus 
binding sites (CEBP). We predict that only a fraction of the differentially expressed genes are true 
targets of C/EBPα, which would explain why no consensus site was found. 
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Figure 1. Overview CEBPAsilenced targets genes and enriched pathways. (A) Genes that are bound by wild-type C/EBPα in 
the 32D model-system (n=529, yellow circle), and that overlap with the CEBPAsilenced leukemias when compared to normal 
CD34+ and versus the other AMLs. The blue circle indicates the upregulated (n=286) genes from which 24 genes are 
bound by C/EBPα in the proximal promoter region. The green circle indicates the downregulated (n=403) genes from 
which 25 genes are bound by C/EBPα in the proximal promoter region. (B) Graphical representation of enriched pathways 
(shown in bar graphs) that overlapped between the 286 upregulated and 403 downregulated genes. (C) Graphical repre-
sentation of the enriched categories for the 24 upregulated and 25 downregulated genes that were bound by C/EBPα in 
the 32D model-system. 
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C/EBPα requires its DNA-binding domain to induce myeloid differentiation
Abnormal myeloid maturation in the bone marrow of Cebpa knock-out mice defines the critical 
function of CEBPA as a potent inducer of myeloid differentiation. Upon the loss of CEBPA 
expression in CEBPAsilenced AML, it is hypothesized that a subset of genes involved in myeloid 
lineage commitment and differentiation are aberrantly regulated and differentially expressed. 
Briefly, cells were retroviral transduced with murine C/EBPα coding sequence fused to the 
ligand-binding domain (LBD) of the human estrogen receptor alpha (ERa) (C/EBPα-ER), acting as 
an inducible system upon estradiol (E
2
) exposure. The LBD of ERa engages E2, become activated 
and relocate to the nucleus as a CEBPA-ER fusion protein. Once C/EBPα is in the nucleus, it 
accesses regulatory regions of downstream target genes that are responsible for myeloid 
differentiation.
E2-induced differentiation was observed when the cells were cultured in the presence of 
interleukin 3 (IL-3) (Figure S3A and B)) or G-CSF183 (Figure S3C and D) showing that C/EBPα is 
a potent inducer of differentiation even at proliferative conditions when cells were cultured 
in the presence of IL-3. A construct expressing the LBD of ERa (ER) only (without C/EBPα) was 
introduced into 32D cells that did not differentiate upon E
2
 exposure when cultured in the 
presence of IL3 (Figure S3B). In the presence of G-CSF these cells showed the expected neutrophil 
development (Figure S3D). To study requirement of DNA-binding of C/EBPα-ER protein, a mutant 
was constructed, which carried an insertion of 6 amino acids in the bZIP domain of C/EBPα (C/
EBPα-mutant-ER). This mutant was identified in a human AML patient and was predicted to 
lack DNA-binding activity27. Morphological analysis revealed that differentiation of the C/EBPα-
mutant-ER 32D cells was absent when stimulated with IL3 plus E
2
 (Figure S3A and B). Strongly 
delayed differentiation was observed when cells were stimulated with G-CSF plus E2 (Figure S3C 
and D). We hypothesized that defective differentiation by mutant CEBPA was caused by a lack of 
ability to bind DNA and to regulate the expression of genes critical for myeloid differentiation. 
We postulate that these genes can be identified using chromatin immunoprecipitation (ChIP) 
and by comparing the binding of C/EBPα-ER versus C/EBPα-mutant-ER in 32D cells.
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Figure 2. C/EBPα binding for Il6ra. (A) Affymetrix genome browser illustrates relative probe intensity signal with 
vertical bars of three C/EBPα-ER clones compared to C/EBPα-mutant-ER. The red rectangle illustrate the significantly 
detected binding region in the promoter region of Il6ra in all C/EBPα-ER experiments. (B) Bar plots depicts the binding of 
C/EBPα-ER and ER in three experiments using a quantitative ChIP-Q-PCR.
Discovery of C/EBPα interacting loci in C/EBPα-ER 32D cells
Anti-ER ChIP was carried out for C/EBPα-ER and C/EBPα-mutant-ER 32D clones followed by 
Affymetrix promoter chip hybridization. The immunoprecipitated fragments were analyzed 
using HAT which resulted in the detection of C/EBPα-ER binding regions, i.e. loci that interacted 
with C/EBPα-ER but not with mutant C/EBPα-ER within 529 unique gene promoters. Among 
those previously described C/EBPα targets were present, as an example, the binding of C/EBPα 
to the Il6ra82 promoter (Figure 2A). These results were validated using a quantitative ChIP-Q-PCR 
experiment for Il6ra (Figure 2B). 
Transcription factor binding site analysis revealed that only the CEBP consensus binding site 
was significantly enriched (Table S3, P < 1x10-28) in the detected binding regions within the 
529 promoters. The detected binding sites were uniformly distributed within the upstream 
sequences (Figure S4). Using this approach we identified several known but also many novel 
putative target genes of C/EBPα.
Differentially expressed genes in CEBPAsilenced leukemias are enriched for C/EBPα target genes
We next addressed the question whether among the 689 differentially expressed genes identified 
in CEBPAsilenced leukemias, direct C/EBPα targets were present that were identified by ChIP-on-
chip using the C/EBPα-ER 32D model. We overlaid the 529 C/EBPα targets found in the 32D 
model-system (yellow circle in Figure 1A) with the 689 differentially expressed genes identified 
in CEBPAsilenced leukemias (green circle and blue circles in Figure 1A) and found an overlap of 49 
genes (Figure 1A). The chance that two gene sets of this size show an overlap of 49 genes is 
P = 1x10-7. Of these 49 genes, 25 were downregulated and 24 upregulated in CEBPAsilenced 
leukemias (P = 1.2x10-3 and P = 1.6x10-5 respectively, Table 1). A selection of these genes are 
depicted in the heat map in Figure 3. These data suggest that upon binding to a promoter, 
C/EBPα may affect the expression of a putative target gene in different ways, i.e. it may act as a 
transcriptional activator or it may function as a repressor of transcription. 
Table 1. Candidate target genes for CEBPAsilenced, prior the scenarios of the 32D model-system. 
Group
Overlap with wild-type C/EBPα in 32D cells (n=529)
Upregulated Downregulated
CEBPAsilenced
ACAD8, ATP6V1B2, B3GNT2, B4GALT1, 
BCL2*, CASP1, CCR9*, CD47, CEBPG*, 
CEPT1, FBXW2, GOPC, HMGCR, MAP2K4, 
MRPL41, NIN, NMT1, OGT, SEPX1, SLC7A11, 
SSBP2, STK38, UBTD1, YPEL1 
ACSL1, ARSB, ATP6V0A1, COL4A3BP, CTSB, 
DEGS1, EVI2B, FOSL2, FYB, GOSR1, H2AFJ, HIPK1, 
HSP90B1, IRAK3, LIN7C, MBTD1, MSRA, MYCT1, 
PLA2G4A, PLEK, PPM1A, PXK, RANBP9, STX11, 
TOB1
(689 genes) (49 genes, P = 1x10-7)
Human gene-symbols are listed that overlapped with the candidate C/EBPα target genes from the 32D model and were 
called differential expressed for CEBPAsilenced group. The P-value indicates the probability of detecting this overlap by 
chance. Gene-symbols with an asterisk are previously reported in literature to interact with C/EBPα. 
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Figure 3. Aberrant mRNA expression levels of C/EBPα target genes in the CEBPAsilenced group. Pairwise correlations 
between the 506 AML cases (A). The cells in the visualization are colored by Pearson correlations values, depicting higher 
positive (red) or negative (blue) correlations, as indicated by the scale bar. The cytogenetical groups; inv(16), t(8;21), 
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upregulated and 11 downregulated genes we illustrate the expression profile on the diagonal as black bars that were 
detected as significantly differential expressed in human AML and bound by C/EBPα in the 32D model-system. 
The putative C/EBPα target genes upregulated in CEBPAsilenced leukemias are relevant for T-cell 
development
We hypothesize that among the 24 genes that are upregulated in CEBPAsilenced leukemias 
and bound by C/EBPα, are under normal conditions repressed in myeloid cells upon C/EBPα 
interaction. We already demonstrated that the 286 upregulated genes in CEBPAsilenced AMLs 
were enriched for T-cell associated genes. Pathway analysis for these 24 upregulated genes in 
CEBPAsilenced leukemias showed enrichment for pathways involved in T-cell development (Figure 
1C and Table S4). The networks are illustrated in Figure S5A-C. This observation suggests that 
the transcription factor C/EBPα may act as a repressor of genes such as BCL2, CCR9, B3GNT2, 
CD47, CASP1 or MAP2K4.
Twenty-five C/EBPα genes bound in the 32D model were absent in CEBPAsilenced human AML 
but transcribed in other myeloid leukemias. Apart from TOB1, these genes appeared not to be 
associated with T-cell related functions (Figure 1C, Table S4 and Figure S5D-E). In fact, TOB1 is 
a gene that encodes an inhibitor of transcription of cytokines and cyclins and represses T-cell 
proliferation. 
T-cell related genes are upregulated in Cebpa knock-out murine bone marrow progenitor 
cells
To study whether the regulation of the differentially expressed genes required C/EBPα in normal 
myeloid progenitors, a Cebpa-knock-out (KO) mouse model-system was applied. We purified 
short-term (ST, n=2) and long-term (LT, n=2) hematopoietic stem cell (HSC) from wild-type 
as well as Cebpa-KO bone marrow as decribed previously184, isolated mRNA and carried out 
microarray hybridizations. We selectively studied the 49 genes (Table 1) and compared the 
mRNA-expression of those genes in ST-HSCs and LT-HSCs. We overlaid the 24 upregulated genes 
in CEBPAsilenced leukemias (Table 1) with the genes that showed a fold-increase of > 1 in separately 
the KO-LT-HSC and KO-ST-HSC and detected an overlap of 6 genes, including CCR9 and CEBPG 
(Figure S6A-B). These genes are strongly upregulated in the absence of wild-type CEBPA, 
indicating a putative role for C/EBPα as a repressor in HSCs. For the 25 downregulated genes 
in CEBPAsilenced leukemias (Table 1), we detected downregulation for 11 genes in the Cebpa-KO 
marrow HSCs, among them TOB1 (Figure S6C-D). 
C/EBPα acts synergistically with other transcription factors for T-cell repression
To reveal transcriptional modules that contribute to the activation of genes, we analyzed the 
promoter regions of the 49 genes. The C/EBPα consensus binding sites were detected in the 
promoter regions of 20/24 and 16/25 upregulated and downregulated genes respectively. The 
promoter regions of the upregulated genes (n=24) revealed 27 significantly enriched TFBSs 
for 23 families. Besides the C/EBPα consensus site and sites that are described in literature to 
interact synergistically with wild-type C/EBPα (PU.1185,186, SP1187 and E2F188,189), we also detected 
20 other TFBSs which are listed in Table S5. Interestingly, for E2F it has been reported that it 
interacts with CEBPAwt and is involved in the downregulation of genes188,189. We furthermore 
detected E4BP4190 for which is known to be involved in the regulation of T-cell interleukins. 
Transcription factor (TF) interactions are a crucial aspect of the gene regulatory system191. Thus 
the T-cell repressor function of C/EBPα may be performed by synergistically interacting with 
these transcription factors185,186,188,189,192-194.
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DISCUSSION
In this study, we investigated the DNA-interaction of exogenous C/EBPα on target loci using 
CHIP coupled with genome wide promoter arrays. We determined C/EBPα interaction in a 
32D model and compared the binding of C/EBPα with a C-terminal DNA-binding mutant form 
that was previously found in AML35. Moreover, we demonstrate that combining ChIP-on-chip 
with gene expression data reveals the effects of direct target interactions. More specifically, 
we identified a subset of putative C/EBPα target genes that were differentially expressed in 
CEBPAsilenced AMLs compared to CEBPA expressing AML samples. Importantly, the overlapping 
list of gene promoters was highly enriched for C/EBPα binding sites. In other words, this list 
may contain genes that are bound by wild-type and not by mutant C/EBPα through interaction 
with “classical” C/EBPα binding sites. It is predicted that differential gene expression profiles 
between CEBPA silenced and other AML samples is at least partially causing the effects. The 
overlap was highly significant, meaning that determining actual binding of C/EBPα to promoters 
in a murine cell line model, provides insight into the effects of C/EBPα in human AML cells. It is 
important to realize that the use of array-data, such as ChIP-on-chip is limited to the promoters 
defined on the chip. A large number of regulatory regions lie outside the promoter regions and 
sometimes at long distances from the genes targeted by these factors. It will therefore be of 
interest to carry out deep sequencing rather than ChIP hybridizations following chromatin-IP 
of wild-type versus mutant C/EBPα binding in 32D model. Moreover, we compared binding of 
C/EBPα in mouse models, and it is known that there are differences between mouse and human 
myeloid cells. Our data show that it is possible to identify direct targets of transcription factors 
in leukemia samples.
We overlaid the detected direct binding targets of C/EBPα in 32D cells, with the differentially 
expressed genes in the CEBPAsilenced group and identified 49 overlapping genes as putative 
direct targets. Among these 49 genes, 25 were downregulated and 24 were upregulated in 
the primary CEBPAsilenced AML group. The 25 downregulated genes represent putative targets of 
C/EBPα that are activated under normal conditions. The 24 upregulated genes are highly enriched 
for pathways in T-cell development and are repressed in wild-type CEBPA expressing cells and 
activated when CEBPA was silenced. This suggests that the transcription factor C/EBPα may also 
acts as a repressor of gene transcription. Transcription factor binding site analysis showed that 
20 of the 24 upregulated genes contain the CEBP consensus sequence. Moreover, other known 
transcription factor binding sites, e.g. PU.1185,186, SP1187 and E2F188,189 were found as well in the 
promoter regions (all located within 2kb). Transcription factors recognizing these binding sites 
were previously identified to interact with C/EBPα. Interestingly, E2F has been reported to be 
involved in the downregulation of genes188,189. In fact, it was recently shown that CEBPA represses 
Cebpg expression by affecting E2F1 transcriptional activity184. In luciferase reporter assays using 
the C/EBPg proximal promoter it was demonstrated that both C/EBPα isoforms, i.e. the p30 
and the p42 isoform can repress C/EBPg transactivation. Our studies are also in line with our 
previous report, showing that multiple T-cell related genes, e.g. CD7 or LCK are downregulated by 
C/EBPα195. Similar to what we have demonstrated here, these genes were strongly upregulated 
in mouse bone marrow LSK cells in which Cebpa was knocked out. Upon reintroduction of 
Cebpa, the expression of these genes rapidly declined195. Taken together, these findings suggest 
that C/EBPα can not only act as an activator, but also as a repressor of transcription. Whether 
C/EBPα functions as an activator or a repressor is most likely determined by distinct complexes 
containing additional transcriptional repressors and activators. Both functions seem essential 
for a proper balance between proliferation and differentiation of primitive progenitor cells in 
the bone marrow.
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SUPPORTING MATERIAL
C/EBPα-ER cells differentiate upon E2 treatment while C/EBPα-mutant-ER cells show impaired 
differentiation
Stable 32D clones expressing a fusion protein of murine C/EBPα and the ligand-binding 
domain (LBD) of the human estrogen receptor alpha (ERá) (C/EBPα-ER) were generated. 32D 
cells proliferate when stimulated with IL-3 and differentiate into granulocytes when induced 
by G-CSF183. Upon addition of E
2
, C/EBPα-ER cells morphologically differentiated into mature 
granulocytes even in the presence of IL-3 (Figure S3A), while their proliferation rate dropped 
(Figure S3B). This effect appeared even more pronounced when the cells were treated with 
G-CSF plus E2. (Figure S3, panel C-D). As expected, control cells only expressing the LBD of ERá 
(ER) did not show a response to E
2
 (Figure S3B and data not shown).
32D cells expressing a mutant C/EBPα-ER fusion with an insertion of 6 amino acids in the 
bZIP domain (C/EBPα-mutant-ER) as previously found in a human AML patient36 showed 
less pronounced inhibition of proliferation upon treatment with E
2
 in the presence of IL3. 
Morphological differentiation of these cells could hardly be detected under IL3 plus E2 conditions 
(Figure S3A-B). In the presence of G-CSF, C/EBPα-mutant-ER cells demonstrated delayed 
differentiation with the suggestion of a partial block (Figure S3C).
Candidate C/EBPα targets by using ChIP-on-chip promoter arrays
For the detection of candidate target genes that are bound by wild-type protein C/EBPα, we 
used HAT182 and compared C/EBPα-ER clones (n=3) to C/EBPα-mutant-ER clones (n=2). The 
C/EBPα-mutant-ER clones cannot bind to the DNA compared to the ER clones, and eliminates 
DNA-binding effects caused by ER. In any of the wild-type C/EBPα-ER clones versus C/EBPα-
mutant-ER, we detected 2732 statistically significant binding regions sized between 104 and 
9928 nucleotides (median 823nt); 80% (2185) of these binding regions were detected in two or 
more clones whereas the 2732 binding regions could be mapped to 964 unique genes within 2Kb 
of the transcriptional-start-site.
To investigate the enrichment of transcription factor binding motifs for the detected binding 
regions, we utilized F-MATCH163,164. This resulted in the detection of six highly enriched TFBSs 
(P < 1x10-28) from which five are known to be C/EBPα consensus sites. Furthermore, TFBSs were 
four times more observed than in the background set (fold-increase > 4) (Table S3). This indicates 
high specificity of C/EBPα binding in the detected regions.
Among the mapped genes we observed genes that have previously been reported to be 
regulated by C/EBPα, such as Il6ra82, C352, Hp52, Mpo196, Myc197 and Sfpi1198. The gene encoding 
the IL-6 receptor alpha has previously been identified as a critical downstream target of C/EBPα. 
These latter findings give confidence, that among the putative novel C/EBPα target genes, critical 
players may be hidden, important in neutrophilic development and consequently in myeloid 
transformation.
Plasmids
A pBabe-Cebpa-ER fusion construct and pBabe-ER construct were provided by Dr. Daniel Tenen 
(Harvard Institutes of Medicine, Boston, MA, USA). The Cebpa-ER fusion gene was re-cloned into 
the pLNCX-neo vector using polymerase chain reaction (PCR) amplification with primers that 
included appropriate restriction sites, i.e. HpaI and ClaI. Primer sequences were: fw 5’-GTA CGT 
TAA CAG GAA TTC GCG CCA CCA TGG A-3’ and rev 5’-AGG AAT CGA TCT CTC AGA CTG TGG CAG 
GGA A-3’. A mutant construct was generated using the QuikChange site-directed mutagenesis 
kit (Stratagene, La Jolla, CA, USA), using the following oligos (insertion mutation is underlined): 
5’-GAT AAA GCC AAA CAA CGT AAT GTG GAC AAG CAG CGC AAC GTG GAG-3’ (sense) and 5’-CTC 
CAC GTT GCG CTG CTT GTC CAC ATT ACG TTG TTT GGC TTT ATC-3’ (anti-sense). A pLNCX-ER 
construct was generated with primers fw 5’-TAT GGT TAA CAT CTG CTG GAG ACA TGA GAG 
CT-3’ and the reverse primer used for the Cebpa-ER construct. The cloned constructs and site of 
inserted mutation were nucleotide-sequenced.
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Figure S1. Enriched functional pathways for the 286 upregulated and 403 downregulated genes that are detected in 
the CEBPAsilenced cases. Graphical representation of the functional pathways (shown in bar graphs) that are significantly 
enriched in (A) 286 upregulated genes, and (B) 403 downregulated genes for the CEBPAsilenced AMLs.
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Figure S2. Enriched canonical pathways for the 286 upregulated and 403 downregulated genes that are detected in 
the CEBPAsilenced cases. Graphical representation of the canonical pathways (shown in bar graphs) that are significantly 
enriched in (A) 286 upregulated genes, and (B) 403 downregulated genes for the CEBPAsilenced AMLs.
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Figure S3. Differentiation of C/EBPα among IL3 conditions. (A) Representative cytospins of C/EBPα-ER cells (clone 
C-E.4) and C/EBPα-mutant-ER cells (clone Cmut-E.9) in the absence (-) and presence (+) of E
2
 for 3 or 7 days. The cells 
were cultured in the presence of IL3. (B) Proliferation curves of C/EBPα-ER cells (C/EBPα) and C/EBPα-mutant-ER cells 
(C/EBPα-mutant) stimulated with IL3 alone (IL3 -) or IL3 in combination with E2 (IL3 +est). The graph represents the 
average and standard deviations for the individual clones for the cell types. (C) Representative cytospins of C/EBPα-ER 
cells (clone C-E.4) and C/EBPα-mutant-ER cells (clone Cmut-E.9) in the absence (-) and presence (+) of E2 for 3 or 7 
days. The cells were cultured in the presence of G-CSF. (D) Proliferation curves of C/EBPα-ER cells (C/EBPα) and C/EBPα-
mutant-ER cells (EBPα-mutant) stimulated with G-CSF alone (G-CSF -) or IL3 in combination with E2 (G-CSF +est). The graph 
represents the average and standard deviations for the individual clones for each of the cell types.
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Figure S4. Distribution of the detected CEBP consensus sites. Graphical representation of the genomic distance (base 
pairs; bp) for the CEBP consensus sites that are detected in the proximal promoter regions of the 529 genes. Dark blue is 
the average number of sites detected per position whereas light blue the actual number of sites per position.
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Figure S5. Enriched networks for the 24 upregulated and 25 downregulated genes that are detected in the CEBPAsilenced 
cases. Illustration of networks that are enriched using IPA for the 24 upregulated genes (panel A, B and C), and 25 down-
regulated genes (Panel D and E). The genes are dark grey coloured in the networks and are bound by wild-type C/EBPα 
in the 32D model system and differentially expressed in the CEBPAsilenced group.
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Figure S6. Validation with LT-HST and ST-HST Cebpa-KO mouse and wild-type 32D C/EBPα-ER cell line. The 24 upregu-
lated genes among the CEBPAsilenced leukemias are overlaid with (A) the genes that showed a fold-change > 1 in the 
ST-HSC wild-type versus ST-HSC knockout expression levels and (B) the genes that showed a fold-change > 1 in the 
LT-HSC wild-type versus LT-HSC knockout expression levels. The red-circled genes illustrates the overlap between A and 
B. The 25 downregulated genes among the CEBPA silenced leukemias are overlaid with (C) the genes that showed a 
fold-change < 1 in the ST-HSC wild-type versus ST-HSC knockout expression levels and (B) the genes that showed a 
fold-change < 1 in the LT-HSC wild-type versus LT-HSC knockout expression levels. The blue-circled genes illustrates the 
overlap between C and D.
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Table S1. Enriched canonical pathways for the 286 upregulated and 403 downregulated genes of CEBPAsilenced cases 
Canonical Pathways Regulation  -log10(P-value) Gene symbols
 T Cell Receptor Signaling
upregulated 6.92  MAP2K4, CD247, CD3G, LCK, PRKCQ, GRAP2, SOS1, ZAP70, NFATC4, CD3D, ATM
downregulated
 PKCθ Signaling in T Lymphocytes
upregulated 5.40  MAP2K4, CD247, CD3G, LCK, PRKCQ, GRAP2, SOS1, ZAP70, NFATC4, CD3D, ATM
downregulated
 Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells
upregulated 5.04  CD247, CD3G, PRF1, APAF1, CD3D, FAS, BCL2
downregulated
 iCOS-iCOSL Signaling in T Helper Cells
upregulated 4.96  CD247, CD3G, LCK, PRKCQ, GRAP2, ZAP70, TRAT1, NFATC4, CD3D, ATM
downregulated 0.32  CD40, NFATC2, PPP3CA
 Type I Diabetes Mellitus Signaling
upregulated 4.77  MAP2K4, CD247, CD3G, PRF1, APAF1, JAK2, SOCS7, CD3D, FAS, BCL2
downregulated
 CTLA4 Signaling in Cytotoxic T Lymphocytes
upregulated 4.65  CD247, CD3G, LCK, GRAP2, ZAP70, TRAT1, JAK2, CD3D, ATM
downregulated
 CD28 Signaling in T Helper Cells
upregulated 4.59  MAP2K4, CD247, CD3G, LCK, PRKCQ, GRAP2, ZAP70, NFATC4, CD3D, ATM
downregulated
 Prolactin Signaling
upregulated 3.46  PRKCQ, SOS1, JAK2, SOCS7, STAT5B, TCF7, ATM
downregulated 0.24  PRKCI, PRKCD
 Calcium-induced T Lymphocyte Apoptosis
upregulated 3.38  CD247, CD3G, LCK, PRKCQ, ZAP70, CD3D
downregulated 1.86  PRKCI, PRKCD, NFATC2, CAPN2, PPP3CA
 Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes
upregulated 3.35  MAP2K4, CD247, CD3G, SOS1, ZAP70, NFATC4, CD3D
downregulated 0.49  TOB1, NFATC2, PPP3CA
 Myc Mediated Apoptosis Signaling
upregulated 3.21  MAP2K4, SOS1, APAF1, FAS, ATM, BCL2
downregulated
 Role of NFAT in Regulation of the Immune Response
upregulated 3.18  CD247, CD3G, LCK, PRKCQ, SOS1, ZAP70, NFATC4, CD3D, ATM, ATF2
downregulated 0.61  GNAS, CSNK1G3, GNA11, NFATC2, GNG7, PPP3CA
 Glycosphingolipid Biosynthesis - Globoseries
upregulated
downregulated 3.74 NAGA, GLA, HEXB, B3GALNT1, FUT4    
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Ingenuity pathway analysis is performed on the 286 upregulated and 403 downregulated genes. The enriched 
Upregulation and downregulation is relative for the CEBPAsilenced group compared to normal cells (CD34+ group).
canonical pathways (P < 0.001) are sorted on their presence in the upregulated and downregulated genes. 
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Table S2. Transcription factor binding sites for the upregulated (n=286) and downregulated (n=403) genes specific for 
the CEBPAsilenced leukemias. 
Regulation Matrix name Recognized factors Fold increase P-value
Upregulated DMRT1_01 DMRT1 2.26 < 0.001
Upregulated ARNT_01 arnt, arnt-L 2.20 < 0.001
Upregulated CETS1P54_03
Ets-1, Ets-1 deltaVII, c-Ets-1, c-Ets-1 
54, c-Ets-1A, c-Ets-1B
1.97 0.001
Upregulated ZF11_01 SZF1-isoform3 1.91 0.001
Upregulated ELK1_02 Elk-1, Elk1-isoform1 1.89 0.001
Upregulated NRF1_Q6 NRF-1 1.81 < 0.001
Upregulated E2F6_01 E2F-6 1.77 0.001
Upregulated R_01 R 1.69 < 0.001
Upregulated USF_02 USF, usf1 1.57 < 0.001
Upregulated MAX_01 max-isoform2 1.55 < 0.001
Upregulated AHRARNT_02 AhR, AhR2, arnt, arnt-L 1.53 0.001
Upregulated WHN_B FOXN1 1.53 < 0.001
Upregulated USF_Q6
USF, USF2, USF2A-delta-H, USF2a, 
USF2b, usf1, usf1:USF2
1.53 < 0.001
Downregulated ARNT_01 arnt, arnt-L 1.71 0.001
Downregulated CMYC_02 c-Myc, c-Myc I 1.63 0.001
Downregulated ARNT_02 arnt, arnt-L 1.59 < 0.001
Downregulated CLOCKBMAL_Q6 Clock:BMAL1, Clock:BMAL2 1.54 0.001
Transcription factors binding sites (TFBS) that are enriched among the promoter regions (2Kb upstream) of the 286 
upregulated and 403 downregulated genes (HG19). The 2Kb upstream sequences for each gene is gathered from the 
UCSC database. Regulation: genes that are upregulated and downregulated compared to CD34+. Matrix name: Enriched 
transcription factor binding name. Recognized factors: Binding sites that are recognized. Fold-increase: the ratio that a 
TFBS is enriched compared to 5000 randomly selected genes.
Table S3. Enriched transcription factor binding sites for the detected binding regions.
Transcription 
Factor Recognized factors Fold increase P-value Site
CEBP_Q2
C/EBP, C/EBPalpha, C/EBPalpha(p20),  
C/EBPalpha(p30)
4.26 2.5E-38 consensus
CEBP_Q2_01
C/EBPalpha, C/EBPalpha(p20, p30), C/
EBPbeta(LAP, p20, p34, p35), C/EBPgamma, 
CRP2, CRP3, LAP*-NF-M, NF-IL6-1, NF-IL6-2, 
NF-IL6-3, cebpe
4.28 2.1E-39 consensus
CEBPA_01
C/EBP, C/EBPalpha, C/EBPalpha(p20),  
C/EBPalpha(p30)
3.93 0 consensus
CEBPB_01 C/EBPbeta(LAP), C/EBPbeta(p35), CRP2 4.95 1.1E-39 consensus
CEBPB_02 C/EBPbeta(LAP), C/EBPbeta(p35), CRP2 5.20 5.8E-42 consensus
CEBPDELTA_Q6 CRP3 3.80 3.8E-29
TFBS analyses among the detected binding regions (based on wild-type C/EBPα from chip-on-ChIP), resulted in the 
detection of the C/EBPα consensus sites.
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Table S4. Enriched pathways for the 24 upregulated and 25 downregulated genes of CEBPAsilenced cases. 
Regulation Function Function Annotation P-value Genes Nr. of genes
Upregulated
Cell-mediated Immune Response
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
T cell development 2.64E-3 BCL2, CASP1, CCR9, CD47, MAP2K4 5
Hematological System Development and Function
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
hematopoiesis 2.22E-3 BCL2, CASP1, CCR9, CD47, MAP2K4, OGT 6
T cell development 2.64E-3 BCL2, CASP1, CCR9, CD47, MAP2K4 5
cell movement of neutrophils 5.79E-3 B4GALT1, CASP1, CD47 3
proliferation of T lymphocytes 6.55E-3 B3GNT2, BCL2, CD47, MAP2K4 4
Hematopoiesis
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
hematopoiesis 2.22E-3 BCL2, CASP1, CCR9, CD47, MAP2K4, OGT 6
T cell development 2.64E-3 BCL2, CASP1, CCR9, CD47, MAP2K4 5
cell movement of bone marrow cells 3.91E-3 B4GALT1, CASP1, CD47 3
Cell Death
cell death of leukemia cells 6.52E-5 BCL2, CASP1, CD47 3
apoptosis of B lymphocytes 3.73E-4 BCL2, CASP1, CD47 3
killing of eukaryotic cells 4.11E-4 BCL2, CD47, CEBPG 3
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
cell viability of normal cells 4.96E-4 BCL2, CD47, OGT 3
apoptosis of cardiomyocytes 8.15E-4 BCL2, CASP1, MAP2K4 3
cell viability of eukaryotic cells 8.50E-4 BCL2, CASP1, CD47, OGT 4
apoptosis of fibroblasts 3.09E-3 BCL2, CASP1, MAP2K4 3
Cell Morphology
autophagy of eukaryotic cells 1.14E-3 BCL2, CASP1, GOPC 3
transmembrane potential of mitochondria 2.47E-3 BCL2, CD47, MAP2K4 3
Cellular Development
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
developmental process of leukocytes 2.54E-3 BCL2, CASP1, CCR9, CD47, MAP2K4, OGT 6
T cell development 2.64E-3 BCL2, CASP1, CCR9, CD47, MAP2K4 5
Cellular Function and Maintenance
apoptosis of T lymphocytes 4.50E-4 BCL2, CASP1, CD47, MAP2K4 4
autophagy of eukaryotic cells 1.14E-3 BCL2, CASP1, GOPC 3
T cell development 2.64E-3 BCL2, CASP1, CCR9, CD47, MAP2K4 5
Post-Translational Modification
modification of protein 8.30E-7 B3GNT2, B4GALT1, BCL2, CASP1, CD47, FBXW2, MAP2K4, NMT1, OGT, SEPX1, STK38 11
moiety attachment of protein 8.02E-6 B3GNT2, B4GALT1, BCL2, CD47, FBXW2, MAP2K4, NMT1, OGT, STK38 9
glycosylation of protein 2.15E-4 B3GNT2, B4GALT1, OGT 3
Downregulated
Cell death killing of cells 1.64E-3 HSP90B1, MSRA, PLA2G4A 3
Lipid metabolism accumulation of lipid 6.42E-3 ACSL1, COL4A3BP, PLA2G4A 3
Small Molecule Biochemistry accumulation of lipid 6.42E-3 ACSL1, COL4A3BP, PLA2G4A 3
Molecular Transport accumulation of lipid 6.42E-3 ACSL1, COL4A3BP, PLA2G4A 3
Connective Tissue Development and Function differentiation of osteocytes 6.65E-3 FOSL2,IRAK3,TOB1 3
Cellular Development differentiation of osteocytes 6.65E-3 FOSL2,IRAK3,TOB1 3
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Ingenuity pathway analysis is performed on the 24 upregulated and 25 downregulated genes. Enriched functional 
relative for the CEBPAsilenced group compared to normal cells (CD34+ group).
pathways are considered if P < 0.01 and the pathway contains more than 3 genes. Upregulation and downregulation is 
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Table S5. Enriched TFBSs in the 2Kb upstream promoter regions of the 24 upregulated genes.  
Transcription 
Factor Recognized factors
Fo
ld
 in
cr
ea
se
P-
va
lu
e
SL
C7
A1
1
M
RP
L4
1
CE
PT
1
BC
L2
U
BT
D1
AT
P6
V1
B2
ST
K3
8
G
O
PC
CA
SP
1
O
GT
M
AP
2K
4
CD
47
AC
AD
8
YP
EL
1
CC
R9
SS
BP
2
B3
G
N
T2
HM
G
CR
FB
XW
2
N
IN
SE
PX
1
B4
G
AL
T1
CE
BP
G
N
M
T1
AFP1_Q6 AFP1, ATBF1 3.83 0.001 0 0 1 0 0 0 3 1 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0
EVI1_04 Evi-1 3.34 0.001 2 0 3 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1
SP1_Q6 Sp1, Sp1-isoform1, Sp1-isoform2 3.12 < 0.001 0 8 0 0 2 0 0 0 0 0 0 1 0 3 0 0 3 0 0 0 3 2 0 0
GC_01 3.09 < 0.001 0 8 0 0 2 0 0 0 0 0 0 1 0 2 0 0 3 0 0 0 3 2 0 0
SP4_Q5 sp4 2.88 < 0.001 0 8 0 0 1 0 0 0 0 0 0 1 0 3 0 0 1 0 0 0 1 1 0 0
SP1_Q6_01 Sp1, Sp1-isoform1, Sp1-isoform2, sp3, sp3-isoform1, sp3-xbb1, sp4 2.83 < 0.001 0 8 0 0 2 0 0 0 0 0 0 1 0 3 0 0 3 0 0 0 3 2 0 0
AP2ALPHA_03 AP-2alphaA 2.72 < 0.001 0 2 2 0 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 2 2 0 4
RP58_01 RP58 2.71 0.001 0 0 1 0 0 1 1 0 0 1 1 0 1 0 1 1 1 0 0 0 1 2 1 0
EVI1_01 Evi-1 2.51 0.001 1 1 2 0 0 2 2 0 0 0 0 0 0 1 0 1 0 0 1 1 1 0 0 1
SP1_Q4_01 Sp1, Sp1-isoform1, Sp1-isoform2, Sp2, sp3, sp3-isoform1, sp3-xbb1, sp4 2.42 < 0.001 0 8 1 0 2 0 0 0 0 0 0 1 0 3 0 0 4 0 0 0 3 2 0 0
CNOT3_01 CNOT3 2.10 0.001 0 3 0 7 0 0 0 0 0 0 0 0 0 3 0 1 0 0 2 2 0 4 1 0
MUSCLE_INI_B 2.01 0.001 0 11 0 5 1 0 1 0 0 0 1 2 0 1 0 3 1 0 0 1 1 1 0 0
MYCMAX_B c-Myc, c-Myc I, max-isoform1, max-isoform2 1.78 < 0.001 0 4 1 5 4 0 2 2 0 0 0 4 1 4 0 1 2 1 4 1 3 1 1 1
DMRT1_01 DMRT1 1.7 < 0.001 5 0 4 0 0 2 2 2 5 4 2 4 2 7 4 1 4 0 0 4 1 0 3 4
AP4_Q6 AP-4, TFAP4 1.66 0.001 0 24 2 0 0 0 0 0 1 3 2 2 0 0 1 0 3 0 0 0 3 2 1 0
AP2ALPHA_02 AP-2alphaA 1.62 0.001 0 4 4 1 6 1 4 0 1 1 0 2 3 0 0 4 1 1 1 0 7 2 1 6
CEBPB_01 C/EBPbeta(LAP), C/EBPbeta(p35), CRP2 1.61 0.001 4 0 3 1 3 5 2 5 2 2 3 0 1 1 0 1 2 4 3 3 2 1 1 1
PU1_Q4 PU.1-xbb1, SPI1 1.58 < 0.001 5 2 4 2 1 8 22 2 5 0 1 2 4 1 6 5 1 3 2 2 2 7 2 3
E4BP4_01 E4BP4 1.52 < 0.001 16 1 2 1 8 4 3 5 5 3 3 0 3 2 2 2 1 5 4 5 0 1 0 0
NMYC_01 N-Myc 1.50 < 0.001 0 7 5 14 6 4 4 5 0 3 0 8 5 5 3 3 5 1 5 2 2 1 1 4
BEN_01 Ben 1.49 < 0.001 0 15 5 14 5 1 1 2 0 2 0 5 3 5 2 5 2 0 3 2 3 5 5 2
NRF1_Q6 NRF-1 1.48 0.001 0 5 6 10 6 4 4 2 0 3 0 9 1 6 1 2 2 4 3 1 0 1 2 2
NKX61_01 NKX6A 1.47 < 0.001 14 0 6 0 4 6 7 3 6 8 14 3 2 1 7 5 3 8 5 3 2 0 2 5
OCT1_07 Oct-1, POU2F1, POU2F1a, POU2F1b, POU2F1c 1.45 < 0.001 10 0 8 1 4 8 2 6 6 7 5 0 8 0 7 1 2 6 4 5 3 1 1 1
CREBP1_01 ATF-2-xbb4 1.44 < 0.001 9 1 3 8 3 8 5 8 10 0 4 0 4 2 2 4 2 8 4 4 0 2 2 1
CEBPGAMMA_Q6 C/EBPgamma 1.41 0.001 14 0 6 2 4 6 2 7 6 6 1 4 4 2 2 3 1 4 2 4 0 1 1 3
DMRT3_01 DMRT3 1.40 0.001 6 0 6 1 6 7 2 8 9 9 5 5 5 3 8 1 1 2 5 4 1 2 1 3
IPF1_Q6 PDX1, ipf1 1.37 < 0.001 18 1 8 0 4 7 6 5 11 7 10 6 9 2 8 8 4 8 5 6 2 1 3 2
VBP_01
TEF-xbb1, Thyrotroph embryonic factor, Thyrotroph embryonic factor-
isoform1, Thyrotroph embryonic factor-isoform2, Thyrotroph embryonic 
factor-isoform3, VBP
1.37 < 0.001 20 1 4 2 12 9 5 13 9 8 8 1 4 2 4 4 3 7 6 8 1 2 1 2
R_01 R 1.33 0.001 1 27 5 18 7 1 3 0 1 2 4 4 3 7 2 6 8 4 3 3 10 4 6 2
SOX9_B1 Sox9 1.33 0.001 7 3 4 2 6 13 5 9 3 8 6 11 9 3 8 2 3 5 4 5 3 2 6 2
LHX3_01 LHX3a, LHX3b, Lhx3a, Lhx3b 1.31 0.001 11 2 10 1 3 7 14 11 8 8 13 6 5 1 11 10 2 6 6 3 1 0 2 2
ARNT_01 arnt, arnt-L 1.30 0.001 2 8 8 17 9 8 7 9 4 8 3 6 7 6 6 2 6 2 6 4 4 5 4 6
IPF1_Q4_01 Ipf1, ipf1, ipf1:Pbx 1.30 0.001 16 0 9 0 3 7 5 5 13 8 7 9 14 3 5 8 4 7 5 6 2 2 3 2
E2F_Q2
DP-1, E2F, E2F-1, E2F-3, E2F-3A, E2F-3B, E2F-3a, E2F-4, E2F:DP, 
E2F:DP:E4
1.30 0.001 0 13 8 24 9 1 3 3 0 0 5 7 2 17 2 7 12 1 2 5 10 14 12 3
S8_01 S8 1.29 0.001 17 2 14 1 7 6 8 7 10 11 9 3 4 2 7 4 4 5 4 4 4 1 5 4
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Transcription factors binding sites (TFBS) that are enriched among the promoter regions (2Kb upstream) of the 24 
sequences for each gene is gathered from the UCSC database. Transcription Factor: The enriched transcription factor
5000 randomly selected genes. The numbers under the gene-symbols indicate how often the representative TF
upregulated genes (HG19) that also showed binding by CEBPA within the 32D-model-system. The 2Kb upstream 
name. Recognized factors: Binding sites that are recognized. Fold-increase: the ratio that a TFBS is enriched compared to
was detected.
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Prognostic Impact, Concurrent Genetic Mutations and Gene Expression Features of AML with CEBPA 
Mutations in a Cohort of 1182 Cytogenetically Normal AML: Further Evidence for CEBPA Double-mutant 
AML as a Distinctive Disease Entity
ABSTRACT
We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of 
CEBPA double mutations (CEBPAdm) versus single (CEBPAsm) mutations in 1182 cytogenetically 
normal AML (CN-AML) patients (16-60 years). We identified 151 (12.8%) patients with CEBPA 
mutations (91 CEBPAdm and 60 CEBPAsm). The incidence of germline mutations was 7% (5 
out of 71), including three C-terminal mutations. CEBPAdm patients had a lower frequency of 
concurrent mutations than CEBPAsm patients (P < .0001). Both, CEBPAdm and CEBPAsm were 
associated with favorable outcome compared to CEBPAwt [5-year overall survival (OS), 63% 
and 56% versus 39%; P < .0001 and P = .05, respectively]. However, in multivariable analysis 
only CEBPAdm was a prognostic factor for favorable outcome [OS, hazard ratio (HR): .36, P < 
.0001; event-free survival, HR: .41, P < .0001; relapse-free survival, HR: .55, P = .001)]. Outcome 
in CEBPAsm is dominated by concurrent NPM1 and/or FLT3 internal tandem duplication (ITD) 
mutations. Unsupervised and supervised GEP analyses showed that CEBPAdm AML (n=42), but 
not CEBPAsm AML (n=18) expressed a unique gene signature. A 25-probeset prediction signature 
for CEBPAdm AML showed 100% sensitivity and specificity. Based on these findings, we propose 
that CEBPAdm should be clearly defined from CEBPAsm AML and considered as a separate entity 
in the classification of AML.
INTRODUCTION
In the current World Health Organization (WHO) classification of acute myeloid leukemia (AML), 
“AML with mutated CEBPA (CCAAT/ enhancer binding protein alpha)” has been designated as 
a provisional disease entity in the category “AML with recurrent genetic abnormalities” 199,200. 
CEBPA encodes a transcription factor that is essential for neutrophil development. Targeted 
disruption of Cebpa in mice results in a selective block in early granulocyte development, 
a hallmark of AML 165,175. Two proteins may be translated from the CEBPA transcripts, i.e., a 
42kDa (p42) and a shorter 30kDa (p30) protein both translated from the same mRNA transcript. 
The p42 isoform contains two regulatory transactivation domains (TAD1 and TAD2) in the 
N-terminus, while the shorter p30 isoform only carries the TAD2 domain. Both isoforms contain 
the C-terminal basic DNA-binding domain and the leucine zipper (bZIP), involved in DNA-binding 
and protein dimerization. In AML, CEBPA mutations mainly occur in cytogenetically normal 
(CN) AML (CN-AML) with an incidence of 5-14% 27,28,31,36 -42. Two main types of mutations can be 
distinguished: N-terminal frame-shift mutations resulting in the translation of a 30-kDa protein 
only, and the C-terminal in-frame mutations in the basic zipper region affecting DNA-binding and 
homodimerization and heterodimerization 28,43. As a consequence, these mutations create an 
imbalance between proliferation and differentiation of hematopoietic progenitors 40,180. 
AML with CEBPA mutations can be separated into two subgroups, i.e., those with a single 
mutation (CEBPAsm) and those with double mutations (CEBPAdm) 35,45-48. In the majority of 
CEBPAdm AML, both alleles are mutated 46. These biallelic mutations frequently consist of an 
N-terminal mutation on one allele and a C-terminal bZIP mutation on the other. In CEBPAsm AML, 
mutations occur either in the N-terminus or in the C-terminus of the gene. In previous studies, 
in which these two subgroups were not considered, AML with mutated CEBPA had a relatively 
good outcome 31,36,38,41. More recent data suggest that this favorable outcome is mainly observed 
in AML with CEBPAdm and not CEBPAsm 35,45-48. Moreover, it has been suggested that concurrent 
mutations may occur more frequently in CEBPAsm than in CEBPAdm AML. The impact of coexisting 
mutations remains elusive and needs to be validated in large cohorts. 
By applying gene expression profiling (GEP), it was demonstrated that CEBPAdm AML can be 
distinguished from CEBPAsm and the majority of CEBPAwt AML based on a characteristic signature 
35. However, a CEBPAdm GEP signature did not predict CEBPAdm AML with maximum accuracy, 
since AML in which CEBPA was silenced by promoter hypermethylation (CEBPAsilenced) carried a 
highly similar signature18,34.
Objectives of this study were to evaluate the impact of CEBPAdm versus CEBPAsm on clinical 
outcome of CN-AML and to investigate the impact of concurrent NPM1mutant and/or FLT3ITD. In 
addition, we searched for CEBPA-associated gene signatures and determined the frequency 
of predisposing CEBPA germline mutations. For these purposes, we combined data sets from 
the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical 
Cancer Research (SAKK) and the German-Austrian AML Study Group (AMLSG).
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PATIENTS AND METHODS
Patients and molecular analyses
Diagnostic bone marrow (BM) or peripheral blood (PB) samples from 1182 younger adults (16-
60 years) with CN-AML were analyzed; 193 patients were enrolled on HOVON/SAKK protocols 
-04, -04A, -29, and -42 (available at www.hovon.nl) 201-204, and 989 patients on AMLSG protocols 
AMLHD93 (n=74) 205, AML HD98A (n=313) 206, AMLSG 07-04 (n=376; ClinicalTrials.gov Identifier 
NCT00151242), AML SHG 02-95 (n=94) 207, and AML SHG 01-99 (n=180, ClinicalTrials.gov 
Identifier NCT00209833). All patients provided written informed consent in accordance with the 
Declaration of Helsinki. All trials were approved by the Institutional Review Board of Erasmus 
University Medical Center, the University of Ulm, and Hannover Medical School.
Mutation analyses for the genes FLT3 (internal tandem duplications [ITD] and tyrosine kinase 
domain mutations [TKD]) and NPM1 were performed as described previously 24,208,209. CEBPAdm and 
CEBPAsm AML were identified by denaturing high-performance liquid chromatography (dHPLC) 
or direct sequencing as described 35. Cases that carried an insertion polymorphism 35,48 (http://
www.ncbi.nlm.nih.gov/sites/snp; http://genome.ucsc.edu/cgi-bin/hgGateway; http://www.
ensembl.org/Homo_sapiens/Gene/Variation_Gene) or variation(s) that did not lead to amino 
Table 1. Patient demographics and clinical and molecular characteristics of CEBPAwt, CEBPAsm, and CEBPAdm CN-AML 
cases. 
Characteristic
CEBPAwt
(n = 1031)
CEBPAsm
(n = 60)
P, CEBPAsm vs
CEBPAwt
CEBPAdm
(n = 91)
P, CEBPAdm vs
CEBPAwt
P, CEBPAsm vs
CEBPAdm
Median age, years (range) 48 (16-60) 46 (18-60) 0.28  44 (16-60) 0.04* 0.66
Sex, n (%) 0.79 0.74 0.74
 Male 500 (48) 28 (47) 46 (51)
 Female 531 (52) 32 (53) 45 (49)
WBC count, x109/L 0.23 0.062 0.86
 Median (range) 28 (0.2-372) 25 (1.1-345) 28 (1.5-262)
 Missing 34 1 4
Platelet count, x109/L 0.77 < 0.0001* < 0.0001*
 Median (range) 65 (5-746) 62 (10-361) 38 (4-265)
 Missing 40 3 4
Bone marrow blasts 0.83 0.53 0.76
 Median (range) 80 (0-100) 80 (0-97) 78 (2-100)
 Missing 80 7 4
Molecular abnormalities, n (%)
 FLT3ITD 347 (33.7) 18 (30) 1 7 (7.7) < 0.0001* 0.00015*
 Missing 69 9 5
 FLT3TKD 95 (9.2) 4 (6.7) 0.81 2 (2.2) 0.018* 0.2
 Missing 48 6 3
 NPM1+ 560 (54.3) 21 (35) 0.018* 3 (3.3) 0 < 0.0001*
 Missing 88 10 8
Number of cases (percentage), median, range, or missing values are indicated. WBC indicates white blood cell. *P < .05 
computed using the Mann-Whitney U test (continuous variables) and 2-sided Fisher exact test (categorical variables).
acid changes were considered wild-type. Cases were categorized as CEBPAdm when two different 
mutations or one homozygous mutation were present as determined by sequencing analysis; 
cases with only a single heterozygous mutation were designated as CEBPAsm. In 71 of the 151 
patients with CEBPA mutations, DNA obtained from buccal swabs (n=52), PB (n=8) or BM (n=11) 
in complete remission (CR) was studied for the presence of CEBPA germline mutations. Patient 
demographics and molecular characteristics are summarized in Table 1. All CEBPA-mutated 
patients, except for 07-04 treated patients within the AMLSG protocol, have been previously 
reported in different studies 31,35,38.
Gene Expression Profiling
Data from GEP analysis were available in 674 AML (53% CN-AML, HOVON-SAKK and AMLSG-
cohorts), generated using Affymetrix (Santa Clara, CA, USA; Table S1). Sample processing and 
quality control were carried out as described previously 18,181. For both cohorts, normalization 
of raw data was processed with Affymetrix Microarray Suite 5 (MAS5) to target intensity values 
at 100. Intensity values were log2 transformed and mean centered per probeset per cohort. 
GEP data are available at the NCBI Gene Expression Omnibus [accession numbers GSE14468 
(HOVON-SAKK cohort) and GSE22845 (AMLSG-cohort)]. There were 42 CEBPAdm and 18 CEBPAsm 
cases for which the GEP was determined (Table S1). 
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N-terminal truncation in CEBPA
In-frame insertion or deletion in bZIP in CEBPA
colorcorrection
CEBPAsm CEBPAdm(n=60) (n=91)
NPM1+
FLT3ITD
FLT3TKD
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P<.0001
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Figure 1. Distribution of concurrent mutations in CEBPAdm and CEBPAsm patients. Columns represent patients and rows 
the genotypes FLT3TKD, FLT3ITD and NPM1mutant (black), wild-type (white) or missing (grey). The in-frame insertion or 
deletion in bZIP and N-terminal truncation mutations in CEBPA are highlighted in black.
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Statistical Analyses
Statistical analyses were performed using Mathworks (Matlab R2009b) with the statistical, 
bioinformatics and pattern recognition toolbox (Prtools). For clinical, molecular, univariate and 
multivariate analyses, patients with CN-AML and age ≤ 60 (Table S1) were included. Molecular 
and clinical variables of both patient cohorts (HOVON-SAKK and AMLSG) were comparable. 
Differences were assessed for CEBPAsm and CEBPAdm groups in comparison with CEBPAwt group 
(Table 1), by using the Mann-Whitney-U test for continuous variables and the two-sided Fisher 
exact test for categorical variables.
Outcome measures of the HOVON-SAKK and AMLSG-cohorts were comparable (log-rank test 
overall survival (OS), P = .08; event-free survival (EFS), P = .47; Figure S1A and S1B, respectively). 
There were no statistical differences in outcome in patients receiving autologous or allogeneic 
hematopoietic stem cell transplantation between the HOVON-SAKK and AMLSG-cohorts (log-
rank test OS, P = .68; EFS, P = .89; Figure S2A and S2B respectively).
For univariate analysis, significance was assessed using the stratified log-rank test and Kaplan-
Meier estimates for OS, EFS and relapse-free survival (RFS). The recommended consensus 
criteria 210 were used for the definition of CR and survival endpoints such as OS, EFS, and RFS. 
Multivariate analysis was performed by using stratified Cox proportional hazard model. For all 
analyses, a P-value less or equal than .05 was considered statistically significant and for survival 
analyses, P-values were computed using the full time span. Note that the close testing procedure 
211 was applied and a correction for multiple testing 212 was only performed if the global log-rank 
test resulted in a P-value > .05.
For gene expression-based classification of CEBPAdm cases, GEP of the HOVON-SAKK cohort was 
used to derive the 25-probeset predictive signature and the AMLSG-cohort as validation set. To 
summarize, a logistic regression model with Lasso regularization (a continuous feature selection 
procedure) was used as it takes the correlation structure between the probesets into account 
(Supplementary material: creation and evaluation of the CEBPAdm predictive signature).
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Figure 2. Kaplan-Meier survival curves of overall survival. (A) Kaplan-Meier survival curves for overall survival (OS) among 
the three groups CEBPAdm, CEBPAsm and CEBPAwt. (B) Kaplan-Meier survival curves for OS of the four genotypes FLT3ITD/
NPM1mutant, FLT3ITD/NPM1wt, FLT3wt/NPM1mutant, and FLT3wt/NPM1wt within the CEBPAsm group. (C) Kaplan-Meier survival 
curves for OS of the four genotypes within CEBPAwt. The asterisk indicates the P-value for the global log-rank test.
RESULTS
Frequency and types of acquired CEBPAdm and CEBPAsm mutations
CEBPA mutations were detected in 151 of the 1182 (12.8%) CN-AML; 91 (60%) patients had 
CEBPAdm, within these the combination of N-terminal and C-terminal mutations was the 
predominant genotype (82/91). CEBPAdm cases with only N-terminal or C-terminal mutations 
were less frequently observed (4/91 and 5/91, respectively). Sixty of the 151 (40%) CEBPA-
mutated cases had CEBPAsm which occurred most frequently in the N-terminus (47/60). Only 13 
of the 60 CEBPAsm cases had in-frame insertion or deletion mutations affecting the bZIP domain 
(Figure 1).
CEBPA germline mutation analysis
Five out of 71 (7%) CEBPA-mutant AML patients analyzed carried CEBPA germline mutations: in 
two of the 5 patients, the germline mutation was localized in the N-terminus and both acquired 
a C-terminal mutation. Both patients had a family history of AML and were diagnosed at young 
age. In the remaining three patients, the germline mutation was in the C-terminus; one of 
these patients gained an additional N-terminal mutation and the second patient an additional 
C-terminal mutation at the time of AML diagnosis. None of these three patients had a family 
history of AML. Alignment to distinct SNP databases (http://www.ncbi.nlm.nih.gov/sites/snp; 
http://genome.ucsc.edu/cgi-bin/hgGateway; http://www.ensembl.org/Homo_sapiens/Gene/
Variation_Gene) did not identify one of these germline sequence variations as a polymorphism. 
Using the PolyPhen (http://genetics.bwh.harvard.edu/pph/) database, all three C-terminal 
mutations were predicted to be damaging to the function and structure of the protein (Table 2).
Table 2. Germline patient demographics and molecular characteristics. 
Patient ID
Age at diagnosis, 
(year)
Germline 
mutation
Acquired mutation*
Additional 
mutation†
Familial 
AML
History CEBPA 
mutation
98A-751 28 338delC 1080insGAA Yes CEBPAdm
07/04-268 (ULM_10) 25 307delG
1122_1123
ins1075_1225
KRAS, WT1 Yes CEBPAdm
BioID 769 51 1096T>C 478_485del No CEBPAdm
98A-543 33 1164G>A None FLT3TKD, NPM1 No CEBPAsm
07/04-48 (ULM_20) 59 1036G>T 1086insAAG No CEBPAdm
Characteristics of 5 of 71 (7%) CEBPA-mutant AML patients who carried CEBPA germline mutations. CBL indicates Casitas 
B-lineage lymphoma; KRAS, Kirsten Rat sarcoma; NRAS, neuroblastoma Rat sarcoma; RUNX1, runt-related transcription 
factor 1; and WT1, Wilms tumor 1. *Data according to GenBank accession number Y11525. †Patients 98A-751, 07/04-268 
(ULM_10), 98A-543, and 07/04-48 (ULM_20) were screened for FLT3ITD, FLT3TKD, NPM1, NRAS, KRAS, WT1, RUNX1, 
and CBL mutations; patient BioID 769 was analyzed for FLT3ITD, FLT3TKD, and NPM1 mutations.
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Association of acquired CEBPAdm and CEBPAsm mutations with concurrent gene mutations and 
clinical characteristics
Concurrent mutations were seen less frequently in CEBPAdm than in CEBPAsm AML (22% versus 
60%; P < .0001, Figure 1); frequencies for NPM1mutant were 3.3% and 35% (P < .0001), and for 
FLT3ITD were 7.7% and 30% (P = .00015), respectively (Table 1). When comparing CEBPAsm 
and CEBPAwt AML, NPM1mutant were slightly less frequent in CEBPAsm AML (35% versus 54.3%; 
P = .018); the frequency of FLT3ITD was comparable between the two groups (30% versus 33.7%).
Regarding presenting clinical characteristics, CEBPAdm mutations were associated with younger 
age (median 44 versus 48 years; P = .04) and lower platelet counts (median 38x109/L versus 
65x109/L; P < .0001) compared with CEBPAwt patients (Table 1).
Impact of CEBPAdm and CEBPAsm on response to induction therapy and clinical outcome
For clinical outcome analyses, 1182 CN-AML were considered. CEBPAdm was associated with a 
higher CR rate when compared with CEBPAsm (92% versus 78%, P = .02) and CEBPAwt (92% 
versus 79%, P = .002). There was no difference in CR probability between CEBPAsm and CEBPAwt 
patients (78% versus 79%, P = .86). 
The median follow-up time for survival in the 1182 CN-AML patients was 33 months (95%-CI, 
25.6 to 40.4); the estimated 5-year OS and RFS were 42% (95%-CI, 39% to 45%) and 34% (95%-
CI, 31% to 38%), respectively.
CEBPAdm AML was associated with a significantly superior outcome compared with CEBPAwt AML 
(5-year OS, 63% versus 39%, P < .0001; EFS, 45% versus 28%, P < .0001; RFS, 44% versus 32%, 
P = .05; Figures 2A and supplementary Figures S3A and S3D). A somewhat better outcome was 
also found for CEBPAsm AML compared with CEBPAwt AML (5-year OS, 55% versus 39%, P = .05; 
RFS, 49% versus 32%, P = .02; but not EFS, 37% versus 28%, P = .22). No significant difference 
was evident between CEBPAdm and CEBPAsm AML (5-year OS, P = .06; EFS, P = .16; RFS, P = .48). Of 
note, no differences in outcome were observed between CEBPAsm patients with either C-terminal 
(n=13) or N-terminal (n=47) mutations (5-year OS, 54% versus 56%, P = .58; Figure S4).
In multivariate analyses considering other prognostic indicators (listed in Table 3), the presence 
of CEBPAdm was an independent prognostic factor for favorable OS (HR, .36, P < .0001), 
EFS (HR, .41, P < .0001) and RFS (HR, .55, P = .001), whereas CEBPAsm did not impact these three 
endpoints (Table 3). 
Table 3. Multivariate analysis for overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) in 
CN-AML.  
Variables HR 95% CI (low-high) P-value*
Overal survival
 CEBPAsm α 0.70 0.46 1.07 0.1
 CEBPAdm α 0.36 0.23 0.55 < 0.0001*
 FLT3ITD β 1.78 1.49 2.14 < 0.0001*
 FLT3TKD β 0.84 0.61 1.15 0.28
 NPM1+ β 0.56 0.46 0.67 < 0.0001*
 WBC countδ, x109/L 1.35 1.12 1.62 < 0.0001*
 Age $ 1.02 1.01 1.03 < 0.0001*
Event-free survival   
 CEBPAsm α 0.86 0.6 1.22 0.4
 CEBPAdm α 0.41 0.29 0.57 < 0.0001*
 FLT3ITD β 1.56 1.33 1.84 < 0.0001*
 FLT3TKD β 0.8 0.6 1.07 0.13
 NPM1+ β 0.45 0.39 0.53 < 0.0001*
 WBC countδ, x109/L 1.27 1.08 1.5 0.003*
 Age $ 1.01 1.01 1.02 0.003*
Relapse-free survival   
 CEBPAsm α 0.79 0.51 1.22 0.3
 CEBPAdm α 0.55 0.38 0.79 0.001*
 FLT3ITD β 1.75 1.45 2.12 < 0.0001*
 FLT3TKD β 0.82 0.59 1.13 0.22
 NPM1+ 0.56 0.46 0.68 < 0.0001*
 WBC count δ, x109/L 1.33 1.10 1.61 0.002*
 Age $ 1.01 1.00 1.02 0.001* 
Stratified Cox proportional hazard model for multivariable analyses of CEBPAdm and CEBPAsm as prognostic marker for 
overall survival, event-free survival and relapse-free survival. Analyses included 1182 cytogenetically normal acute 
myeloid leukemia (CN-AML) patients with age ≤ 60. Abbreviations: HR, hazard ratio; CI, confidence interval; FLT3ITD, FLT3 
Internal Tandem Duplications; FLT3TKD, FLT3 Tyrosine Kinase Domain.
* P-value ≤ 0.05
α CEBPA status versus CEBPAwt
β FLT3ITD versus no FLT3ITD mutation
β FLT3TKD versus no FLT3TKD mutation
β NPM1 mutant (+) versus no NPM1wt
δ WBC count higher than 20x109/L versus lower than 20x109/L
$ Age is used as continuous variable
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Treatment outcome of AML with CEBPAsm is dominated by FLT3 / NPM1 genotypes
Finally, we performed explorative subgroup analyses in CEBPAsm and CEBPAwt AML to evaluate 
the impact of four FLT3/NPM1 genotype subgroups: FLT3ITD/NPM1mutant (n=10); FLT3ITD/NPM1wt 
(n=8); FLT3wt/NPM1mutant (n=11);
 
and FLT3wt/NPM1wt (n=21). Ten cases from the CEBPAsm group 
were excluded for which the genotypes were unknown.
Among patients with CEBPAsm AML, the FLT3ITD/NPM1wt genotype had an inferior OS compared 
to those with the FLT3wt/NPM1wt genotype (5-year OS, 25% versus 49%, P = .05; Figure 2B); for 
EFS and RFS, there was a trend towards an inferior outcome (Figure S3B and S3E); in contrast, 
the FLT3wt/NPM1mutant genotype associated in trend with a favorable outcome compared with 
the FLT3wt/NPM1wt genotype (5-year OS, 78% versus 49%, P = .2, EFS: 59% versus 32%, P = .08, 
RFS: 66% versus 40%, P = .38, Figure 2B, S3B and S3E). In analogy, in the CEBPAwt group the 
FLT3ITD/NPM1wt genotype had a significantly inferior survival compared with the FLT3wt/NPM1wt 
genotype (5-year OS, 17% versus 34%, P = .001; EFS, 11% versus 14%, P = .04; RFS, 15% versus 
24%, P = .002; Figure 2C, S3C and S3F), whereas the FLT3wt/NPM1mutant genotype was associated 
with a favorable outcome (5-year OS, 57% versus 34%, P < .0001; EFS, 47% versus 14%, 
P < .0001; RFS: 50% versus 24%, P < .0001; Figure 2C, S3C and S3F). Thus, we observed comparable 
trends for favorable (FLT3wt/NPM1mutant) and inferior (FLT3ITD/NPM1wt) outcome in the CEBPAsm 
and CEBPAwt subgroups. The outcome for all CEBPAsm FLT3/NPM1 genotypes was higher (not 
significant, P > .05), compared to the CEBPAwt genotypes, however, the distinct groups were 
relatively small. For CEBPAdm AML, sample sizes of the composite genotypic subgroups were too 
small for analysis.
Unsupervised analyses of GEP showed homogeneity in CEBPAdm AML cases
Gene expression profiling (GEP) was performed in a subset of the CN-AMLs patients and also 
includes cytogenetically abnormal patients (Table S1; n=674). Unsupervised analyses, i.e. by 
computing pair-wise Pearson correlation coefficients of 674 AML cases, revealed distinct GEP 
clusters (Figure 3A), including the known clusters of AML with inv(16), t(15;17) or t(8;21), as 
shown previously 18. These subtypes revealed high correlation within the GEP cluster (average 
correlation: .42, .49 and .49, respectively) and differed significantly between the AML cases with 
any of these aberrations (P < .0001, P < .0001, and P < .0001, Figure S5B, S5C and S5E). We 
observed that the CEBPAdm AML cases were highly similar within the cluster (average correlation: 
.35) and differed significantly from cases without a CEBPAdm (P < .0001, Figure S5D). CEBPAsm 
AML cases showed reduced similarity (average correlation: .15) and did not differ from cases 
without CEBPAsm (P = .12, Figure S5A and Figure 3A). 
CEBPAdm AML is accurately predicted based on GEP
The previously predictive CEBPAdm signature 35 was hampered by the recently reported CEBPA 
silenced AML cases that carry a similar GEP 34. Two independent AML cohorts were used to train 
and evaluate the predictive value of the CEBPAdm signature in terms of sensitivity and specificity. 
A predictive signature was created, containing 25-probesets by using a logistic regression 
model with Lasso regularization (Figure 3B and Supplementary material Table S2) 213,214, which 
selects discriminative probesets between the classes, CEBPAdm (n=26) and all other AML cases, 
CEBPAwt and CEBPAsm (n=494). Subsequently, a classifier was trained on the entire HOVON-SAKK 
cohort based on a two class approach; 26 CEBPAdm versus 494 cases (CEBPAwt and CEBPAsm). 
This trained classifier subsequently classified 16 candidate CEBPAdm cases (Supplementary 
material Table S3) in the AMLSG-cohort out of 154 AML cases (16 CEBPAdm, 6 CEBPAsm and 132 
CEBPAwt: Supplementary material Table S1). Among the CEBPAdm cases were 5 cases with either 
homozygous N-terminal or C-terminal CEBPAdm mutations, and a CEBPAdm patient with a germline 
C-terminal mutation. This approach showed perfect sensitivity and specificity (both 100%, Figure 
3C). In addition, we performed a classification between CEBPAdm, CEBPAsm, and CEBPAwt to infer, 
if we were able to accurately classify CEBPAsm cases. We observed that all CEBPAsm cases were 
classified as CEBPAwt, thus CEBPAsm cases did not have a consistent gene expression pattern and 
were different from the CEBPAdm group. 
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Figure 3. Unsupervised analyses and classification results of candidate CEBPAdm cases with their gene expression pro-
file and their molecular characteristics. (A) Pair-wise correlations between the 674 AML cases (Table S1). The cells in 
the visualization are colored by Pearson correlations values, depicting higher positive (red) or negative (blue) correla-
tions, as indicated by the scale bar. CEBPAsm, CEBPAdm, CEBPAC-terminal mutation, CEBPAN-terminal mutation, CEBPAsilenced, together with 
inv(16), t(15;17) and t(8;21) cases are depicted on the diagonal with a red or blue colored bar. CEBPAC-terminal mutation and 
CEBPAN-terminal mutation indicates the presence of homozygous mutations. (B) Candidate CEBPAdm patients and the unambigu-
ous CEBPAsm patients. The expression levels are defined by the 25-probeset signature. The colors of the hierarchical clus-
tering are relative to the mean. (C) Computed posterior probabilities, indicating the prediction of a CEBPAdm case, given 
the 25 predictive probeset signature: P(CEBPAdm | 25-probesets). The ordering of patients is based on the classification 
probabilities. The true labels (molecular characteristics) are depicted in (D). Black indicates the mutation status in CEBPA 
(CEBPAdm or CEBPAsm), NPM1 (NPM1mutant), or FLT3 (TKD or ITD), white represents no mutation in the particular patient 
and a missing value is depicted in grey. The asterisk indicates the germline CEBPAdm cases.
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DISCUSSION
Here, we established the value of CEBPAdm mutation in a large cohort of CN-AML patients from 
AMLSG and HOVON-SAKK treatment trials. Applying dHPLC and whole-gene sequencing, we 
detected 91 (7.7%) double CEBPA and 60 (5.1%) single CEBPA mutations among 1182 patients. 
In multivariate analyses, we demonstrate that the presence of CEBPAdm but not CEBPAsm is an 
independent factor for favorable outcome in AML, which confirms previous findings reported in 
studies with relatively small cohorts 35,45,46,48.
Concurrent mutations were significantly less frequent in CEBPAdm compared with CEBPAsm AML. 
This was true for FLT3ITD and in particular for NPM1mutant that were virtually not present among 
CEBPAdm cases, a finding that is consistent with previously published data 47. 
Compared to previous studies 35,45-48, and the large number of cases, we were able to evaluate the 
prognostic impact of the CEBPA mutational status in the context of the FLT3/NPM1 genotypes. 
Among CEBPAsm AML, the four combined genotypes showed similar trend with regard to outcome 
as compared with CEBPAwt AML (Figure 2B and 2C). Nevertheless, we observed a higher outcome 
(not significant) for all CEBPAsm FLT3/NPM1 genotypes compared to the CEBPAwt genotypes, but 
these groups are relatively small. These findings, supported by data from multivariable analysis, 
strongly suggest that not the existence of CEBPAsm per se but rather the combined effects of 
CEBPAsm and FLT3ITD and/or NPM1mutant determine outcome in these AML patients. 
We have previously derived gene expression signatures that predict AML with inv(16), t(15;17) 
and t(8;21) with 100% accuracy. Here, we generated a refined GEP signature, consisting out 
of 25-probesets that predict CEBPAdm AML cases (six genes overlapped with the previous 
signature35, indicated in supplementary). This signature showed sensitivity and specificity of 
100% and has a better predictive power than the CEBPAdm signature that we defined before35. 
In fact, in contrast to the previous signature, the new signature also discriminates CEBPAdm from 
AML with hypermethylation of the proximal promoter region of CEBPA 34. Classification results 
were not affected by homozygous N-terminal or C-terminal CEBPAdm mutations or those due to 
germline mutation. Since this 25-probeset signature was optimized for classification it does not 
necessarily provide insight into the biological meaning of CEBPAdm mutations.
Currently, nucleotide sequencing is used as the gold standard for the identification of CEBPA 
mutations. Due to the much higher effort of gene expression profiling this technique should not 
be considered as a primary diagnostic tool in AML. However, GEP can be confirmatory, especially 
in cases where the CEBPA gene appears difficult to sequence. More importantly, GEP provides 
relevant insights in the biology of the disease and the affected signaling pathways and therefore 
allows further classification/refinement of AML. 
Finally, we evaluated the frequency of CEBPA germline mutations in this large cohort of CEBPA-
mutated cases. Among 71 mutated patients, 5 revealed germline mutations. Four of these cases 
developed CEBPAdm AML, i.e., these cases acquired a mutation in the second allele. This finding 
is in line with previous data 215,216. Interestingly, we for the first time identified three C-terminal 
germline mutations. Two of these C-terminal mutated germline cases acquired a second CEBPA 
mutation at the time of AML diagnosis. In GEP analysis both cases clustered within the CEBPAdm 
group and were classified as a CEBPAdm, providing evidence that these C-terminal sequence 
variations are mutations rather than polymorphisms. All three C-terminal germline mutations 
were predicted to be damaging for the function and the structure of the protein.
In the current World Health Organization (WHO) classification AML, “AML with mutated CEBPA” 
has been designated as a provisional disease entity in the category “AML with recurrent genetic 
abnormalities”. Based on our data obtained from a large patient cohort together with findings 
from previous reports we propose that CEBPAdm AML should be clearly distinguished from 
CEBPAsm AML and that only “AML with CEBPAdm” should be considered as an independent entity 
in the classification of the disease.
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SUPPORTING MATERIAL
CEBPA mutation screening
Blast cells were purified using Ficoll-Hypaque (Nygaard, Oslo, Norway) centrifugation. Patients 
from the AMLSG-cohort (n=989) has been identified by direct sequencing, allowing the detection 
of homozygous mutations whereas the The 193 patients from HOVON-SAKK cohort have been 
pre-screened by dHPLC as previously described 35. However, the C amplicon covering the region 
encoding the C-terminus of CEBPA was split into two smaller amplicons using two additional 
primers (C1B rev 5’-ACTTCTTGGCCTTGCCCGCG-3’ and C2 fw 5’-CCTCCGCGCGAGTGGCGGCA-3’). 
Amplicon C1 was generated using primer set C fw and C1B rev and amplicon C2 with primer set 
C2 fw and C rev. This dHPLC strategy using these 5 CEBPA amplicons (fragment, A, B, C, C1 and 
C2) has been validated on a cohort of 550 AML cases. All known insertion/deletion and point 
mutants were detected. Mutations in CEBPA in AML patients from the AMLSG-cohort (n=989) 
have been identified by sequencing and confirmed by the above mentioned dHPLC strategy.
Creation and evaluation of the CEBPAdm predictive signature
For the classification procedures we used a logistic regression model with Lasso regularization2,3, 
which selects discriminative probesets between the classes, CEBPAdm (n=26) and 494 remaining 
cases (CEBPAwt and CEBPAsm) (HOVON-SAKK cohort). To determine the optimal signature 
(25-probesets, Figure 3B) we proceed with a 10-fold cross-validation where we optimized the 
cross-validated likelihood. With this signature we were able to discriminate the CEBPAdm cases 
from CEBPAsm, CEBPAsilenced 4, and CEBPAwt cases. This 25-probeset signature showed overlap with 
six genes (DLC1, MARVELD1, NDFIP1, RAB13, RAB34, UMODL1) with the previous signature 1. 
More details about the derived 25-probesets can be found in Supplementary material Table S2. 
Furthermore, we inferred an optimal signature from the combined datasets (HOVON-SAKK and 
AMLSG-cohort). By increasing the number of training samples we introduce more information 
and therefore better estimations of the variance into the model. A downside is that no estimation 
of the test error could be inferred. For this reason we subject ourselves to the use of estimated 
statistics. First, we make use of the globaltest 5 which has the following null hypothesis:
H0: There is no information/pattern in the given data related to the outcomes (i.e. class labels).
When applied to the HOVON-SAKK and AMLSG-cohort, the null hypothesis can clearly be 
rejected (P = 2.6x10-18, P = 7x10-7 respectively). Finally, the globaltest is applied to the combined 
dataset and showed that the addition of the AMLSG-cohort introduced valuable information 
with respect to the classification of CEBPAdm (P = 2.1x10-32). Using 10-fold cross-validation, we 
determined an optimal signature containing 36 probesets (Supplementary material Table S4) 
which attained a slightly lower estimated test error (.014 instead of .018), based on the cross-
validation of the training sample, when compared to the 25-probeset signature.
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Figure S1. Kaplan-Meier survival curves of HOVON-SAKK and AMLSG-cohort. Kaplan-Meier survival curves for OS (A) 
and EFS (B) based on 193 and 989 patients for HOVON-SAKK cohort and AMLSG-cohort respectively. Log-rank test was 
assessed to indicate the significance between the two cohorts.
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Figure S2. Kaplan-Meier survival curves of HOVON-SAKK and AMLSG-cohort with respect to therapy. Kaplan-Meier sur-
vival curves for OS (A) and EFS (B) based on 93 and 341 patients who were treated with autologous or allogeneic hema-
topoietic stem cell transplantation in HOVON-SAKK cohort and AMLSG-cohort respectively. Log-rank test was assessed to 
indicate the significance between the two cohorts with respect to therapy.
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Figure S4. Kaplan-Meier survival curves of N-terminal, C-terminal CEBPAsm and N+C CEBPAdm. Kaplan-Meier survival 
curves for OS among the groups: N-terminal CEBPAsm (n=47), C-terminal CEBPAsm (n=13), N+C terminal CEBPAdm (n=82) 
and CEBPAwt (n=1031). Nine cases (homozygous CEBPAdm) are excluded. Log-rank test was assessed to indicate the sig-
nificance between the different groups.
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Figure S5. Assessing significance of the detected clusters. With the use of unsupervised clustering (using Pearson cor-
relation coefficient) on 776 probesets, we observed that the groups; inv(16), t(15;17), t(8;21) and CEBPAdm form unique 
clusters whereas CEBPAsm did not. To assess the significance within the GEP cluster compared to AML cases with any 
of these aberrations (rest-group), we used the Mann- Whitney-U test. High correlation is observed in (B): inv(16), (C): 
t(8;21), (D): CEBPAdm and (E): t(15;17) (on average: .42, .49, .35 and .49 respectively) and differed significantly between 
the AML cases with any of these aberrations (P < .0001). Low correlation within the cluster is observed for CEBPAsm (A) 
(on average: .15) and did not differ significantly from cases without CEBPAsm (P=.12).
Table S1. Molecular data and Gene Expression Profiles. 
 HOVON-SAKK cohort AMLSG-cohort Total
Molecular data , n (%) 193 989 1182
 CEBPAdm 18 (9.3%) 73 (7.4%) 91 (7.7%)
 CEBPAsm 6 (3.1%) 54 (5.5%) 60 (5.1%)
GEP data 520 154 674
 CEBPAdm 26 (5%) 16 (10.4%) 42 (6.2%)
 CEBPAsm 12 (2.3%) 6 (3.9%) 18 (2.6%)
Data originates from the Erasmus University Medical Center (HOVON-SAKK cohort) and the University of Ulm (AMLSG-
cohort). Molecular data of 1182 CN-AML patients with age ≤ 60 is determined with a mutational screening of gene CEBPA. 
Gene Expression Profiles of 674 patients is derived using Affymetrix (Santa Clara, CA, USA) HGU133Plus 2.0 GeneChips.
Table S2. 25-probeset predictive signature. 
Probe sets Gene names Regr.coef. CEBPAwt Regr.coef. CEBPAdm
204039_at CEBPA -0.57251  0.57251
210762_s_at DLC1 -0.27537  0.27537
223095_at MARVELD1  0.19285 -0.19285
1553183_at UMODL1 -0.16304  0.16304
214651_s_at HOXA9  0.13178 -0.13178
1555630_a_at RAB34  0.13111 -0.13111
222423_at NDFIP1  0.12159 -0.12159
203305_at F13A1  0.11138 -0.11138
202252_at RAB13  0.10715 -0.10715
209686_at S100B -0.09809  0.09809
211709_s_at CLEC11A  0.08409 -0.08409
34210_at CD52  0.07837 -0.07837
206698_at XK -0.07267  0.07267
205624_at CPA3  0.06188 -0.06188
201161_s_at CSDA  0.05761 -0.05761
219463_at C20orf103 -0.04653  0.04653
201427_s_at SEPP1  0.03573 -0.03573
223708_at C1QTNF4 -0.03452  0.03452
238021_s_at hCG-1815491  0.02297 -0.02297
220010_at KCNE1L -0.02197  0.02197
210387_at HIST1H2BG -0.0125  0.0125
210116_at SH2D1A  0.01169 -0.01169
202242_at TSPAN7 -0.00961  0.00961
212775_at OBSL1  0.0094 -0.0094
201841_s_at HSPB1//MEIS3  0.00725 -0.00725
The 25-probeset predictive signature is created using the logistic regression model with Lasso regularization, which 
determined the discriminative probesets between the classes, CEBPAdm (n=26) versus no CEBPAdm (n=494) (HOVON-
SAKK). CEBPAwt; CEBPA wild-type, CEBPAdm; CEBPA double mutation, Probesets; the 25 selected probesets, Gene names; 
the complementary gene names for the selected probesets, Regr.coef.; Regression coefficient derived from the Lasso 
procedure for the CEBPAwt and CEBPAdm cases.
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Table S3. Classification results. 
True label Sample ID P(CEBPAwt|25 probe sets) P(CEBPAdm|25 probe sets)
CEBPAsm ULM 001 0.99995 0.00004
CEBPAsm ULM 002 0.99985 0.00014
CEBPAsm ULM 003 0.99969 0.0003
CEBPAsm ULM 004 0.99943 0.00056
CEBPAsm ULM 005 0.99939 0.0006
CEBPAsm ULM 006 0.98616 0.01383
CEBPAdm ULM 007 0.31343 0.68656
CEBPAdm ULM 008 0.19452 0.80547
CEBPAdm ULM 009 0.12677 0.87322
CEBPAdm ULM 010 0.11421 0.88578
CEBPAdm ULM 011 0.10167 0.89832
CEBPAdm ULM 012 0.07047 0.92952
CEBPAdm ULM 013 0.06327 0.93672
CEBPAdm ULM 014 0.06322 0.93677
CEBPAdm ULM 015 0.06044 0.93955
CEBPAdm ULM 016 0.05167 0.94832
CEBPAdm ULM 017 0.04757 0.95242
CEBPAdm ULM 018 0.02838 0.97161
CEBPAdm ULM 019 0.02626 0.97373
CEBPAdm ULM 020 0.01683 0.98316
CEBPAdm ULM 021 0.01048 0.98951
CEBPAdm ULM 022 0.0054 0.99459
Abbreviations: True label; CEBPAsm and CEBPAdm are determined using sequencing and denaturing high performance 
liquid chromatography (dHPLC), Sample ID: Sample identification number, P(CEBPAwt |25-probesets): probability that 
sample ID is classified as CEBPAwt given the 25-probeset predictive signature, P(CEBPAdm |25-probesets): probability that 
sample ID is classified as CEBPAdm given the 25-probeset predictive signature. CEBPAwt; CEBPA wild-type, CEBPAdm; CEBPA 
double mutation, CEBPAsm; CEBPA single mutation.
Chapter 7
Table S4. 36 probeset predictive signature.
Probesets Gene names Regr.coef. CEBPAwt Regr.coef. CEBPAdm
202007_at NID1  0.01636 -0.01636
202018_s_at LTF -0.00318  0.00318
202252_at RAB13  0.06454 -0.06454
202382_s_at GNPDA1  0.02519 -0.02519
203305_at F13A1  0.12536 -0.12536
203860_at PCCA  0.04591 -0.04591
204039_at CEBPA -0.08967  0.08967
206210_s_at CETP -0.0517  0.05170
209686_at S100B -0.02699  0.02699
209905_at HOXA9  0.06141 -0.06141
210298_x_at FHL1  0.01507 -0.01507
210762_s_at DLC1 -0.00626  0.00626
211209_x_at SH2D1A  0.05816 -0.05816
211341_at LOC100131317 // POU4F1 -0.00442  0.00442
211560_s_at ALAS2 -0.02554  0.02554
211682_x_at UGT2B28 -0.07277  0.07277
211709_s_at CLEC11A  0.06346 -0.06346
212062_at ATP9A  0.00432 -0.00432
214146_s_at PPBP  0.07145 -0.07145
214651_s_at HOXA9  0.1766 -0.1766
214835_s_at SUCLG2  0.10251 -0.10251
215772_x_at SUCLG2  0.0422 -0.0422
217800_s_at NDFIP1  0.00914 -0.00914
219463_at C20orf103 -0.09278  0.09278
220807_at HBQ1 -0.03991  0.03991
222288_at PPP4R2  0.0637 -0.0637
222463_s_at BACE1  0.00838 -0.00838
223708_at C1QTNF4 -0.10196  0.10196
224710_at RAB34  0.34355 -0.34355
229638_at IRX3  0.11367 -0.11367
235099_at CMTM8  0.01472 -0.01472
235289_at EIF5A2 -0.00758  0.00758
235438_at CYP7B1 -0.23982  0.23982
235818_at VSTM1 -0.05598  0.05598
239791_at LOC100130740  0.08214 -0.08214
34210_at CD52  0.13627 -0.13627
The 36 probeset predictive signature is created using the logistic regression model with Lasso regularization, which 
determined the discriminative probesets between the classes, CEBPAdm (n=42) versus no CEBPAdm (n=632) (HOVON-SAKK 
and AMLSG-cohort). CEBPAwt; CEBPA wild-type, CEBPAdm; CEBPA double mutation, Probesets; the 36 selected probesets, 
Gene names; the complementary gene names for the selected probesets, Regr.coef.; Regression coefficient derived from 
the Lasso procedure for the CEBPAwt and CEBPAdm cases.
Prognostic Impact, Concurrent Genetic Mutations and Gene Expression Features of AML with CEBPA 
Mutations in a Cohort of 1182 Cytogenetically Normal AML: Further Evidence for CEBPA Double-mutant 
AML as a Distinctive Disease Entity
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KEY POINTS: 
•  In AML with bialleleic CEBPA-mutant relapse-free survival was improved by allogeneic and 
autologous hematopoietic stem cell transplantation.
•  In relapsed patients second complete remission rate was high and survival was favorable after 
an allogeneic transplantation.
ABSTRACT
The clinical value of allogeneic and autologous hematopoietic stem cell transplantation 
(alloHSCT, autoHSCT) in the subtype of acute myeloid leukemia (AML) with double-mutant 
CEBPA (CEBPAdm) has remained unsettled.
Among 2983 patients analyzed for CEBPA mutational status (age 18-60 years) treated on four 
HOVON/SAKK and three AMLSG protocols; 124 had AML with CEBPAdm and achieved first 
complete remission (CR1). Evaluation of the clinical impact of alloHSCT and autoHSCT versus 
chemotherapy was performed by addressing time dependency in the statistical analyses. 
Thirty-two patients proceeded to alloHSCT from a matched related (MRD, n=29) or matched 
unrelated donor (MUD, n=3) and 20 to autoHSCT in CR1; 72 received chemotherapy. Relapse-
free survival (RFS) was significantly superior in patients receiving an alloHSCT or autoHSCT in 
CR1 as compared to chemotherapy (P < 0.001), whereas overall survival (OS) was not different 
(P = 0.12). Forty-five patients relapsed. Of 42 patients treated with reinduction therapy, 35 
achieved a second CR (83%) and most (n=33) patients received an alloHSCT (MRD, n=11; MUD, 
n=19; haplo-identical donor, n=3). Survival of relapsed patients measured from date of relapse 
was 46% after 3 years. 
Adult AML patients with CEBPAdm benefit from alloHSCT and autoHSCT; relapsed patients still 
have a favorable outcome after reinduction followed by alloHSCT.
INTRODUCTION
Acute myeloid leukemia with mutated CCAAT/enhancer binding protein alpha (AML with 
mutated CEBPA) gene represents a provisional disease entity in the current World Health 
Organization classification in the category “AML with recurrent genetic abnormalities”.119,200 
However, multiple studies demonstrated that AML with double-mutant CEBPA (CEBPAdm) could 
be clearly distinguished from AML with single mutant CEBPA with respect to biological and 
prognostic features.35,45-48,178,259 In the majority of AML with CEBPAdm, one allele is affected by 
an N-terminal mutation and the second allele carries the mutation in the C-terminus (bZIP), 
whereas in AML with single mutant CEBPA, mutations occur either in the N-terminus or in the 
C-terminus of the gene. The previously shown favorable impact of mutant CEBPA in various 
independent comprehensive studies on prognosis259 has more recently been specifically related 
to the subtype of AML with CEBPAdm.35,45-48,178
The incidence of AML with mutated (single and double) CEBPA ranges from 7.5% to 11% of all 
AML patients and from about 13% to 18% in AML exhibiting a normal karyotype. 31,35,38,41,45-48,178 
Furthermore, the incidence of AML with mutated CEBPA in patients above the age of 60 years 
range from 8.5%260 to 18%.261 Young and middle aged adults (age 18-60 years) with AML and 
mutated CEBPA and especially those with CEBPAdm have a comparatively high probability of 
achieving a complete remission after standard “7+3” induction therapy with remission rates 
exceeding 90%.46,178 Treatment outcome data revealed a favorable prognosis with an overall 
survival after 5-years ranging between 50% and 70%35,45-48,178 including different types of 
consolidation therapy with intensive chemotherapy, autologous and allogeneic hematopoietic 
stem cell transplantation (autoHSCT and alloHSCT). However, relapse still remains the major cause 
of treatment failure occurring mainly within the first 2 years after achieving a complete remission 
(CR). This has for instance raised the question whether autoHSCT and alloHSCT in first CR should 
be recommended in patients with this genetic abnormality. So far, analyses according to the type 
of postremission treatment in CEBPAdm AML patients have not become available mainly due to 
limited patient numbers precluding informative statistical analyses. Thus, it remains still unclear 
whether the favorable prognosis of AML with CEBPAdm can be attributed to the mutation itself 
irrespective of the type of applied postremission therapy (i.e. prognostic marker) or whether 
the favorable prognosis is the result of a high rate of cure after autoHSCT and alloHSCT in first 
CR and after relapse (i.e. predictive marker). Informative insight into these factors could be of 
direct clinical relevance as it may guide treatment decisions on the application of autoHSCT and 
alloHSCT already in first CR or alternatively to hold back on these approaches and reserve the 
option especially of an alloHSCT as salvage only in relapsed patients. To address this question, 
the Dutch-Belgian-Swiss HOVON/SAKK and the German-Austrian AMLSG leukemia cooperative 
groups performed in a joint effort an individual-patient based meta-analysis focusing on the AML 
CEBPAdm subtype in first CR. The aim was to evaluate different postremission strategies with 
major focus on the comparison between alloHSCT, autoHSCT and intensive chemotherapy in a 
large series of CEBPAdm AML patients in first CR. Furthermore, in an integrated approach we also 
included treatment after relapse and its impact on outcome.
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PATIENTS AND METHODS 
Patients and Treatment
All patients included in this study were recruited within two major leukemia cohorts. AML 
patients from Cohort I (n=3450) were enrolled in the Dutch-Belgian-Swiss Hemato-Oncology 
Cooperative Group (HOVON/SAKK) trials HOVON04(A), HOVON29/SAKK30/95203,263,264, 
HOVON42(A)/SAKK30/00 and HOVON92/SAKK30/08263-265 (www.hovon.nl). Patients received 
two successive cycles of anthracycline-cytarabine and amsacrine-cytarabine based remission 
induction chemotherapy and, subsequently, in first CR consolidation chemotherapy, autoHSCT 
after myeloablative therapy according to a randomization against chemotherapy and depending 
on an adequate stem cell collection265, or alloHSCT following mainly myeloablative conditioning 
depending on the availability of a matched related donor.
Cohort II (n=2274) comprised patients who were enrolled in the German-Austrian AML Study 
Group (AMLSG) trials AML HD93,266 AML HD98A267 and AMLSG 07-04 (ClinicalTrials.gov Identifier: 
NCT00151242). Consistently throughout all AMLSG trials, patients with AML exhibiting an 
intermediate-risk karyotype with mutant CEBPA were intended to receive, i) a double induction 
therapy with ICE (idarubicin, cytarabine, etoposide) and, ii) repetitive cycles of high-dose 
cytarabine based consolidation therapy or, if an HLA-matched family donor was available, an 
allogeneic HSCT after a myeloablative conditioning regimen. 
Patients were selected from the total cohort, if they fulfilled all three of the following 
criteria, i) normal karyotype or intermediate-risk karyotype according to ELN criteria200, 
ii) CEBPAdm, iii) CR after induction therapy. The selection process is illustrated in Figure 1. 
3450 2274
2972
1174
Karyotype available 2175
CEBPA status available 1809
53 84CEBPAdm
52 74CR after induction
*Non Intermediate-I or intermediate-II 
karyotype according to ELN classification 
n=2*
*i) complex karyotype including -5/7(q)-, ii) inv(16)(p13q22)
Intermediate karyotype 50 74
Final Cohort 124
HOVON/SAKK
Cohort
AMLSG
Cohort
Figure 1. Flow chart on patient selection. Number of patients according to each selection step.
In 90% (5147/5724) of the patients information on cytogenetics was available. In these 5147 
patients the CEBPA mutation status was available in 2983 (58%); of those 137 exhibited a 
CEBPAdm in the context of a normal karyotype or intermediate-risk cytogenetics (4.6%).One-
hundred-twenty-four achieved a first CR after induction therapy within the different protocols 
(90.5% CR rate) and were included into this study. 
All patients provided written informed consent in accordance with the Declaration of Helsinki. All 
trials were approved by the Institutional Review Boards. CEBPA mutational status was identified 
by denaturing High-Performance Liquid Chromatography (dHPLC), PCR amplification followed 
by direct sequencing or fragment-length analysis (GeneScan) and subsequent sequence analysis 
in any positive cases.35,46 Cytogenetics and molecular analyses were performed as described 
before.24,31,178,208,209
Statistical analysis
The definition of CR and survival endpoints such as overall survival (OS), cumulative incidence 
of relapse (CIR) and death (CID), as well as relapse-free survival (RFS) were based on the 
recommended consensus criteria.200 Actuarial estimates were used for assessment of the 
median follow-up for survival. Patient characteristics were compared by the Kruskal-Wallis test 
(continuous variables) and the Fishers exact test (categorical variables). Cumulative incidence 
of relapse (CIR) and death (CID) were analyzed according to the method of Gray.268 To address 
the time dependence of the variables alloHSCT and autoHSCT, the graphical representation 
according to the method of Simon and Makuch was used as well as the Mantel-Byar test, as 
appropriated statistical approach in univariable analyses.269,270 For multivariable analyses an 
extended Cox regression model was used according to the method of Andersen and Gil.271 For 
all analyses, a P-value was considered statistically significant if it was less or equal than .05. 
All statistical analyses were performed using the statistical software Stata Statistical Software, 
Release 12.
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Figure 2. Influence of karyotype abnormalities on outcome. Kaplan-Meier plots for the endpoints a) RFS and b) OS 
according to the karyotype (normal versus abnormal).
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RESULTS 
Demographics and clinical baseline characteristics of the study population
In this cooperative individual-patient data meta-analysis, 124 CEBPAdm AML patients were 
included with normal karyotype or intermediate-risk cytogenetics, age between 18 and 60 years, 
and first CR after induction therapy. The patients were selected from the total study population 
treated in HOVON/SAKK and AMLSG prospective multicenter clinical trials recruited between 
1987 and 2009 (Figure 1). Baseline characteristics and demographics for the total cohort are 
shown in Table 1. 
No significant difference in overall survival was seen between HOVON/SAKK and AMLSG 
CEBPAdm patient cohorts (n=50 vs. n=74, Cox test, P = .36); molecular and clinical variables were 
comparable between HOVON/SAKK and AMLSG CEBPAdm patient cohorts with exception of 
platelet counts (P = .02, lower in AMLSG) and bone marrow blasts (P < .0001, lower in HOVON/
SAKK). 
Postremission therapy, Cumulative Incidence of Relapse (CIR) and Death in CR (CID) in 
CEBPAdm patients
Distribution of postremission treatment modalities in the 124 patients was as follows: alloHSCT, 
n=32 (matched related donor [MRD] n=29, matched unrelated donor [MUD] n=3); autoHSCT, 
n=20; intensive chemotherapy, n=72. The median time interval from diagnosis to achievement 
of first CR was 1.1 months (range 0.36 - 4.11) with a trend (P = 0.053) for a longer interval 
in patients who received an autoHSCT as postremission treatment (median, 1.25 months) 
compared to those who received an alloHSCT (median, 1.1 months) or chemotherapy (median, 
1.1 months). The median time interval from first CR to alloHSCT and autoHSCT was 4.0 months 
(range 0.8-6.5) and 2.3 months (range 0.4-6.2), respectively. 
In total, 45 relapses (one after alloHSCT, 5 after autoHSCT, and 39 after intensive chemotherapy) 
and 19 treatment-related deaths (7 after alloHSCT, 3 after autoHSCT, and 9 after intensive 
chemotherapy) after a median time measured from CR1 of 10.8 months (range, 4.4-61) and 15 
months (range, 1.2-144) occurred. This leads to estimates of CIR and CID after 5-years of 3% (SE 
3%) and 24% (SE 8%) for alloHSCT, 27% (SE 11%) and 13% (SE 9%) for autoHSCT, and 58% (SE 6%) 
and 10% (SE 4%) for intensive chemotherapy, respectively. 
Treatment after relapse
After relapse, 41 patients received intensive reinduction therapy, one patient had repetitive 
cycles of subcutaneous azacitidine and three patients were treated with supportive care only. 
The second CR rate in all relapsed patients was 78% (35/45) and in those receiving reinduction 
therapy (including azacitidine) 83% (35/42). Thirty-three patients received an alloHSCT (MRD 
n=11, MUD n=19, haplo-identical donor n=3) after reinduction therapy. At the time of alloHSCT, 
28 patients achieved a second CR after reinduction therapy, four had refractory disease and one 
patient who relapsed after alloHSCT in first CR, received a stem cell boost from the same donor 
in second CR. Only one patient was treated with an autoHSCT after relapse. 
Table 1. Clinical and genetic characteristics of the total cohort and according to applied postremission therapy. 
 Total cohort Allo-HSCT Auto-HSCT no-HSCT P-value
Characteristics n=124 n=32 n=20 n=72
Age, years
    Median (range) 44 (16-60) 40 41 45 0.124
Sex, no. (%)
    Male 66 (53%) 21 (66%) 12 (60%) 33 (46%) 0.147
    Female 58 (47%) 11 (34%) 8 (40%) 39 (54%)
WBC, x 109/L
    Median (range) 32 (2-248) 16 (2-174) 36 (3-157) 34 (2-248) 0.228
    Missing 1 1
Platelets, x109/L
    Median (range) 41 (4-319) 39 (11.282) 47 (10-115) 40 (4-319) 0.421
    Missing 3 3
Bone marrow blasts
   Median % (range) 75 (7-100) 71 (7-99) 77 (31-99) 75 (25-100) 0.535
    Missing 5 1 4
Type of AML, n (%)
    De novo AML
    M0 6 (5%) 1 (3%) 5 (7%) 0.237
    M1 45 (36%) 10 (31%) 9 (45%) 26 (36%)
    M2 54 (44%) 16 (50%) 6 (30%) 32 (44%)
    M4 6 (5%) 2 (6%) 2 (10%) 2 (3%)
    M5 2 (2%) 1 (3%) 1 (5%)
    M6 1 (1%) 1 (5%)
    Unclassified 1 (1%) 1 (1%)
    Missing 9 (7%) 2 (6%) 1 (5%) 6 (9%)
Cytogenetics, n (%)
    Normal karyotype 92 (74%) 21 (66%) 14 (70%) 57 (79%) 0.317
Molecular characteristics, n (%)
    FLT3ITD 11 (9%) 5 (16%) 1 (5%) 5 (7%) 0.38
    NPM1+ 2 (2%) 1 (3%) 1 (1%) 0.67
    Missing 1 1
Abbreviations: AML, acute myeloid leukemia; WBC: white blood cell count; FLT3ITD, FLT3 internal tandem duplication; 
NPM1+, nucleophosmin 1; Subheadings under “de novo AML” refer to French American British classification subtypes; 
wt, wild-type; neg, negative. 
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Survival analysis
The median follow-up time of patients still alive at the date of last contact was 62 months. 
RFS and OS of the whole CEBPAdm patient cohort after 5-years were 48% (95%-CI, 38-57%) and 
63% (95%-CI, 53-72%), respectively. There was no difference in RFS (P = 0.24) and OS (P = 0.87) 
between patients exhibiting a normal karyotype and those with intermediate-risk karyotypes 
(Table 2, Figure 2). Based on the Mantel-Byar test including alloHSCT and autoHSCT applied 
in first CR as time dependent variables, RFS is significantly superior in patients receiving an 
HSCT (P < 0.001), with significant differences in favor of alloHSCT and autoHSCT as compared 
to intensive chemotherapy (P < 0.001 and P = 0.019, respectively) (Figure 3a). Multivariable 
analysis based on an Andersen-Gill model including time dependent postremission strategy 
as well as pretreatment values (Table 1) of WBC, platelets, BM-blast percentage, age and 
karyotype (normal versus abnormal) revealed that alloHSCT (HR, 0.23; P < 0.001) and autoHSCT 
(HR, 0.37; P = 0.012) applied in first CR had independently a favorable prognostic impact with 
regard to RFS (Table 3). However, apparently due to a high second CR rate after salvage therapy, 
the superior RFS after alloHSCT and autoHSCT did not translate into a better OS in univariable 
(P = 0.12) (Figure 3b) and multivariable analyses (Table 4).
In 45 relapsed patients OS measured from the date of relapse was 46% (95%-CI, 30-60%) after 
3 years (Figure 4). All patients surviving more than 2 years after first relapsed had undergone an 
allogeneic HSCT (n=15, Figure 4).
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Figure 3. Influence of postremission treatment modality (alloHSCT, autoHSCT, chemotherapy) on RFS (Fig 3a) and 
OS (Fig 3b). Simon-Makuch plots for the endpoints a) RFS and b) OS according to type of postremission therapy; 
allo, allogeneic HSCT; auto, autologous HSCT; chemotherapy.
Table 2. Abnormal karyotypes grouped according to leading aberrations.
del(9q)
    46,XY,del(9)(q12q31)[20]
    46,XY,del(9)(q12q22),del(11)(q13q23)[21]
    46,XY,del(9)(q12q34),del(11)(p11p15)[12]/46,XY[4]
    46,XX,del(9)(q12q31~32)[26]/47,idem,+21[2]/46,XX[7]
    46,XX,del(9)(q1?2q3?2)[7]/46,XX[14]
    46,XY,del(9)(q13q22)[22]
    46,XY,del(9)(q13q22)[8]/46,XY[18]
    46,XY,del(9)(q13q34)[2]/46,XY[19]
    46,XY,del(7)(q22q32)[30]/46,XY,del(7)(q22q32),del(9)(q13q32)[2]
    46,XX,del(9)(q21q22)
    46,XX,del(9)(q22)[20]
    46,XY,del(9)(q22q34)[13]/46,XY[7]
    46,XY,del(9)(q22q34)[10]
    46,XY,del(9)(q22q34)[2]/46,XY[17]
    46,XY,del(9)(q22q34)[5]/47,XY,del(9)(q22q34),+21[5]/46,XY[1]
    46,XY,del(9)(q3?1)[2]/46,XY[38]
    46,XX,del(9)(q3?1) or del(9)(q22q34)[11]/46,XX[19]
del(11q)
    46,XX,del(11)(q13q25)[20]
    46,XY,del(11)(q14q25)[3]/46,XY[60]
    46,XY,del(11)(q21q23)[6]/46,XY[9]
    46,XY,del(11)(q21q23)[7]
other
    45,X,-Y[14]
    45,X,-Y[8]/46,XY[14]
    46,XX,del(1)(p32p34)[21]
    46,XX,del(7)(p13p15)[4]/46,XX[6]
    46,XX,iso(17)(q10)[10]/46,XX[11]
    47,XX,+5[7]/46,XX[16]
    47,XX,+10[18]/46,XX[2]
    47,XY,+10[20]
    47,XX,+21[22]
    47,XY,+21[6]/46,XY[9]
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Table 3. Andersen-Gill model for the endpoint relapse-free survival. 
Prognostic markers* HR 95%-CI P-value
Allogeneic HSCT 0.23 0.11 - 0.51 < 0.001
Autologous HSCT 0.37 0.17 - 0.80 0.012
Log10 (WBC) 1.40 0.77 - 2.56 0.27
Log10 (platelets) 0.81 0.40 - 1.66 0.57
% BM blasts (difference 10%) 0.94 0.82 - 1.08 0.40
Age (difference of 10 years) 0.86 0.68 - 1.08 0.20
Abnormal karyotype 0.73 0.38 - 1.40 0.35
Abbreviations: HSCT hematopoietic stem cell transplantation; WBC, white blood cell count; % BM blasts, percentage 
bone marrow blasts.
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Figure 4. Outcome of patients after relapse. Simon-Makuch plot for the endpoint OS, second CR rate after salvage remis-
sion induction therapy and treatment details for patients surviving longer than 2 years.
Table 4. Andersen-Gill model for the endpoint overall survival. 
Prognostic markers* HR 95%-CI P-value
Allogeneic HSCT 0.50 0.21 - 1.17 0.11
Autologous HSCT 0.57 0.23 - 1.40 0.22
Log10 (WBC) 1.34 0.64 - 2.80 0.44
Log10 (platelets) 0.95 0.40 - 2.26 0.91
% BM blasts (difference 10%) 1.04 0.87 - 1.24 0.69
Age (difference of 10 years) 1.08 0.82 - 1.42 0.59
Abnormal karyotype 1.14 0.55 - 2.34 0.73
Abbreviations: HSCT hematopoietic stem cell transplantation; WBC, white blood cell count; % BM blasts, percentage 
bone marrow blasts.
DISCUSSION
This report focuses on the evaluation of the clinical impact in CEBPAdm patients of alloHSCT, 
autoHSCT in comparison to intensive consolidation therapy in first CR as well as on the impact of 
reinduction chemotherapy and alloHSCT after relapse. To this attempt, we report on 124 adults 
with AML and a normal karyotype or intermediate-risk karyotypes that harbor a CEBPAdm, and 
are aged 60 years and below. Only one relapsed patient received an autoHSCT in second CR 
and therefore we were not able to evaluate the clinical impact of autoHSCT after relapse. Our 
results clearly show that adult AML patients with the CEBPAdm genotype significantly benefit 
from alloHSCT and autoHSCT in first CR with respect to RFS.
In recent years it has become apparent that the favorable prognosis of CEBPA gene mutations 
largely depends on the presence of the CEBPAdm mutation type. At the molecular level AML 
with the CEBPAdm compared to AML with CEBPA single mutation type is associated with a lower 
frequency of coexisting NPM1 mutations and FLT3 internal tandem duplications (ITD).47,178 
Therefore, several investigators have recently suggested to restrict the provisional WHO 
2008 entity AML with CEBPA mutations to those with biallelic mutations.35,46-48,178 As a direct 
consequence the incidence of this AML entity defined by CEBPAdm decreases by about 40%47,178 to 
a frequency of 3% to 6% of all AML cases. The low frequency of CEBPAdm explains why comparative 
analyses with regard to different postremission strategies such as alloHSCT, autoHSCT and 
intensive chemotherapy have so far not been performed. Beside the recommended ELN-risk 
category200 AML with CEBPA we also included into the analyses the group of intermediate-risk 
karyotypes which includes approximately 30% of patients with chromosomal abnormalities, in 
particular interstitial deletion 9q272 and 11q (Table 2) instead of only patients with AML exhibiting 
a normal karyotype. This approach is supported by the similar favorable outcome in AML with 
CEBPAdm with and without normal karyotype in univariable and multivariable analyses presented 
here (Figure 2). Thus, these data add evidence that AML with CEBPAdm may be regarded as a 
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distinctive AML entity irrespective of additional chromosomal abnormalities categorized within 
the cytogenetically defined intermediate-risk group.200
In the current analyses we started with a total cohort of 5724 patients from which in 5147 a 
karyotype and of those in 2983 the CEBPA mutational status was available. This large cohort 
was required to finally achieve a sufficiently high number of 124 AML patients with CEBPAdm in 
first CR representing the basis of our analyses. This approach underlines that large cooperative 
intergroup meta-analyses are warranted to evaluate treatment effects with acceptable statistical 
power in rare but clinically highly relevant patient subsets. 
Our patients were treated in seven different treatment trials with in part changing therapeutic 
concepts over time. Thus, it is impossible to apply the rigorous statistical standards for 
postremission treatment allocation such as up-front or the so called genetic randomization. 
Instead, we applied statistical methods that have all in common that group allocation is 
implemented as a dynamic process over time with a transition from the no-transplant group to 
the alloHSCT or autoHSCT groups at the time-point of HSCT. This approach reduces the time-to-
treatment bias and provides a solid statistical methodology in situations where simple Kaplan-
Meier plots and log-rank tests as well as simple Cox regression models are no longer valid. 
However, to further reduce selection bias towards HSCT in first CR our univariable comparisons 
were complemented by multivariable Andersen-Gil regression models addressing again the 
time-to-treatment bias271 by including important pretreatment characteristics.
By using methods that adjust for the time from CR to consolidation we were able to show a 
clear superior RFS (P < 0.001) in patients who received an alloHSCT or an autoHSCT in first CR 
of 73% (95%-CI, 54-86%) and 60% (95%-CI, 33-79%) after 5-years, respectively. These survival 
rates compare favorably to the RFS of 32% (95%-CI, 21-45%) in patients receiving intensive 
chemotherapy only. A similarly good outcome has also been reported for other AML entities 
categorized into the favorable ELN-risk group such as core-binding factor AML (CBF-AML) including 
AML with inv(16) or t(16;16) and AML with t(8;21) after both alloHSCT and autoHSCT.273,253 
However, our results suggest that RFS after intensive chemotherapy is substantially lower for 
AML with CEBPAdm as compared to that of CBF-AML.274,275 Nevertheless, due to a high second 
CR rate in reinduced relapsed patients with more than 80% and a high proportion of patients 
proceeding to an alloHSCT after relapse, the high relapse rate in the chemotherapy subgroup 
did not translate into a significant inferior OS. In fact, the high second CR rate and favorable 
survival after relapse observed in the study reported here are comparable to the survival 
probabilities observed in AML with inv(16).274,275 Based on these data, AML with CEBPAdm and 
AML with inv(16) or t(16;16) appear as two well-defined exceptions from the general notion 
that after relapse a second CR is rarely achieved.276 Therefore, instead of applying alloHSCT as 
the compelling option in first CR, an alternative and not unreasonable strategy would be to 
postpone the alloHSCT in first CR and keep the option of alloHSCT for salvage for the restricted 
fraction of patients after relapse.276,277 Indeed, our data supports both strategies, alloHSCT or 
autoHSCT in first CR versus intensive chemotherapy as consolidation in first CR and reinduction 
followed by alloHSCT in case of relapse. Of note, the good results in our study with autoHSCT 
are paralleled by those obtained in Core-binding factor AML253,273 indicating a specific chemo-
sensitivity of these AMLs with favorable risk according to the ELN recommendations200 to dose 
escalation during consolidation therapy in first CR. Patients have to be well informed about the 
risks and consequences of alloHSCT and autoHSCT in first CR regarding: i) short278 and long279 
term physical and psychological impairment, ii) infertility and a higher rate of treatment-related 
mortality (e.g. for alloHSCT we observed in our cohort 24% at 5-years), and iii) increased rates 
of transplantation-related morbidity and mortality for alloHSCT when the latter is performed 
after relapse.262 Besides the survival considerations there are various other arguments that 
would favor the choice of an autoHSCT in first CR as compared to alloHSCT. Given the nearly 
identical RFS and OS rates after alloHSCT and autoHSCT the focus of outcome evaluations can 
be broadened to consider quality of life (QoL) aspects and late effects after transplantation as 
well as health economics, with a significantly better QoL and fewer late effects after autoHSCT 
compared to alloHSCT280 whereas data on health economics are very system specific.281 
In summary, our data provide novel clinical information that may be useful for refining the 
WHO 2008 classification and the ELN-risk categorization for the provisional entity AML with 
CEBPAdm in that beyond normal karyotype all intermediate-risk cytogenetics should be included. 
From a clinical perspective alloHSCT and autoHSCT performed in first CR were associated with 
comparatively excellent RFS and OS, whereas the reduced rate of RFS in patients receiving 
consolidation with intensive chemotherapy could be made up after relapse by a high rate of 
second CR followed by alloHSCT. Thus the marker CEBPAdm develops with respect to RFS to a 
predictive marker indicating superior RFS after autoHSCT and alloHSCT, but remains a prognostic 
marker with respect to OS. The pros and cons of alloHSCT and autoHSCT during first CR or, as an 
alternative option, alloHSCT after relapse have to be carefully considered and discussed with the 
patients with possible individual adaptation of treatment recommendations taking into account 
the patients personal context. 
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KEY POINTS: 
• Splice factor mutant myeloid malignancies transcend the boundaries between AML and MDS. 
•  Integrated analysis of gene expression and DNA-methylation profiles in leukemia uncovers 
novel subtypes.
ABSTRACT
Mutations in splice factor (SF) genes occur more frequently in myelodysplastic syndromes (MDS) 
than in acute myeloid leukemias (AML). We sequenced cDNA from 31 human RAEB (refractory 
anemia with excess of blasts), 49 RAEB in transformation (RAEB-t) and 324 AML patients and 
determined the presence of SF-hotspot mutations in SF3B1, U2AF35, and SRSF2. SF-mutations 
were found in 9 RAEB, 11 RAEB-t and 28 AML cases. SF-mutant AMLs were older, showed lower 
white blood cell counts, lower marrow blast percentages and higher erythroblast percentages 
than SF-wild-type AMLs. An integrated analysis of gene expression (GEP) and DNA-methylation 
profiling (DMP) data revealed two unique patient-clusters highly enriched for SF-mutant AML/
RAEB(T). The combined GEP/DMP signatures revealed one SF-mutant subset with an erythroid 
signature. The other SF-mutant cluster was enriched for NRAS/KRAS mutations and showed 
an inferior survival. We conclude that SF-mutant AML/RAEB(T) constitute a related disorder 
overriding the artificial separation between AML and MDS, and that SF-mutant AML/RAEB(T) 
is composed of two molecularly and clinically distinct subgroups. This suggests that these SF-
mutant malignancies may be considered as myeloid malignancies that transcends the boundaries 
of AML and MDS. 
INTRODUCTION
Myelodysplastic syndromes (MDS) are characterized by a deregulation of blood cell formation 
and frequently develop into acute myeloid leukemia (AML). MDS patients feature recurrent 
somatic mutations in multiple components of the RNA splicing machinery217-220. These mutations 
are frequently seen in the splice factor (SF) genes, SRSF2, U2AF35, ZRSR2, U2AF65, SF1, SF3B1, 
SF3A1 or PRPF40B217-219. Among the many non-recurrent missense mutations, eight mutational 
hotspots were found, i.e. in U2AF35 (two hotspots), SRSF2 (one hotspot) and SF3B1 (five 
hotspots)217. Although, these SF-mutations have been reported to frequently associate with the 
presence of ring sideroblasts (RS)217,221, MDS without RS can harbor SF-mutations as well217,218. 
Mutations in SF3B1 are strongly associated with refractory anemia with ring sideroblasts (RARS), 
whereas in MDS without RS no association with a specific mutation was observed217. Some of the 
SF-mutations also appeared to have prognostic relevance222-225.
The French-American-British (FAB) classification for MDS and AML has been used to delineate 
the transitional zone in marrow and blood blast percentages that separate MDS and AML. RAEB 
is defined as an MDS with ≥ 5% but ≤ 20% blasts in the bone marrow and RAEB-t as ≥5% blasts 
in the blood, or bone marrow blasts > 20% but < 30%, or the presence of Auer rods226,227. RAEB 
is considered to be an MDS subtype closely related to AML, whereas RAEB-t is classified as AML 
according to the WHO228. Thus, the distinction between RAEB, RAEB-t and AML is arbitrary and 
molecular abnormalities have not provided a clear basis for the separation of AML and MDS 
biology. It is therefore possible that subsets of RAEB, RAEB-t and AML, in particular the ones with 
the same class of molecular abnormalities, such as splice factor (SF)-mutations would represent 
one common molecular leukemia subtype. We investigated in this study the distribution of eight 
hotspot SF-gene mutations217 in RAEB (n=31), RAEB-t (n=49) and AML (n=324) samples. The data 
revealed that splice factor (SF) mutant RAEB, RAEB-t and AML share highly similar phenotypes 
and suggest that these malignancies should be considered as one typical SF-mutant AML subset.
AML subtypes with unique molecular defects, such as patients with recurrent chromosomal 
translocations t(8;21), t(15;17), inv(16), or with mutations in CEBPA or in NPM1 can be uncovered 
very specifically using gene expression profiling or DNA-methylation profiling (GEP18 or DMP58) 
data, derived from large AML patient cohorts24,44,121. Application of GEP or DMP in cohorts that 
also included RAEB and RAEB-t patient samples did not reveal distinctive gene expression or 
methylation patterns for these malignancies18,58. We neither obtained evidence of signatures 
that could define SF-mutant myeloid malignancies. Nonetheless, we hypothesize that SF-mutant 
myeloid disorders constitute a biological entity with distinct gene expression and methylation 
patterns. To address this, we developed an approach towards integrative analysis of the GEP 
and DMP-datasets to address this hypothesis. Our data point to the existence of two AML/RAEB/
RAEB-t clusters each with a different GEP/DMP signature, highly enriched for SF-mutant cases.
Two Splice Factor Mutant Leukemia Subgroups Uncovered at the Boundaries of MDS and AML using 
Combined Gene expression and DNA-Methylation Profiling
Ch
ap
te
r 9
Chapter 9
155154
MATERIAL AND METHODS
Patients and molecular analyses
Diagnostic bone marrow (BM) or peripheral blood (PB) samples from 344 adults were analyzed; 
patients were enrolled on HOVON/SAKK protocols -04, -04A, -29, -32, -42 and -43 (available 
at www.hovon.nl)202-204. Patients provided written informed consent in accordance with the 
Declaration of Helsinki and all trials were approved by the Institutional Review Board of Erasmus 
University Medical Center. None of the analyzed AML patients had antecedent MDS before 
inclusion in this study. Among the AML patients that were found in the two newly identified 
clusters (i.e. cluster #3 or #11), one case (#6453) had a known antecedent MDS before inclusion 
in this study. Mutational analyses were carried out as described previously24,36,208,209. Summary of 
clinical, (cyto)genetical and molecular features of the patients have previously been described58. 
Mutation analyses for the genes U2AF35, SRSF2 and SF3B1 were performed by denaturing high-
performance liquid chromatography (dHPLC) for all 344 samples in the cohort. Sanger sequencing 
is subsequently performed on samples with an abnormal dHPLC profile using the primer sets as 
shown in Table S1. RNA and cDNA synthesis was performed as previously described18. Whole 
Exome Sequencing (WES) has been performed on DNA isolated from RAEB, RAEB-t or AML 
blasts (14 patient samples in total) purified by Ficoll-Hypaque (Nygaard) centrifugation and 
cryopreserved in aliquots229. CD3+ T-cells were expanded from diagnostic bone marrow or 
peripheral blood specimens and used as controls for WES to determine acquired mutations in 
AML blasts. Primary cells were seeded in supplemented RPMI (10% FCS/100 U/ml penicillin/
streptomycin) at ~1x106/ml in a 48 well plate (Greiner Bio-One) pulsed with 25 µL of CD3/CD28-
stimulating Dynabeads (Invitrogen Dynal AS, Oslo, Norway) in the presence of 30 U/mL of rIL-2. 
Re-stimulation with same concentrations was performed after 7-9 days, and subsequent re-
stimulations were applied if deemed necessary based on cell numbers determined by microscopy 
and flow cytometry. Following magnetic separation of the CD3+ T-cell fraction with MACS CD3 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturers 
recommendation, CD3+ cell purity was routinely determined > 96% by flow cytometry, and, in 
case of lower purity levels, a second purification was performed.
Pre-processing of gene expression and DNA-methylation profiling
Two high throughput data sets were used in this study: genome wide mRNA expression profiling 
(GEP) and DNA-methylation profiling (DMP) data for 344 samples. GEP data was generated using 
Affymetrix HGU133 plus2.0 (Santa Clara, CA, USA)18,58,62. Sample processing and quality control 
were carried out as described previously18. Normalization of raw data was processed with Robust 
Multi-array Average (RMA)88,230 and probes on the array are remapped to Refseq transcripts using 
a custom Chip Definition File (CDF)231. The custom CDF mapped the original probes to known 
gene-transcripts for UCSC HG19. DMP-data was generated using the HELP-assay, pre-processed 
as described previously58, and annotated using UCSC HG19. GEP and DMP-data are available at 
the NCBI Gene Expression Omnibus accession numbers GSE14468 and GSE18700 respectively.
Pre-processing and the detection of mutations in whole exome sequence data
RAW-FASTQ files were aligned using Burrows-Wheeler Aligner101 (BWA) followed by indel 
realignment using Genome Analysis ToolKit (GATK). The resulting aligned files (e.g. BAM file) 
were then used to remove PCR duplicates using SAM-tools (Sequence Alignment/Map)232. Single 
nucleotide variant variants (SNV) were called using the unified genotyper of GATK whereas all 
variants were annotated using Annovar. These annotations were subsequently used to select for 
nonsynonymous substitutions, stopgain mutations, frameshift insertion or frameshift deletions 
in the exonic or UTR5 regions that were not reported as a SNP, i.e. by using the Single Nucleotide 
Polymorphism Database (dbSNP) and Cosmic database. SNVs were also excluded if these were 
seen in the background, generated by whole exome sequencing of T-cells of the same patient 
samples. Coverage and GATK statistics can be found in supplementary Table S2, whereas the 
frequency of read depth of the aligned loci is illustrated in Figure S1. 
Statistical Analyses
Differentially expressed and methylated genes for the detected clusters are determined by 
comparing GEP and DMP-data of each patient sample within the cluster versus patients outside 
the cluster, using the student T-test. Genes are considered to be differentially expressed or 
methylated when mRNA or DNA-methylation levels differed with P ≤ 0.001 after correcting for 
multiple testing using the Benjamini and Hochberg233 method (denoted as the false discovery 
rate; FDR). Patient characteristics among the clusters were compared using the Mann-Whitney-U 
test (continuous variables) and the Fisher exact test (categorical variables). Outcome measures 
are assessed using Kaplan-Meier estimates in a univariate analysis. Multivariate analyses were 
used according the Cox proportional hazard ratio model. The definition of complete remission 
(CR) and survival endpoints such as overall survival (OS), event-free survival (EFS), and relapse-
free survival (RFS) were based on the recommended consensus criteria234. Pathway analysis is 
performed by utilizing the Molecular Signature Database (MSigDB, v3.0) for the detection of 
enriched BioCarta pathways, KEGG pathways (Kyoto Encyclopedia of Genes and Genomes) and 
transcription factor targets. Pathways and/or gene sets are considered statistically significant 
when the P-value, derived from the hypergeometric test, is less or equal than 0.05 after 
correcting for multiple testing using FDR. In addition, pathways are derived using Ingenuity 
Pathway Analysis (Ingenuity® Systems, http://www.ingenuity.com, IPA 8.8) with P ≤ 0.05.
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RESULTS
Hotspot mutations in splice factor genes SF3B1, U2AF35 and SRSF2 are more frequent in 
RAEB/RAEB-t than in AML
Splice factor mutations (SF-mutations) have been reported to be present in myelodysplastic 
syndromes (MDS) as well in acute myeloid leukemias (AML). We nucleotide sequenced cDNA of 31 
RAEB, 49 RAEB-t and 324 AML patient samples for the eight reported major hotspot mutations1, i.e. 
in SF3B1 (five hotspots: R625L/C; N626D; H662Q/D; K666N/T/E/R; K700E), U2AF35 (two hotspots: 
S34F; Q157P) and SRSF2 (P95H/L/R). In 7 out of 31 RAEB cases we observed mutations in SRSF2. 
In 2/31 RAEB patients, mutations in SF3B1 were present. Eleven of the 49 RAEB-t patients carried 
SF-mutations: U2AF35 (n=4), SF3B1 (n=1) and SRSF2 (n=6). Thus, SF-mutations were frequently 
found in RAEB and in RAEB-t samples. No significant differences in the molecular characteristics 
between both groups were evident (Table S3). There were neither any major clinical differences 
between RAEB and RAEB-t. White blood cell counts RAEB and RAEB-t were significantly lower than 
in primary AMLs, although the levels in REAB-t were higher in RAEB. Based on these combined 
findings, we pooled the RAEB and RAEB-t groups for further analysis. In AML we found mutations 
in SF3B1 (n=7), U2AF35 (n=4) and SRSF2 (n=17) (Table S4). Thus, we observed a much higher 
frequency of SF-mutations in RAEB(T) (RAEB plus RAEB-t) than in AML (25% vs. 8.6%, P < 0.001). 
 
Splice factor mutant AML and RAEB(T) are highly similar
AML patients with SF3B1, U2AF35 or SRSF2 mutations were older (59 vs. 46 years, P < 0.0001), 
showed significantly lower white blood cell counts (24x109/L vs. 37x109/L, P = 0.029), presented 
with lower bone marrow blast percentages (49% vs. 70%, P < 0.0001), and had higher erythroblasts 
percentages (11% vs. 3%, P < 0.0001) (Table S5), than AMLs without mutations in SF-genes. In 
contrast, no significant differences in clinical characteristics were observed between RAEB(T) 
with (n=20) or without (n=60) splice factor gene mutation (Table S6).
Except for the bone marrow blast percentages, (15% in RAEB(T) vs. 49% in AML, P < 0.0001), the 
parameter that a priori defines the separation between RAEB, RAEB-t and AML226, no differences 
were observed between SF-mutant RAEB(T) (n=20) and SF-mutant AMLs (n=28) (Table S4). Ring 
sideroblasts were found in bone marrow samples from the SF-mutant RAEB(T) as well as SF-
mutant AML patients (Table S4). Thus, SF-mutant RAEB(T) and SF-mutant AML are clinically, 
cytologically and molecularly similar.
Two distinct AML/RAEB(T) enriched clusters revealed through integrative analysis of gene 
expression and cytosine methylation profiles
We next evaluated whether SF-mutant malignancies among the cohort of 324 AML and 20 
RAEB(T) patients carried unique combined gene expression (GEP) and DNA-methylation profiles 
(DMP). We carried out 440 distinct hierarchical clustering analyses, using variable combinations 
of differentially expressed or differentially cytosine methylated genes (Figure S2A). For 
each clustering we address whether the grouping of samples was “stable” by computing the 
significance of the clusters with 1000 multi-scale bootstraps. Subsequently we computed the 
silhouette scores235 from the significant clusters, which does describe how distinctive one 
cluster is from another one. Using these statistics, we could computationally select the optimal 
hierarchical clustering.
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Figure 1. Hierarchical clustering of genetic and epigenetic features segregates AML patients into 18 clusters. Heat map 
representing pairwise correlations between the 344 AML cases using the gene expression and DNA-methylation profiles 
of each patient. Ordering of patient samples is based on hierarchical clustering using Pearson correlation and Wards link-
age, which results into clusters of patients that are highly correlated to each other. Colored cells in the heat map depict 
higher positive (red) or lower negative (blue) correlation, as indicated with the scale bar. Bars in the first four rows along 
the diagonal of the heat map indicate presence of the splice factor gene hotspot mutations. In the last row it is indicated 
whether a patient should be considered RAEB(T).
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The criteria used to choose the variable combinations of differentially expressed or differentially 
cytosine methylated genes and the procedures applied to define which is the most optimal 
combination of probesets for clustering is explained in the Supplement (Computing the optimal 
hierarchical clustering). The optimal integrated hierarchical clustering was observed when 
GEP and DMP were combined using 2168 GEP and 2045 DMP probesets, which resulted in the 
segregation of 18 clusters (Figure 1 and Figure S2B). For each of the clusters we assessed the 
enrichment for the currently known molecular and (cyto)genetical abnormalities (Figure 1). 
AMLs with either inv(16), t(15;17), t(8;21) formed three distinct clusters each (cluster # 1, 9, 10). 
CEBPA double-mutant and CEBPAsilenced AMLs formed cluster #16 and #18 respectively. Various 
other abnormalities, i.e. mutations in NMP1, DNMT3A, IDH1 or IDH2, FLT3ITD, FLT3TKD as well 
as chromosomal abnormalities, 3q, 7q or 11q23 defects are depicted in Figure 1. The distribution 
of these well characterized AML subsets using solely GEP or DMP-datasets are represented in 
Figure S3. 
Besides the previously identified AML subgroups, two novel clusters, i.e. #3 (n=25) and 
#11 (n=19) were apparent. Clusters #3 and #11 are highly enriched for RAEB(T) patients 
(both P < 0.0001, Table 1). The unique GEP/DMP signatures that identified clusters #3 and #11 
prompted for further study.
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Figure 2. Gene mutations in patients from cluster #3, cluster #11 and splice factor mutations outside these clusters. 
Associations of gene mutations outlined by a circos diagram for patients in (A) cluster #3, and (B) cluster #11. Gene muta-
tions denoted with a star (*) are significantly overrepresented for the particular cluster. Splice factor mutations outside 
these clusters can be seen in Figure S8.
Table 1: Patient demographics and clinical characteristics of patients in cluster 3 and 11. 
Characteristics Cluster 3 
(n=25)
AML-rest 
(n=319) P1
Cluster 11 
(n=19)
AML-rest 
(n=325) P2 P3
Median age, years (range) 58 (18-72) 47 (15-77) 0.00022* 51 (33-73) 48 (15-77) 0.11 0.17
Sex, n (%) 0.41 0.24 1
 Male 16 (64%) 171 (54%) 13 (68%) 174 (54%)
 Female 9 (36%) 147 (46%) 6 (32%) 150 (46%)
Missing 0 1 0 1
WBC count, (x109/L) 0.85 1.1e-6* 7.9e-6*
 Median (range) 31 (4.8-128) 34 (0.3-274) 6 (1.4-33) 36 (0.3-274)
 Not determined 0 2 0 2
Platelet count, (x109/L) 0.00054* 0.015* 0.67
 Median (range) 83 (26-931) 57 (7-742) 80 (22-374) 57 (7-931)
 Not determined 0 2 0 2
Bone marrow blasts 1.6e-6* 8.1e-7* 0.53
 Median % (range) 34% (6-88) 68% (0-98) 31% (8-64) 68% (0-98)
 Not determined 0 12 0 12
Normal karyotype, n (%) 11 (44%) 141 (44.2%) 1 8 (42.1%) 144 (44.3%) 0.82 1
Fab classification, n (%)
 M0 0 (0%) 11 (3.45%) 1 0 (0%) 11 (3.38%) 1 1
 M1 0 (0%) 68 (21.3%) 0.0068* 1 (5.26%) 67 (20.6%) 0.14 0.43
 M2 3 (12%) 79 (24.8%) 0.22 7 (36.8%) 75 (23.1%) 0.17 0.074
 M3 0 (0%) 7 (2.19%) 1 0 (0%) 7 (2.15%) 1 1
 M4 8 (32%) 59 (18.5%) 0.12 2 (10.5%) 65 (20%) 0.55 0.15
 M5 4 (16%) 68 (21.3%) 0.62 0 (0%) 72 (22.2%) 0.017* 0.12
 M6 0 (0%) 3 (0.94%) 1 1 (5.26%) 2 (0.615%) 0.16 0.43
 RAEB(T) 8 (32%) 12 (3.76%) 1.7e-5* 6 (31.6%) 14 (4.31%) 0.0003* 1
 Not determined 2 3 2 3
Ring sideroblasts, n (%) 4 (16%) 10 (3.1%) 0.23 8 (42%) 6 (1.8%) 0.047* 0.088
 Not determined 0 286 0 286
Erythroblasts, % (range) 5% (1-29) 3% (0-59) 0.14 32% (8-59) 3% (0-52) 2.6e-9* 2e-5*
 Not determined 2 138 3 137
Molecular abnormalities, n (%)
 SRSF2 9 (36%) 12 (3.76%) 1.8e-6* 2 (10.5%) 19 (5.85%) 0.29 0.085
 U2AF35 2 (8%) 5 (1.57%) 0.083 3 (15.8%) 4 (1.23%) 0.0034* 0.63
 SF3B1 2 (8%) 5 (1.57%) 0.087 3 (15.8%) 4 (1.23%) 0.0033* 0.38
 NRAS/KRAS 10 (40%) 30 (9.4%) 1.4e-5* 0 (0%) 40 (12.3%) 0.15 0.0023*
 ASXL1 3 (12%) 16 (5.02%) 0.16 2 (10.5%) 17 (5.23%) 0.27 1
Abbreviations: AML-rest, patients that are not in cluster #3 or #11; Number of cases (percentage), median (range) or 
missing values are depicted were appropriate; WBC count: white blood cell count; Platelet count: number of platelets per 
109/L; Bone marrow blasts (%): Percentage of Bone marrow blasts; Fab class, morphological classification; M0, minimally 
diffentiated; M1, without maturation; M2, with maturation; M3, hypergranular promyelocytic; M4, myelomonocytic; M5, 
(a) monoblastic, (b) monocytic; M6, erytroleukemia; RAEB(T), Refrectory Anemia with Excess Blasts (in Transformation); 
Ring sideroblasts: Patient cells showed Yes/ No Ring sideroblasts; Erythroblasts (%): Percentage of Erythroblasts; Splice 
factor mutations: mutations that are detected in the hotspots of gene SRSF2, U2AF35 and SF3B1; NRAS/KRAS: mutations 
in codon 12,13 or 61; ASXL1 mutations; P1 values indicate the comparison of patients in Cluster #3 versus the patients 
not in cluster #3 (AML-rest); P2 values indicate the comparison of patients in cluster #11 versus the patients not in cluster 
#11 (AML-rest); P3 values indicate the comparison of patients in cluster #3 versus the patients in cluster #11; P-values are 
marked with (*) if lower than 0.05 and are computed using Mann-Whitney-U test (continuous variables) and two sided 
Fisher exact test (categorical variables). Note that percentages are solely based on non-missing values.
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Patients in clusters #3 and #11 are enriched for RAEB(T) and AMLs with splice factor gene 
mutations
Of the 25 cases in GEP/DMP cluster #3, eight were classified as RAEB(T) (32%; 8/25, P < 0.0001, 
Table 1). The cluster was preferentially enriched for splice factor gene hotspot mutations (52%; 
13/25, P < 0.0001), i.e. SF3B1 (n=2), U2AF35 (n=2), and SRSF2 (n=9) (Figure 1 and Figure 2A, 
Table 1). Four out of 8 RAEB(T) and 9/17 AML cases carried SF-mutations (Table S7). The patients 
in cluster #11 were enriched for RAEB(T) (31.6%, 6/19, P = 0.0003), and hotspot mutations 
(42.1%, 8/19, P < 0.0001) as well. The hotspot mutations are detected among SRSF2 (n=2), 
SF3B1 (n=3) and U2AF35 (n=3) (Figure 1, Figure 2B and Table 1). SF-mutations were seen in 2 
out of the 6 RAEB(T) cases, and 6 out of the 13 AML cases (Table S7). In case of using the GEP or 
DMP-data sets separately, there were no clusters that were significantly enriched for patients 
with SF-mutations (Figure S3). Thus the grouping of SF-mutations were only evident when GEP 
and DMP-data were used in combination.
We considered the possibility that in cases of clusters #3 and #11 that did not carry hotspot SF-
mutations other SF-alterations might be present. Whole exome sequencing (WES) was carried 
out on DNA obtained from non-SF-mutant patients of which material was available, i.e. seven 
samples from cluster #3 and seven from cluster #11. We did not find other mutations in any of 
the 8 splice factor genes previously reported to be frequently mutated. However, three acquired 
mutations (absent in T-cells from the same patients) were found in other RNA-binding and RNA-
splice factor genes. In cluster #11 mutations in DHX15 (nonsynonymous; patient #6448), PRPF4B 
(Frameshift deletion; patient #2246) and CELF4 (nonsynonymous; patient #3318) were found 
(Table S8).
Erythroid phenotype of cluster #11 patient samples
Morphological analysis of bone marrow samples from patients of clusters #3 and #11 revealed 
that blast percentages of the two clusters were both significantly lower compared to the other 
AMLs (P < 0.0001; 34% vs. 68% (cluster #3) and P < 0.0001; 31% vs. 68% (cluster #11)) (Table 
1). Higher percentages of erythroblasts were found in cluster #11 marrow preparations when 
compared the other AMLs (P < 0.0001; 32% vs. 3%) (Table 1). White blood cell counts (WBC) 
of cluster #11 cases were significantly reduced in comparison to unselected AMLs (P < 0.0001; 
6x109/; vs. 36x109/L respectively), whereas cluster #3 patients showed WBC counts that were 
equal to other cases (31x109/L, Table 1). Thus the two splice factor mutant clusters which 
are both enriched for RAEB(T) samples show morphological differences for which cluster #11 
patients revealed a strong erythroid phenotype (Table 1).
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Differentially expressed or hypomethylated genes in cluster #11 patient samples strongly 
associate with erythroid development
The signature of 895 differentially expressed and 1180 differentially methylated genes 
characterized the cases in cluster #11 compared to unselected AMLs. Pathway analysis revealed 
that the profiles in cluster #11 were highly enriched for gene sets associated with erythroid 
development and function, e.g. Alpha-Hemoglobin Stabilizing Protein pathway (AHSP)236,237, 
Porphyrin metabolism or P53 signaling (Figure 3). Numerous erythroid genes were found to 
be hypomethylated and comparatively overexpressed, such as GATA1, FECH, ALAS2, AQP1 or 
KLF1. Other erythroid genes were overexpressed with no change in DNA-methylation, such as 
for ALAD, UROS, UROD, AHSP or HBD (Figure S4 and Figure S5). Analysis of transcription factor 
binding sites, using the differentially expressed and methylated genes revealed significant 
enrichment for the E2F and GATA1 transcription factor binding sites among these genes 
(P < 0.002 and P < 0.001 respectively). 
In contrast to cluster #11 AML cases, the 1522 differentially expressed and 74 methylated genes 
that are associated with cluster #3 lacked the dominant erythroid signature (Figure S6A and B). 
Although expression of erythroid genes is seen, these were not significantly higher compared to 
other AMLs. Thus while both clusters #3 and #11 are enriched for RAEB(T) cases and frequently 
harbour SF-mutations, cluster #11 cases are specifically associated with a combined myeloid and 
erythroid phenotype.
Clusters #3 RAEB(T) and AML patients frequently carry RAS mutations
WES on the small selection of cluster #3 and #11 cases revealed one KRAS and 3 NRAS mutants 
among the 6 cases of cluster #3 that were analysed. We applied Sanger sequencing for NRAS 
and KRAS among all patients of the two clusters. Ten out of the 25 (40%) patients in cluster #3 
carried mutations in NRAS (n=9) or KRAS (n=1) (P < 0.0001, Table 1 and Figure 2). In contrast, no 
RAS mutations were found in any of the cluster #11 cases analyzed (Table 1). 
Unfavourable outcome for cluster #3 patients
To verify whether cluster #3 and #11 differed clinically in terms of prognosis, we assessed 
the overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS). The overall 
survival for patients in cluster #3 and #11 showed a 5-year OS of 24% (95% CI, 9%-42%) and 
41% (95% CI, 20%-62%) respectively (Figure 4). In an univariate analysis, cluster #3 patients 
showed significant inferior outcome measures compared to unselected AMLs (OS: P = 0.001, 
Figure 4A, RFS: P = 0.014, Figure S7A, EFS: P = 0.016, Figure S7B), whereas this was not seen for 
cluster#11 cases (OS: P = 0.425, Figure 4A, RFS: P = 0.944, Figure S7A, EFS: P = 0.638, Figure S7B). 
In a multivariate analysis, we could confirm that cluster #3 patients showed a poor treatment 
response, independent from other relevant covariates with prognostic value (age, white blood 
cell count (WBC), FLT3ITD, NPM1pos, NRAS/KRAS, and RAEB(T) and high-risk (cyto)genetics), 
(OS: P = 0.042; Figure 4B, RFS: P = 0.045; Figure S7C, EFS: P = 0.1; Figure S7D). The multivariate 
analysis did not reach significance for cluster #11 (Figure S7E and F). 
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Std.Err z P>|z|
95% Confidence Interval
low high
Cluster 3 1.880 0.584 2.03 0.042* 1.022 3.457
Age 1.022 0.009 2.35 0.019* 1.004 1.041
Log(WBC) 1.003 0.272 0.01 0.991 0.589 1.708
High (cytogenetic) risk group 1.958 0.830 1.58 0.113 0.852 4.496
FLT3ITD 2.419 0.909 2.35 0.019* 1.158 5.052
NPM1+ 0.374 0.229 -1.61 0.108 0.113 1.240
N-RAS/K-RAS 1.583 0.521 1.4 0.163 0.831 3.018
RAEB(T) 0.984 0.413 -0.04 0.97 0.432 2.242
 
Variables Hazard Ratio (HR) Std.Err z P > |z|
95% Confidence Interval
low high
Cluster 3 1.880 0.584 2.03 .042* 1.022 3.457
Age 1.022 0.009 2.35 0.019* 1.004 1.041
Log(WBC) 1.003 0.272 0.01 0.991 0.589 1.708
High (cytogenetic) risk group 1.958 0.830 1.58 0.113 0.852 4.496
FLT3ITD 2.419 0.909 2.35 0.019* 1.158 5.052
NPM1+ 0.374 0.229 -1.61 0.108 0.113 1.240
N-RAS/K-RAS 1.583 0.521 1.40 0.163 0.831 3.018
RAEB(T) 0.984 0.413 -0.04 0.970 0.432 2.242
Figure 4. Survival analysis for patients in clusters #3 and #11. Kaplan-Meier survival curves and multivariate analysis 
for overall survival (OS). Multivariate analysis is based on the Cox proportional hazard ratio (HR) model. The included 
variables into the model are: NPM1mut vs. wild-type NPM1, FLT3ITD vs. no FLT3ITD, NRAS/KRASmut vs. wild-type NRAS/KRAS, 
RAEB(T) vs. no RAEB(T), high cytogenetic risk vs. no high cytogenetic risk; age and white blood cell count (WBC) are used 
as a continuous variable. (A) Kaplan-Meier curves for cluster #3 vs. all patients except for cluster #3 patients, cluster #11 
vs. all patients except for cluster #11 patients, and cluster #3 vs. cluster #11 patients. (B) Multivariate analysis for cluster 
#3 patients.
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DISCUSSION
In this study we evaluated the frequency of SF-mutations in RAEB(T) (RAEB and RAEB-t) and AML 
patients. We demonstrate that the decision to define RAEB as MDS and RAEB-t as AML, solely 
based on percentage of blasts is biologically artificial and that SF-mutant AML/RAEB(T) should be 
viewed as a related disease entity. Secondly, we studied gene expression profiling (GEP) and DNA 
methylation profiling (DMP) data in a considerable cohort of patients with AML, RAEB or RAEB(T), 
with particular focus on patients with SF-mutations. Based on combined GMP/DMP data, two 
distinct SF-mutant RAEB(T)/AML subtypes could be recognized, which differ morphologically, 
molecularly and clinically. Not all patients, in the two clusters that we identified carried one of 
the currently well-described hotspot mutations in the splice factor genes SF3B1, U2AF35, and 
SRSF2. Because we focused in this study on hotspot mutations, we did not analyze the presence 
of the previously reported mutations in ZRSR2, SF1 or PRPF40B. On the other hand, we provide 
data that point to the existence of mutations in other genes encoding RNA-binding/splicing 
factors. Although our detected mutations in DHX15, PRPF4B and CELF4 have not previously 
been reported in AML, other DHX and PRPF family members have been found in AML and MDS 
as reported in The Cancer Genome Atlas (TCGA) http://cancergenome.nih.gov/. Mutations in 
DHX15, PRPF4B and CELF4 have been reported in the COSMIC database (http://cancer.sanger.
ac.uk/cancergenome/projects/cosmic/). Moreover, Yoshida et al217 reported mutations in the 
splice factor gene PRPF40B. Together, these observations favour the hypothesis that more splice 
factor genes may be mutated in the AML/RAEB(T) patients that can be uncovered using GEP 
and DMP-data sets in a combined manner. In addition to the SF-mutations, we did also detect 
mutations in ASXL1. ASXL1 and other genes, such as TET2 and EZH2 are also of interest as these 
are known to co-occur with SF-mutations. 
It has previously been demonstrated that distinct molecularly defined AML subtypes cluster 
using gene expression or DNA-methylation profiles in an unsupervised manner18,58. In contrast 
to AMLs with for instance translocations t(8;21), t(15;17) or with mutations in CEBPA, SF-mutant 
malignancies did not form any unique cluster when GEP or DMP-data were used separately. It 
was only through integrating these datasets that we were able to identify SF-mutant patients as 
being distinct from other cases, and consisting of two subgroups. The reason why these clusters 
can only be discovered by combining data sets is because the gene expression profiles or DNA 
methylation profiles separately did not yield sufficient discriminative features to distinguish 
these patients according the two identifiable clusters. Cluster #11 contains patients with strongly 
expressed as well as hypo-methylated erythroid genes, as illustrated in Figure 3. Samples 
from other clusters sometimes showed high expression of erythroid genes as well, but not in 
combination with hypo-methylation. These combined features, among others could explain why 
these patients clustered so strongly when GEP-data and DMP-data were used in an integrated 
manner (Figure 1). The reason why patients from cluster #3 could only be defined using the 
combination of GEP and DMP data sets is not as clear as for cluster #11. However, based on the 
silhouette scores235 using the bootstrap labels from Pvclust239 (see Supplement), the hierarchical 
clustering appeared stable. This means that a sufficient number of genes, differentially expressed 
and/or methylated, took part in the clustering of this patient group. The fact that samples in this 
group were enriched for SF-mutations and RAS-mutations emphasizes that with combined GEP/
DMP data sets, a unique signature could be derived which recognizes the AML subgroup (cluster 
#3 and #11). 
We found multiple SF-mutant samples outside clusters #3 and #11. The question is whether, 
these SF-mutant AMLs are biologically different or whether they were grouped in different 
clusters due to technical inaccuracies, meaning that they should have been identified as cluster 
#3 or #11 cases when more sophisticated procedures of gene expression and genome wide 
cytosine methylation analyses had been applied. In addition, more SF-mutations are known to 
exist (such as ZRSR2, SF1, PRPF40B) but are not analyzed in this study. Gene chip hybridization 
experiments that we applied in this study, is nowadays being replaced by RNAseq, a procedure 
that not only determines gene expression levels, but also discriminates between different splice 
forms. To study cytosine methylation we applied HELP, an assay that generates “snapshots” of 
small areas within CpG rich regions. We hypothesize that the combination of RNA-Seq with more 
sophisticated tools to determine DNA-methylation profiles, will provide information that will 
allow us to generate even better combined GEP/DMP signatures. It is possible that SF-mutant 
cases that were not found in clusters #3 or #11, potentially belong to either of these two clusters 
but were missed with the currently used methodologies. In any case, our study highlights the 
potential of combining biological data sets such as gene expression and DNA-methylation 
profiling data, and shows that with pursuing such a combined approach, leukemia subtypes with 
a characteristic genotype hidden among the heterogeneity can be uncovered. 
Novel cluster #11 was most remarkable for involving MDS and AML, since these samples 
appeared to share unique erythroid features based on the following findings: 1. Enrichment of 
pathways associated with erythroid development, when differentially expressed and methylated 
genes were analysed. 2. Multiple erythroid genes were simultaneously highly expressed and 
hypomethylated 3. High cytological percentages of erythroblasts. 4. Presence of patient samples 
with a RAEB or a RAEB(T). 5. Frequent appearance of ring sideroblasts. 6. Presence of AML-M6 
(erythroid leukemia) cases. Even though morphological classification pointed towards leukemias 
with strong erythroid developmental defects, the cluster also contained patient samples classified 
as AML-M0, M1, M2 or M4. These AMLs showed differential expression and hypomethylation 
of erythroid genes as well, which separated them from other AMLs with the same FAB-class. 
We conclude that AMLs with defective erythroid development exist more frequently than 
morphological classification would suggest.
The two AML/RAEB(T) clusters show several differences, among which the high percentages 
of N-RAS or K-RAS mutations in cluster #3 and not cluster #11 patients. This striking difference 
between the SF-mutant enriched clusters may explain the much higher white blood cell counts 
found among cluster #3 samples. It may also clarify the inferior response to treatment of cluster 
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#3 patients. Cluster #3 patients also contain more frequent mutations in SRSF2, which has been 
reported to occur in AMLs that develop upon leukemic transformation from myeloproliferative 
neoplasms. We hypothesize that the two clusters that we identified represent two different splice 
factor mutant malignancies, which may embody distinct evolutionary stages of the disease. This 
would mean that certain cases in cluster #11 may become cluster #3 AMLs in a later phase of the 
disease, i.e. upon acquiring mutations in N-RAS or K-RAS. No matter the explanation, our data 
strongly suggest that SF-mutant RAEB(T) and AML constitute a myeloid entity that overrides the 
separation between AML and MDS and is composed of two subgroups which show overlap but 
also differ clinically and molecularly. 
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SUPPORTING MATERIAL
Computing the optimal hierarchical clustering
A major disadvantage of a hierarchical clustering approach is the uncertainty of the derived 
clusters, e.g. the use of different number of features may result in different patient-clusters. We 
assessed the uncertainty of a hierarchical clustering using Pvclust239 that builds on multi-scale 
bootstrap. It computes a bootstrap probability (BP) and an approximately unbiased (AU) P-value 
for each cluster. These P-values indicate how strong a clustering is supported by the data. 
Clusters with significance level < 0.05 are taken into consideration which indicates that these 
clusters do not only “seem to exist” but are stable when we perturb the number of observations. 
In further analyses we used the AU P-value for assessment of uncertainty as this is a better 
approximation than BP P-value according to the authors of Pvclust239. 
To select the hierarchical clustering which is best supported by the data, we used the following 
procedure: i) Ranking the feature sets across-patient standard deviation for each data set 
and selecting an increasing number of probesets using 21 different cut-offs ([0,..,20%]). The 
selected feature sets for GEP and DMP are then iteratively combined. ii) Each feature set (440 
in total) is then used for hierarchical cluster analysis with 1000 multi-scale bootstraps, using 
Wards linkage and Pearson correlation distance. iii) An average silhouette score235 (relatedness 
of samples in a cluster and the separation of different clusters) is computed for each significantly 
observed cluster from Pvclust (Figure S2). iv) Subsequently the hierarchical clustering that is best 
supported by the data is selected. 
One should expect that the highest silhouette score from the significant Pvclust clusters should 
preserve, to some extent, the clusters of currently known abnormalities (CEBPAsilenced, CEBPAdm, 
inv(16), t(8;21) and t(15;17)). This is in line with our findings as the highest silhouette score 
from the significant Pvclust clusters also showed a high silhouette score for the currently known 
clusters. Note that the GEP and DMP-data is mean normalized with unit variance (z-score). 
One should expect that the highest silhouette score from the significant Pvclust clusters should 
preserve, to some extent, the clusters of currently known abnormalities (CEBPAsilenced, CEBPAdm, 
inv(16), t(8;21) and t(15;17)). This is in line with our findings as the highest silhouette score 
from the significant Pvclust clusters also showed a high silhouette score for the currently known 
clusters. Note that the GEP and DMP-data is mean normalized with unit variance (z-score).
Computing the stability of the detected clusters
The stability for the 18 newly derived clusters is examined using all the derived hierarchical 
clusterings as described before. The cluster-labels that are determined for each hierarchical 
clustering are used to determine the average silhouette score for each of the hierarchical 
clustering (Figure S2). We hypothesized that stable clusters are frequently seen among different 
hierarchical clusterings. For the optimal hierarchical clustering we detected that ten out of 
eighteen clusters (# 1, 2, 3, 6, 8, 9, 11, 13, 16, 18) have high silhouette scores [0.5,..,1] based 
on all other hierarchical clusterings. These include the (cyto)genetically groups such as, inv(16), 
t(15;17), CEBPAdm and CEBPAsilenced. Five clusters (# 3, 11, 13, 14, 15) varied in silhouette scores 
[0.4,..,0.5] and, three clusters (# 4, 7 and 12) showed “low” silhouette scores [0,..,0.4]. Based on 
these average silhouette scores we categorized the clusters into high (n=10 clusters), medium 
(n=5 clusters) and low (n=3 clusters) stability (Illustrated with **, * and no asterisks respectively). 
Two Splice Factor Mutant Leukemia Subgroups Uncovered at the Boundaries of MDS and AML using 
Combined Gene expression and DNA-Methylation Profiling
Ch
ap
te
r 9
Chapter 9
169168
Read depth aligned loci
Fr
eq
u
en
cy
200
300
400
500
600
700
800
900
1000
2224
2224 T cells
2228
2228 T cells
2246
2246 T cells
2259
2259 T cells
2278
2278 T cells
3318
3318 T cells
3330
3330 T cells
4340
4340 T cells
5290
5290 T cells
5363
5363 T cells
6373
6373 T cells
6448
6448 T cells
7303
7303 T cells
7309
7309 T cells
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
100
Figure S1. Read depth frequency of the aligned loci. The horizontal axis represents the read depth that is measured for a 
loci and the vertical axis its frequency. As an example, a loci with read depth of 100 is seen 24517 times, whereas a read 
depth of 1000 is seen 4 times (both are averages among all samples).
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Figure S2. Selection of the most optimal hierarchical clustering. Twenty one different cut-offs are chosen based on patient 
standard deviation for GEP and separately for DMP. (A) Iteratively combining gene expression and DNA-methylation 
probesets using one of the 440 combinations: 21x21 minus 1 (zero GEP and zero DMP probesets). (B) The uncertainty of 
each hierarchical clustering is assessed using the estimated bootstrap labels from Pvclust, and scored using the silhouette 
scores. The hierarchical clustering with the highest average silhouette score is best supported by the data and indicated 
with a red rectangle.
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Figure S3. Optimal hierarchical clustering for GEP and DMP separately. Heat map representing pairwise correlations 
between the 344 AML cases for the gene expression or DNA-methylation profiles. The optimal hierarchical clustering for 
(A) GEP was based on 650 probesets, (B) DMP was based on 682 probesets. The diagonal illustrates in red the AML sub-
types, inv(16), t(8;21), t(15;17), CEBPA double-mutants (CEBPAdm), CEBPAsilenced, the splice factor genes U2AF35, SF3B1, 
SRSF2, and the RAEB(T) cases.
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Figure S4: Enriched pathways for cluster #11. Graphical representation of the top 10 enriched pathways/gene sets based 
on the differentially expressed and DNA methylated genes for cluster #11.
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Figure S5: Gene expression and DNA-methylation levels of annotated genes in erythroid development. Heat map rep-
resenting pairwise correlations between the 344 AML cases using the integrated gene expression or DNA-methylation 
profiles. The splice factor mutants are indicated with red bars. Gene expression data of the differential regulated genes, 
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gene expression levels. Blue bars depict hypomethylation levels. 
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Figure S6: DNA-methylation and gene expression levels for cluster #3 and the enriched pathways. (A) Graphical repre-
sentation of the top 10 enriched pathways/gene sets based on the differentially expressed and DNA methylated genes 
for cluster #3. (B) Differential expressed and DNA-methylation genes in patient samples from cluster #3 compared to all 
other AMLs are indicated with different colored dots. The colors depict the gene expression and DNA-methylation status, 
i.e. the right upper corner represents genes that are hypomethylated and overexpressed (green dots). Many of these 
genes encode for proteins involved in erythroid development or function.
Variables
Hazard Ratio 
(HR)
Std.Err z P>|z|
95% Confidence Interval
low high
Cluster 11 1.436 0.622 0.83 0.404 0.614 3.355
Age 1.021 0.009 2.47 0.013* 1.004 1.039
Log(WBC) 1.293 0.352 0.94 0.345 0.758 2.206
High (cytogenetic) risk group 1.661 0.760 1.11 0.268 0.677 4.074
FLT3ITD 1.939 0.738 1.74 0.082 0.920 4.087
NPM1+ 0.303 0.200 -1.81 0.07 0.083 1.103
N-RAS/K-RAS 1.606 0.502 1.52 0.13 0.870 2.963
RAEB(T) 0.926 0.400 -0.18 0.859 0.397 2.159
Variables
Hazard Ratio 
(HR)
Std.Err z P>|z|
95% Confidence Interval
low high
Cluster 3 1.640 0.494 1.64 0.1 0.909 2.960
Age 1.019 0.009 2.13 0.033* 1.001 1.036
Log(WBC) 1.133 0.288 0.49 0.622 0.689 1.866
High (cytogenetic) risk group 1.940 0.820 1.57 0.117 0.848 4.440
FLT3ITD 2.113 0.774 2.04 0.041 1.031 4.332
NPM1+ 0.344 0.209 -1.75 0.08 0.104 1.134
N-RAS/K-RAS 1.467 0.460 1.22 0.222 0.793 2.713
RAEB(T) 0.786 0.346 -0.55 0.584 0.331 1.863
Variables
Hazard Ratio 
(HR)
Std.Err z P>|z|
95% Confidence Interval
low high
Cluster 11 1.167 0.703 0.26 0.798 0.358 3.800
Age 1.005 0.011 0.48 0.634 0.984 1.027
Log(WBC) 1.492 0.495 1.21 0.227 0.779 2.858
High (cytogenetic) risk group 1.516 0.859 0.73 0.463 0.499 4.605
FLT3ITD 0.770 0.488 -0.41 0.679 0.222 2.664
NPM1+ 0.496 0.399 -0.87 0.383 0.102 2.397
N-RAS/K-RAS 1.169 0.447 0.41 0.683 0.552 2.476
RAEB(T) 2.007 1.124 1.24 0.213 0.670 6.014
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Variables
Hazard Ratio 
(HR)
Std.Err z P>|z|
95% Confidence Interval
low high
Cluster 3 2.181 0.848 2 0.045* 1.017 4.675
Age 1.000 0.011 -0.01 0.993 0.978 1.022
Log(WBC) 1.320 0.412 0.89 0.374 0.716 2.434
High (cytogenetic) risk group 1.670 0.861 0.99 0.32 0.608 4.589
FLT3ITD 0.827 0.507 -0.31 0.756 0.248 2.752
NPM1+ 0.418 0.315 -1.16 0.247 0.096 1.828
N-RAS/K-RAS 1.038 0.399 0.1 0.923 0.489 2.203
RAEB(T) 1.667 0.870 0.98 0.327 0.599 4.637
All patients except for cluster 3
Cluster3
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Figure S7: Relapse-free survival and Event-free survival for patients in clusters #3 and #11. Kaplan-Meier survival curves, 
and multivariate analysis for (A) relapse-free survival (RFS) and (B) event-free survival (EFS) for cluster #3 vs. all patients 
except for cluster 3 patients, cluster #11 vs. all patients except for cluster 11 patients, and cluster #3 vs. cluster #11 
patients. Multivariate analysis for cluster #3 for (C) RFS, (D) EFS, and for cluster #11 (E) RFS and (F) EFS. The included 
covariates into the Cox proportional hazard ratio (HR) model are: NPM1mut vs. wild-type NPM1, FLT3ITD vs. no FLT3ITD, 
NRAS/KRASmut vs. wild-type NRAS/KRAS, RAEB(T) vs. no RAEB(T), high cytogenetic risk vs. no high cytogenetic risk; age 
and white blood cell count (WBC) are used as a continuous variable.
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Table S1: Primer sets dHPLC (WAVE).
Gene Mutation Primer
U2AF35 Q157 P/R
FW: GTGAGGAAGATGCGGAAAAG
RV: GGGATCGGGATCTTGATCTAT
U2AF35 34 F/Y
FW: GTATCTGGCCTCCATCTTCG
RV: TGTTCCTGCATCTCCACATC
SF3B1
N626D FW: CCCTGGGCATTCCTTCTTTA
H662Q/D FW: CCCTGGGCATTCCTTCTTTA
R625L/C RV: TCGATACCATAAGGAGTTGCTG
K666N/T/E/R RV: TCGATACCATAAGGAGTTGCTG
K700E RV: TCGATACCATAAGGAGTTGCTG
SRSF2 P95 H/L/R
FW: GCTGAGGACGCTATGGATG
RV: ACCGAGATCGAGAACGAGTG
Primer sets Sanger sequencing
Gene Primer
U2AF35
FW: GTATCTGGCCTCCATCTTCG
RV: ATCTCTCGACCGCCTCCT
SF3B1
FW: TAGAGTGGAAGGCCGAGAGA
RV: CTTTGTTTGCCAACTCCACA
SRSF2
FW: CAAGGTGGACAACCTGACCT
RV: GAGACTTCGAGCGGCTGTA 
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Table S2. Coverage and GATK statistics. 
Sample
Passed 
filtered reads
Mapped 
reads
Mapped 
reads (%) R1 R2 Bases covered Bases aligned
Average coverage 
per base
Variants called 
using GATK:
SNVs called using 
GATK:
substitutions called 
using GATK:
snp137
2224 34091622 32094531 94.14 15258913 16835618 373056003 1986886090 5.326 128702 123419 5283 123739
2224_T_cells 47356836 44225068 93.39 21023174 23201894 472512207 2909908293 6.158 156947 149677 7270
2228 36372200 34375838 94.51 16189738 18186100 331980963 1563965749 4.711 118109 114045 4064 115497
2228_T_cells 39905728 37490043 93.95 17537179 19952864 351006415 1713395904 4.881 123589 119088 4501
2246 35842032 33590830 93.72 16261848 17328982 415628983 2467425001 5.937 144932 137818 7114 140237
2246_T_cells 38694732 36390288 94.04 17611303 18778985 451620796 2696995571 5.972 152047 144855 7192
2259 34117058 32322925 94.74 15264396 17058529 314595972 1487891607 4.730 114225 110448 3777 111983
2259_T_cells 48535354 45439523 93.62 21171846 24267677 398600075 2056532498 5.159 138156 132805 5351
2278 25438736 24442670 96.08 11985020 12457650 363305533 1870456824 5.148 125017 119905 5112 121544
2278_T_cells 53288208 50424209 94.63 24400575 26023634 603520411 3791255408 6.282 186899 178122 8777
3318 28937768 27416617 94.74 13351220 14065397 351752322 1886557606 5.363 126724 120930 5794 122998
3318_T_cells 34143650 31973667 93.64 15466801 16506866 397039231 2317539826 5.837 137582 131213 6369
3330 52979212 49427482 93.30 23746012 25681470 590082375 3648429392 6.183 182246 173493 8753 175803
3330_T_cells 32075508 30568871 95.30 14531117 16037754 303970310 1360117971 4.475 110340 106591 3749
4340 47247930 44456569 94.09 20832604 23623965 408942685 2013605323 4.924 149246 143844 5402 145294
4340_T_cells 51454366 48043928 93.37 22316745 25727183 432515914 2163016414 5.001 150247 144848 5399
5290 42173302 39338107 93.28 18525214 20812893 431114646 2392225490 5.549 143426 137360 6066 137176
5290_T_cells 31745666 30204773 95.15 14482603 15722170 376004965 1972052221 5.245 131462 126021 5441
5363 55344164 51188451 92.49 24475525 26712926 602900742 3591679671 5.957 179430 171128 8302 171701
5363_T_cells 43951406 41441614 94.29 20035614 21406000 537334926 3060382687 5.695 166267 158656 7611
6373 46915790 44068392 93.93 21243020 22825372 576622910 3241057394 5.621 171046 163305 7741 165604
6373_T_cells 44088884 41370529 93.83 19959477 21411052 490831326 2970759336 6.053 154930 147915 7015
6448 34280072 32414880 94.56 15733795 16681085 414714015 2346944269 5.659 137129 131142 5987 131892
6448_T_cells 43679746 41084267 94.06 19870521 21213746 488886149 2988629222 6.113 156717 149587 7130
7303 34784714 33122410 95.22 16004614 17117796 419375019 2348115345 5.599 141797 135452 6345 137425
7303_T_cells 49855982 46224692 92.72 21296701 24927991 379789014 2065561416 5.439 130225 124955 5270
7309 43975726 40959900 93.14 18972037 21987863 355613368 1832904708 5.154 124274 119590 4684 121639
7309_T_cells 55736448 51289139 92.02 23420915 27868224 416743495 2256744655 5.415 137125 131597 5528
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Abbreviations: Sample: Sample number, Passed filtered reads: Number of reads that are processed by the Illumina
Mapped reads (%): Percentage of mapped reads, R1 and R2: Paired end reads R1 and R2, Bases covered: Number of
aligned on the reference genome, Average coverage: Bases aligned / Bases covered, snp137: the overlap of the variants,
software and are present in the Fastq file, Mapped reads: Number of reads mapped on the genome by using BWA,
loci covered on reference genome by the aligned reads (at least one read per locus), Bases aligned: Number of bases
SNVs and substitutions that are called using GATK and are present in the snp137 data base.
177176
Table S4: Comparison of patient demographics, clinical and molecular characteristics between: RAEB(T) with Splice 
factor mutations versus AMLs with Splice factor mutations.
Characteristics RAEB(T) with splice factor 
mutations (n=20)
AMLs with splice factor 
mutations (n=28)
P-value
Median age,  y (range) 66 (42-84) 59 (37-77) 0.17
Sex, n (%) 0.56
Male 14 (70%) 17 (61%)
Female 6 (30%) 11 (39%)
WBC count, (x109/L) 0.19
Median (range) 6 (1.6-127) 24 (2.1-109)
Platelet count, (x109/L) 0.63
Median (range) 71 (15-740) 65 (10-931)
Bone marrow blasts 3.6e-7*
Median % (range) 15% (1-29) 49% (6-93)
Not determined 0 3
Erythroblasts 0.28
Median % (range) 13% (1-60) 11% (1-52)
Not determined 0 7
Ring Sideroblasts, n (%) 4 (20%) 7 (25%) 1
Not determined 1 0
Molecular Abnormalities, n (%)
SRSF2, 13 (65%) 17 (60.7%) 1
U2AF35 4 (20%) 4 (14.3%) 0.71
SF3B1 3 (15%) 7 (25%) 0.49
FLT3ITD ϴ 0 (0%) 8 (28.6%) 0.17
FLT3TKD ϴ 0 (0%) 0 (0%) 1
NPM1+ ϴ 0 (0%) 4 (14.3%) 0.56
CEBPA double mutationϴ 0 (0%) 1 (3.57%) 1
CEBPA single mutationϴ 1 (14.3%) 1 (3.57%) 0.36
IDH1ϴ 1 (14.3%) 3 (10.7%) 1
IDH2ϴ 1 (14.3%) 4 (14.3%) 1
DNMT3Aϴ 4 (57.1%) 7 (25%) 0.15
NRAS/KRASϴ 1 (14.3%) 3 (10.7%) 1
ASXL1ϴ 1 (14.3%) 6 (21.4%) 1
Fab classificationϴ, n (%)
M0 0 (0%) 1 (3.57%) 1
M1 0 (0%) 4 (14.3%) 0.56
M2 0 (0%) 8 (28.6%) 0.17
M3 0 (0%) 0 (0%) 1
M4 0 (0%) 7 (25%) 0.3
M5 0 (0%) 4 (14.3%) 0.56
M6 0 (0%) 0 (0%) 1
RAEB(T) 7 (100%) 0 (0%) 1.5e-7*
Not determined 0 3
Number of cases (percentage), median, range, or not determined values are indicated. The (ϴ) symbol indicates com-
parison of 7 RAEB(T) with splice factor mutations versus 28 AMLs with splice factor mutations. P-values indicate the com-
parison between the two groups and are marked with (*) if lower than 0.05 and are computed using Mann-Whitney-U 
test (continuous variables) and two sided Fisher exact test (categorical variables). Note that percentages are solely based 
on non-missing values.
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Table S3: Comparison of patient demographics, clinical and molecular characteristics between: RAEB with RAEB(t ).
Characteristics RAEB (n=31) RAEB-T (n=49) P-value
Median age, y (range) 67 (20-81) 61 (30-84) 0.13
Sex, n (%) 0.45
Male 21 (68%) 37 (76%)
Female 10 (32%) 12 (24%)
WBC count, (x109/L) 0.000007*
Median (range) 3 (1.1-22) 11 (1.4-127)
Platelet count, (x109/L) 0.08
Median (range) 109 (9-740) 66 (7-618)
Bone marrow blasts 0.0078*
Median % (range) 13% (1-19) 17% (2-29)
Erythroblasts 0.032*
Median % (range) 25% (2-60) 13% (1-59)
Not determined 2 1
Ring Sideroblasts, n (%) 10 10 0.3
Molecular Abnormalities, n (%)
SRSF2 7 (22.6%) 6 (12.2%) 0.35
U2AF35 0 (0%) 4 (8.16%) 0.15
SF3B1 2 (6.45%) 1 (2.04%) 0.56
FLT3ITD ϴ 0 (0%) 1 (7.69%) 1
FLT3TKD ϴ 0 (0%) 1 (7.69%) 1
NPM1+ ϴ 0 (0%) 1 (7.69%) 1
CEBPA double mutationϴ 0 (0%) 1 (7.69%) 1
CEBPA single mutationϴ 1 (14.3%) 1 (7.69%) 1
IDH1ϴ 1 (14.3%) 1 (7.69%) 1
IDH2ϴ 1 (14.3%) 0 (0%) 0.35
DNMT3Aϴ 0 (0%) 4 (30.8%) 0.25
NRAS/KRASϴ 2 (28.6%) 1 (7.69%) 0.27
ASXL1ϴ 1 (14.3%) 1 (7.69%) 1
Number of cases (percentage), median, range, or not determined values are indicated. The (ϴ) symbol indicates com-
parison of 7 RAEB versus 13 RAEB-t. P-values indicate the comparison between the two groups and are marked with (*) 
if lower than 0.05 and are computed using Mann-Whitney-U test (continuous variables) and two sided Fisher exact test 
(categorical variables). Note that percentages are solely based on non-missing values. 
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Table S5: Comparison of patient demographics, clinical and molecular characteristics between: AML with splice factor 
mutations versus AMLs without splice factor mutations.  
Characteristics
AML with splice factor 
mutations (n=28)
AMLs without splice factor 
mutations (n=283)
P-value
Median age,  y (range) 59 (37-77) 46 (15-77) 6.6e-7*
Missing 0 1
Sex, n (%) 0.43
Male 17 (61%) 144 (51%)
Female 11 (39%) 138 (49%)
Missing 0 1
WBC count, (x109/L) 0.029*
Median (range) 24 (2.1-109) 37 (0.3-274)
Not determined 0 2
Platelet count, (x109/L) 0.17
Median (range) 65 (10-931) 56 (7-742)
Not determined 0 2
Bone marrow blasts 0.00092*
Median % (range) 49% (6-93) 70% (0-98)
Not determined 3 8
Normal karyotype 11 (39.3%) 131 (46.3%) 0.84
Fab classification, n (%)
M0 1 (3.57%) 10 (3.53%) 1
M1 4 (14.3%) 60 (21.2%) 0.47
M2 8 (28.6%) 69 (24.4%) 0.65
M3 0 (0%) 7 (2.47%) 1
M4 7 (25%) 59 (20.8%) 0.63
M5 4 (14.3%) 65 (23%) 0.35
M6 0 (0%) 3 (1.06%) 1
RAEB(T) 0 (0%) 0 (0%) 1
Not determined 3 2
Erythroblasts 0.00064*
Median % (range) 11% (1-52) 3% (0-54)
Not determined 7 123
Molecular Abnormalities, n (%)
FLT3ITD 8 (28.6%) 84 (29.7%) 1
FLT3TKD 0 (0%) 38 (13.4%) 0.033*
NPM1+ 4 (14.3%) 97 (34.3%) 0.034*
CEBPA double mutation 1 (3.57%) 22 (7.77%) 0.71
CEBPA single mutation 1 (3.57%) 8 (2.83%) 0.58
IDH1 3 (10.7%) 21 (7.42%) 0.47
IDH2 4 (14.3%) 28 (9.89%) 0.51
DNMT3A 7 (25%) 67 (23.7%) 0.81
SRSF2 17 (60.7%) 0 (0%) 5.0e-21*
U2AF35 4 (14.3%) 0 (0%) 4.7e-5*
SF3B1 7 (25%) 0 (0%) 2.3e-8*
Number of cases (percentage), median, range, or not determined values are indicated. P-values indicate the compari-
son between the two groups and are marked with (*) if lower than 0.05 and are computed using Mann-Whitney-U test 
(continuous variables) and two sided Fisher exact test (categorical variables). Note that percentages are solely based on 
non-missing values.
Table S6: Comparison patient demographics, clinical and molecular characteristics between: RAEB(T) with Splice factor 
mutations versus RAEB(T) without Splice factor mutations.
Characteristics
RAEB(T) with splice factor 
mutations (n=20)
RAEB(T) without splice 
factor mutations (n=60)
P-value
Median age,  y (range) 66 (42-84) 62 (20-81) 0.42
Sex, n (%) 0.78
Male 14 (70%) 44 (73%)
Female 6 (30%) 16 (27%)
WBC count, (x109/L) 0.7
Median (range) 6 (1.6-127) 7 (1.1-91)
Platelet count, (x109/L) 0.55
Median (range) 71 (15-740) 68 (7-618)
Bone marrow blasts 0.86
Median % (range) 15% (1-29) 15% (2-29)
Erythroblasts 0.68
Median % (range) 13% (1-60) 19% (1-54)
Not determined 0 3
Ring Sideroblasts 4 15 1
Not determined 1 6
Molecular Abnormalities, n (%)
SRSF2 13 (65%) 0 (0%) 2.9e-10*
U2AF35 4 (20%) 0 (0%) 0.0031*
SF3B1 3 (15%) 0 (0%) 0.014*
FLT3ITD ϴ 0 (0%) 1 (8.33%) 1
FLT3TKD ϴ 0 (0%) 1 (8.33%) 1
NPM1+ ϴ 0 (0%) 1 (8.33%) 1
CEBPA double mutationϴ 0 (0%) 1 (8.33%) 1
CEBPA single mutationϴ 1 (14.3%) 1 (8.33%) 1
IDH1ϴ 1 (14.3%) 1 (8.33%) 1
IDH2ϴ 1 (14.3%) 0 (0%) 0.37
DNMT3Aϴ 4 (57.1%) 0 (0%) 0.0063*
NRAS/KRASϴ 1 (14.3%) 2 (16.7%) 1
ASXL1ϴ 1 (14.3%) 1 (8.33%) 1
Number of cases (percentage), median, range, or not determined values are indicated. The (ϴ) symbol indicates com-
parison of 7 RAEB(T) with splice factor mutations versus 13 RAEB(T) without splice factor mutations. P-values indicate 
the comparison between the two groups and are marked with (*) if lower than 0.05 and are computed using Mann-
Whitney-U test (continuous variables) and two sided Fisher exact test (categorical variables). Note that percentages are 
solely based on non-missing values.
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Table S7: Bone marrow blast, Ring sideroblast, Erythroblast and Platelet characteristics cluster #3 and #11 
Cluster Patient ID RAEB(T)
WBC count 
(x109/L)
Platelet count 
(x109/L)
Bone 
marrow 
blasts (%)
Ring 
sideroblasts
Erythroblasts 
(%) SF-mutant
3
5349 RAEB-t 31 86 25 - 1 Yes
5354 RAEB-t 54 54 20 - 2 Yes
7311 RAEB-t 99.5 46 9 - 5 Yes
7116 RAEB-t 8.4 266 24 - 5 -
7118 RAEB 4.8 35 13 - 29 Yes
3330 RAEB 22 145 41 - ND -
7177 RAEB 19.2 26 19 - 25 -
7312 RAEB 13 217 17 Yes 15 -
7309 - 35 70 22 - 1 -
7117 - 109 64 6 - 10 Yes
2228 - 38 931 34 - 16 Yes
2259 - 57.1 74 49 - 3 -
2278 - 28 78 46 Yes 23 -
2279 - 23 104 59 - ND -
2283 - 47.4 64 49 - 18 Yes
3323 - 23 83 42 Yes 11 Yes
5290 - 8.4 181 49 - 16 -
5363 - 54 191 31 - 6 -
6247 - 11.2 115 34 - 1 Yes
6454 - 43 42 63 - 1 -
7137 - 37 283 74 - 5 Yes
7167 - 60.7 57 52 - 16 Yes
7172 - 128 211 88 - 2 ND
7183 - 12.8 195 66 - 2 Yes
7325 - 26 65 29 Yes 1 Yes
11
3481 RAEB-t 2 65 20 - 37 Yes
6450 RAEB-t 3.9 134 14 Yes 59 Yes
6359 RAEB-t 7.1 57 10 Yes 44 -
6373 RAEB-t 13 67 17 Yes ND -
6448 RAEB-t 11 66 8 - 34 -
7303 RAEB-t 5.8 23 11 - 54 -
7317 - 16.5 135 17 Yes 52 Yes
2224 - 1.4 22 24 - 54 -
2246 - 2.4 198 54 Yes 41 -
2256 - 4.7 152 31 Yes 25 Yes
3318 - 6.6 87 35 Yes 19 ND
3489 - 5 374 64 - 8 Yes
4340 - 14.3 64 33 - 9 -
5287 - 13.5 80 39 - 18 Yes
6374 - 33 71 63 - 21 -
6378 - 11.8 160 61 - 18 -
6453 - 2.1 87 47 Yes 30 Yes
7071 - 2 125 31 - ND ND
7419 - 5 51 35 - ND Yes
Abbreviations: Cluster: Patients are detected in cluster 3 or 11; Patient ID: Patient identification number; RAEB(T), 
Refrectory Anemia with Excess Blasts (in Transformation); WBC count: white blood cell count; Platelet count: number of 
platelets per 109/L; Bone marrow blasts (%): Percentage of Bone marrow blasts; Ring sideroblasts: Patient cells showed 
Yes/No Ring sideroblasts; Erythroblasts (%): Percentage of Erythroblasts; SF-mutants: Splice factor mutation in SRSF2, 
U2AF35 or SF3B1.
Table S8: Newly identified putative splice factor mutations 
Patient
Genomic 
location
Reference Altered
Variation 
situated
Gene 
affected
Gene effect Genotype
6448
chr4: 24572314- 
24572314
G C exonic DHX15
nonsynonymous 
SNV
DHX15:uc003gqx.3:exon3: 
c.C664G:p.R222G
2246
chr6: 4032794- 
4032794
G _ exonic PRPF4B
frameshift 
deletion
PRPF4B:uc003mvv.3:exon2: 
c.1043delG:p.R348fs
2246
chr6: 4032796- 
4032796
A T exonic PRPF4B
nonsynonymous 
SNV
PRPF4B:uc003mvv.3:exon2: 
c.A1045T:p.S349C
3318
chr18: 34901838- 
34901838
G A exonic CELF4
nonsynonymous 
SNV
CELF4:uc002laf.2:exon3: 
c.C364T:p.R122W
Patient: patient number. Reference: Reference human genome 19 sequence. Altered: Measured variation in DNA 
sequence. Variation situated: genomic-location of the detected variation in the DNA sequence. Gene affected: The gene 
that is affected by the variation the DNA sequence. Gene effect: nonsynonymous SNV (Single Nucleotide Variation) alters 
the amino acid sequence of a protein, Frameshift deletion: a number of nucleotides that is deleted in the DNA sequence. 
Genotype: Characteristics of the detected variation.
Abbreviations: RAEB(T): Refractory anemia with excess blasts (in transformation). With splice 
factor mutations: mutations that are detected in the hotspots of gene SRSF2, U2AF35 and 
SF3B1; WBC count: white blood cell count; Platelet count: number of platelets per 109/L; Bone 
marrow blasts (%): Percentage of Bone marrow blasts; Fab class, morphological classification; 
M0, minimally diffentiated; M1, without maturation; M2, with maturation; M3, hypergranular 
promyelocytic; M4, myelomonocytic; M5, (a) monoblastic, (b) monocytic; M6, erytroleukemia; 
Erythroblasts (%): Percentage of Erythroblasts; Ring sideroblasts: Patient cells showed Yes/No 
Ring sideroblasts; FLT3ITD: internal tandem duplication in FLT3; FLT3TKD: tyrosine kinase domain 
mutation in FLT3; NPM1: Nucleophosmin 1; CEPBA double mutant: double mutation in CEBPA; 
CEPBA single mutant: single mutation in CEBPA; IDH1/IDH2: Isocitrate dehydrogenase 1 or 2; 
DNMT3A: DNA (cytosine-5)-methyltransferase 3A; NRAS/KRAS: mutations in codon 12,13 or 61; 
ASXL1 mutations; SRSF2, U2AF35 and SF3B1 are splice factor mutations that are detected in the 
hotspots.
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This thesis is divided into four sections in which we aim to develop and apply statistical 
approaches to understand the meaning of genome wide molecular data determined in the cells 
of patients with Acute Myeloid Leukemia. Central in the studies is one group of patients that 
have abnormalities in the gene called CEBPA. Although we addressed very specific biological 
questions regarding CEBPA in AML, the statistical approaches that are presented can also be 
used for other groups of patients. In this Chapter, we discuss potential future research directions 
and the results in an integrated manner.
IDENTIFICATION OF POTENTIAL FUNCTIONAL REGIONS IN THE GENOME 
In Chapter 2, 3 and 4 we describe the development, implementation and application of 
HAT(SEQ) (Hypergeometric Analysis of Tiling-arrays and Sequence data), a method to detect 
potential functional regions in the genome defined with chromatin immunoprecipitation on chip 
(ChIP-on-chip) or by massively parallel DNA sequencing (ChIP-Seq) data. Together with HATSEQ, 
multiple other methods74,147,151,240-242 have been developed to analyze tiling-array and NGS data 
with the purpose to define potential functional regions (regions-of-interest, ROI). The various 
methods use different statistical approaches and therefore, if these methods are used to analyze 
the same dataset, differences in the results can be found. An obvious question is therefore: 
“What is the best method to use?”.
The most common approach that is used to test the performance of different methodologies 
is by overlaying the detected regions. It has been shown that different methodologies do show 
significant overlap in detected regions95. It is very likely that these similarly detected regions 
are represented by genomic regions with high signals (read depth or intensity values). The 
differences in detected regions between various methodologies are likely the regions with subtle 
changes (low read depth or intensity values) or an “unexpected” size of the region. A reason why 
one methodology may detect a particular region whereas another does not, may be because 
methodologies can be designed and optimized for the analysis of one type of tiling-array or 
ChIP-Seq application; the expected signal and/or size of the binding region is then modeled. 
Unfortunately, there is no golden standard that defines such parameters of candidate regions as 
it depends on the biological experiments (e.g. protein properties). Thus, overlaying the detected 
regions using different methodologies will not per definition define true binding regions but only 
emphasizes the similarity of detected regions between the methodologies.
In general, the most straightforward way to measure the performance of a methodology is by 
validating each detected candidate region by directed PCR and Sanger sequencing243. However, 
this process is expensive and time consuming when even tens of candidate regions need to be 
validated. In general, hundreds or thousands of candidate regions can be detected in a single 
experiment, and consequently, PCR-Sanger sequencing is not an option to validate all ROIs. An 
approach to test the performance of a method can be by using in silico data sets244-248 (e.g. 
simulated data sets). In these simulated data sets, the “true binding regions” and background-
noise-signal (technical variation) is included. However, a disadvantage of in silico data sets is 
the applicability of the model. For example, a true binding region in a biological experiment 
for protein-DNA-binding depends on the properties of the protein, such as flexibility, binding-
strength, molecular conformation and/or the interaction with other molecules. The signal and 
size of the binding regions are therefore affected by the properties of the protein. Thus the 
creation of in silico data set requires many well characterized (validated) binding regions among 
different types of biological experiments to model true-binding regions.
Coming back to the initial question, “What is the best method to use?” appears to be a too 
generic question as the choice of the best method depends on the exact research question. 
As an example, if one is interested in the genes that are in close proximity of the top enriched 
candidate binding regions, the majority of methodologies will likely give very similar results. 
However differences in results between methodologies may occur if one is interested in the 
motifs (instead of neighboring genes) among the (top) detected binding regions. 
Motif analysis is a straight-forward approach to benchmark the detected binding regions 
determined using a particular methodology. It could for instance address the question whether 
expected consensus binding sites are detected. Such findings may help deciding which 
methodology to choose. It is important to note that in the end, laboratory experiments are 
indispensable to demonstrate the biological significance of particular detected region. For 
instance in case transcription factor binding regions are identified by means ChIP-on-chip or 
ChIP-Seq, these interactions should be validated using ChIP-PCR and possibly using a combination 
in functional experiments to demonstrate the real meaning of such interactions. 
The advantage of our methodology is that it detects candidate regions without defining a priori 
the expected size of the ROI, and is therefore applicable for different biological experiments 
(protein-DNA-binding, DNA-methylation, histone modifications). Although we are able to easily 
follow-up biological relevance of the detected binding regions, data integration (e.g. with gene 
expression profiles) may be the key to gain more insights in the disease state as these approaches 
can speed up the identification of critical leukemogenic hits.
IDENTIFICATION OF C/EBPΑ TARGETS BY PROMOTER BINDING AND MRNA 
CHANGES
A powerful technology to detect potential functional regions on the genome is by using tiling-
array (e.g. ChIP-on-chip) or by massive parallel DNA sequencing (e.g. ChIP-seq) data. The 
binding of proteins to the DNA does not necessarily result in changes of mRNA expression levels 
(relative gene activation or repression can be measured with the use of, e.g. gene expression 
profiling). Integration of e.g. ChIP-on-chip or ChIP-seq with gene expression profiles (GEP) is of 
great importance to get better understanding in the involved pathways and the exact functional 
role of transcription factors on gene expression regulation (such as for CEBPA). Such results can 
then be instrumental for the development of novel targeted therapies for specific subtypes in 
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AML. Although ChIP-on-chip or ChIP-seq and gene expression data sets are widely used, it is not 
straightforward to integrate data sets as these procedures are not standard.
In Chapter 6 we provide data to demonstrate that C/EBPα may not only act as an activator but also 
as a repressor of transcription. We proposed that absence of C/EBPα is one of the transforming 
events towards mixed myeloid/T-lymphoid leukemia. In particular T-cell related genes, that are 
upregulated when C/EBPα is absent, are predicted to be targets of C/EBPα and repressed in the 
presence of this transcription factor. Such transformation effect is likely to be caused by a very 
complex network of relationships between proteins, motifs and epigenetic regulation, such as 
DNA-methylation. In addition, our results are detected in a 32D cell line model, and may not be 
identical to the human situation. The use of (public) ChIP-on-chip or ChIP-Seq data sets of the 
identified binding-proteins, gene expression and DNA-methylation profiles in large cohorts of 
AML samples will undoubtedly contribute to further insights. 
THE IMPORTANCE OF INTEGRATIVE AND COMBINATORIAL ANALYSES OF 
GEP AND DMP
The use of gene expression profiling (GEP), to measure changes in mRNA expression levels in patient 
samples, has become very important in cancer research because of its wide applicability18,24,61,62. 
An example is the discovery of previously unrecognized subgroups18. However, measurements 
of mRNA expression levels is only one type of disturbance that may occur in malignant cells. 
Another type of disturbance in malignant cells are changes in DNA-methylation249, which can be 
measured in patient samples using DNA-methylation profiling (DMP)250. Relations between DNA-
methylation and mRNA expression in AML are known to exist251, however no comprehensive 
integrative analysis has been performed between GEP and DMP so far in AML. Combining these 
data sets may result in unique cancerous patterns that characterizes subgroups in AML. There 
are two major challenges: the development of a statistical approach to combine both data sets, 
and secondly the identification of novel subgroups in AML which are not artifacts induced by the 
statistical approach. In Chapter 9 we show with an unsupervised analysis that the combined data 
sets revealed two unrecognized subgroups in AML. These two subgroups could not be identified 
using GEP or DMP alone18,58. 
There are still questions to be addressed to learn more about the biological relations between 
gene expression and DNA-methylation. Question such as, “how does DNA-methylation influences 
the change of gene expression for a specific AML subtype?” will undoubtedly contribute to further 
insights. This is particularly of interest for patient groups that have malignant cells affected by 
both abnormal gene expression and DNA-methylation levels. 
EVALUATION OF TREATMENT EFFECTS FOR PATIENT SUBGROUPS  
REQUIRES LARGE STUDY-SIZES
The identification of different subtypes in AML is especially of importance as it can be used in 
treatment protocols35,228,252,253. We needed a large cohort of 1182 normal karyotype patients 
to show that favourable outcome is mainly observed in AML with CEBPAdm and not in CEBPAsm 
178 (Chapter 7). In addition, we showed that concurrent mutations occur more frequently in 
CEBPAsm than in CEBPAdm AML and affects outcome, e.g. CEBPAsm is dominated by concurrent 
NPM1 and/or FLT3 internal tandem duplication (ITD) mutations. We therefore proposed that 
only CEBPAdm should be considered as a separate entity in the classification of AMLs. The 
importance of CEBPAdm as a separate entity is stressed by the notion that various genetic and 
cytogenetic abnormalities in AML have clinical value as they may predict disease outcome and 
response to treatment254. To address this question, thus the impact of allogeneic and autologous 
Hematopoietic Stem Cell Transplantation (alloHSCT, autoHSCT respectively) in comparison to 
chemotherapy consolidation, required even more patient samples. By combining clinical data 
from Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group (HOVON/SAKK) and German-
Austrian AML Study Group (AMLSG) trials we compiled 5724 patients. The number of patients 
that accomplished to our selection was however only 124 CEBPAdm patients (Chapter 8). These 
were subsequently split into smaller subgroups based on how these patients were treated. A 
challenge in the analysis is to overcome the time-to-treatment bias from the no-transplant group 
to the alloHSCT or autoHSCT groups at the time-point of HSCT. Without correction for the time-
to-treatment bias, the results in terms of outcome may be misleading or even incorrect because 
patients that received alloHSCT or autoHSCT treatment are consolidated after chemotherapy. 
We were able to show that patients receiving an alloHSCT or autoHSCT in first CR, showed 
significantly less relapses compared to patients receiving chemotherapy. Meaning that relapse-
free survival (RFS) was significantly superior in patients receiving an alloHSCT or autoHSCT in first 
CR compared to patients receiving chemotherapy. However, the superior RFS after alloHSCT and 
autoHSCT did not translate in a significant better overall survival (OS). This may be caused due 
to a high second complete remission rate for patients that received intensive chemo treatment. 
Thirty-eight out of 70 patients relapsed after intensive chemo therapy, and only 6 out of 38 
patients relapsed after receiving alloHSCT or autoHSCT treatment. It seems that alloHSCT is a 
good option in first CR, but an alternative and not unreasonable strategy would be to postpone 
the alloHSCT in first CR and keep the option of alloHSCT for salvage for the restricted fraction 
of patients after relapse. Our data supports both strategies, on the one hand an alloHSCT or 
autoHSCT in first CR and on the other hand intensive chemotherapy as consolidation in first 
CR and an alloHSCT in case of relapse. An important notion is however that patients have to be 
well informed about the risks and consequences of alloHSCT and autoHSCT in first CR. Recent 
findings showed frequently associated of CEBPAdm with GATA2 zinc finger 1 mutations255,256, and 
that GATA2 mutations are associated with favorable outcome compared to other GATA2wild-type 
Ch
ap
te
r 1
0
General DiscussionChapter 10
189188
genotypes. Although no significant differences in outcome were observed between the groups 
GATA2mutant/CEBPAdm versus GATA2wild-type/CEBPAdm, it requires further investigation with even 
larger cohorts to investigate the exact role of mutant GATA2 on top of CEBPAdm in terms of 
patients receiving an alloHSCT or autoHSCT in first CR.
NEXT-GENERATION SEQUENCING AND THE DISCOVERY OF AML SUBTYPES
The ultimate goal in cancer research is the development of personalized treatment based on the 
specific cancerous patterns in a single patient. The introduction of next-generation sequencing 
technology257 may be a first step in this process as it allows us to accurately characterize all 
the abnormalities for a single patient. However, the generated data that need to be processed, 
analysed and confirmed may remain a challenge for the coming decennia. So far, microarray 
experiments (with relatively limited resolutions compared to NGS data) are intensively used to 
find groups of patients with similar cancerous patterns (denoted as subtype) 18. Although many 
subtypes are already identified and recognized by the World Health Organization228, it is highly 
conceivable that more AML subtypes do exist but are hidden due to the complex relationships 
of molecules in cancerous cells. 
A challenge is to find these AML subtypes and to infer whether these subgroups are “true” and not 
artefacts induced by the inherent tendency of the probabilistic models. A “true” subtype of AML 
is defined as a group of samples that can be identified with common features, such as common 
molecular aberrations and/or clinical responses. Ideally, AML subtypes can be discovered by: 
1. analyzing various data sources of the same samples in an integrative manner, such as gene 
expression, DNA-methylation, microRNAs and pathways. 2. Using high data-resolutions, and 3. 
Using a high number of patient data. 
The use of NGS technology will cover the first two points. The third point is crucial as it may 
reveal the existence of subtypes that are only seen in low frequencies, and importantly it will 
increase the computational power to find with high confidence (novel) AML subtypes. So far, 
small numbers of patient samples is the most important limiting factor in integrative studies, and 
for the detection of AML subtypes. As an example, if multiple data sets are combined (point 1) 
that have high genomic coverage (point 2), it will result in an exploding number of features that 
heavily increases the number of computations (e.g. degrees of freedom increases). This suggests 
that it becomes harder to find true positive relationships if only point 1 and 2 are followed. This 
can particularly become a problem as we enter the sequencing era where the genome coverage 
is massively increased without massively increasing the number of samples. 
A key to continue expanding our knowledge about diseases such as leukemia (with the use of NGS 
data) is to share data across the world and to make IT frameworks accessible for data sharing and 
computations. Without such as an approach, and under the assumption of continuous increase 
of high data-resolutions but steady (low) sample sizes, the balance is disturbed and leads to 
the “curse of dimensionality258”. Which may result in a dramatically increase of false positives. 
Validation of the results will be stressed even more.
NGS technology can nowadays be of great value in many other applications such as for the 
detection of gene mutation or the determination of binding regions of proteins, but also to 
support the analysis of conventional experiments (tiling-arrays) in applications such as the 
detection of AML subtypes (Chapter 9). In contradiction to the statistical approaches that are 
known for tiling-array experiments, NGS data analysis has started very recently. The required 
statistical approaches are still immature and need to be developed, optimized, and validated. A 
new statistical-era for NGS data analysis has just been started.
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SUMMARY
This thesis consists out of four sections: 1. the creation of a statistical methodology for the 
detection of candidate regions in the genome using tiling-array or next-generation sequencing 
technology. 2. Applications of the newly developed method to study DNA-interaction of wild-
type and mutant C/EBPα, and to unravel the role of C/EBPα in transformation of cells with 
myeloid/T-lymphoid features. 3. Analysis of the molecular and clinical behaviour of one specific 
subtype of human leukemia: patients with mutations in CEBPA, the gene encoding C/EBPα. 
4. Discovery of specific AML subtypes using combined gene expression and DNA-methylation 
profiles by bioinformatical approaches in a cohort of human AML. 
The first section (chapter 2 to 4) describes a novel tool to analysis data obtained from tiling-
array hybridizations and next-generation sequencing of DNA obtained from, e.g. chromatin 
immunoprecipitation (ChIP) experiments. These technologies are frequently used to address 
fundamental biological questions, such as: “Where does a transcription factor bind to the 
DNA?”, “Can we discriminate active from inactive chromatin in the genome?” Or “Can we 
identify methylated regions in the genome?”. These questions may lead to better understanding 
of protein-DNA-interactions, gene activation or the identification of important tumour 
suppressor genes that are repressed as the result of DNA-methylation. By array hybridization 
or next-generation sequencing millions of signal data-points on the genome are determined. 
To detect biological relevant regions, signals should be discriminated from non-specific signals 
(background/ technical variation) to minimize the number of false positives. Candidate regions in 
the genome are defined by an increase of the signal (read depth or probe intensity) but depends 
on the type of experiment. There are no standard criteria that define the signals of the candidate 
regions. So far multiple methods have been developed for the detection of candidate regions 
but many of these methods are designed for one particular type of experiment and/or require 
various user defined parameters to model a candidate region, such as maximum bandwidth, 
the minimum number of data-points in a region or a minimum signal intensity. In chapter 2 
we describe our statistical framework called HAT (Hypergeometric Analysis of Tiling-arrays) 
to more accurately detect candidate regions that are the result of hybridization of chromatin 
immunoprecipitated DNA-fragments to tiling-arrays. We show that HAT has superior advantages 
over existing methodologies as it detects candidate regions by specifying only one parameter, 
the significance level α. We detected candidate regions in various tiling-array experiments such 
as ChIP-on-chip, MeDIP-on-chip or modified histone pool down experiments.
Although the successes of HAT, we are passing a phase where next-generation sequencing 
technology is replacing tiling-array technology. In chapter 3 we describe HATSEQ 
(Hypergeometric Analysis of Tiling-arrays and Sequence data), which uses the statistical 
framework of HAT but with substantial improvements so that it can be applied to next-
generation chip sequencing data. A comparison with existing ChIP-Seq methodologies showed 
strong overlap in the detection of candidate regions but our method showed consistently better 
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delineation of the region boundaries and therefore more specificity for the actual binding site. In 
addition, HATSEQ includes analysis to address the biological meaning of the detected candidate 
regions and, includes a graphical-user-interface that lowers the barrier for researcher to analyze 
their data without the need of scripting languages. 
In chapter 4 we used HAT for the detection of viral integration sites that potentially harbour 
new tumour suppressor genes in a so called MeDIP-on-chip dataset. This resulted into the 
identification of a tumour suppressor gene that is associated with outcome in AML. In the 
second section (chapter 5 and 6) we studied the molecular mechanisms of action and DNA-
binding of C-terminal mutant C/EBPα (chapter 5) and wild-type C/EBPα (chapter 6) in a myeloid 
cell line model using ChIP-on-chip, and by utilizing our previously developed model (HAT). For 
the latter experiment we detected binding-partners of C/EBPα that are associated with T-cell 
development. This is especially of interest because it has previously been shown that silencing 
of CEBPA expression levels in AML was negatively correlated with the expression levels of T-cell 
related genes. We therefore pursued the relation between CEBPA expression levels and the 
downregulated expression levels of T-cells genes. We propose a functional role of C/EBPα among 
the transforming events that drives the development of mixed myeloid/T-lymphoid leukemia.
In the third section of this thesis (chapter 7 and 8) we investigated a group of patients carrying a 
mutation in the gene CEBPA. In Acute Myeloid Leukemia (AML), CEBPA mutations can roughly be 
separated into two subgroups, i.e., those with a single mutation (CEBPAsm) and those with double 
mutations (CEBPAdm). In chapter 7 we investigated the clinical outcome and gene expression 
profiles of CEBPAdm versus CEBPAsm and the effect of concurrent gene mutations (NPM1/ FLT3ITD). 
We show for CEBPAdm patients a lower frequency of concurrent mutations compared to CEBPAsm 
patients. The outcome for CEBPAsm patients is dominated by concurrent mutations in the genes 
NPM1 and FLT3 (FLT3ITD). We report that CEBPAdm is an independent prognostic factor for 
favourable outcome. In support of the prognostic differences between CEBPAdm and CEBPAsm, 
striking differences between the gene expression profiles are detected. Patient with CEBPAdm 
expressed a unique gene expression signature that allows further classification/refinement of 
AML whereas this was not possible for CEBPAsm patients. For the group of CEBPAdm patients 
we describe in chapter 8 the effect of post remission allogeneic and autologous hematopoetic 
stem cell transplantation (alloHSCT, autoHSCT respectively) compared to CEBPAdm patients 
consolidated with chemotherapy. We show that adults with AML with the distinctive CEBPAdm 
genotype benefit from alloHSCT and autoHSCT in first complete remission (CR) with respect to 
relapse-free survival (RFS) compared to patients consolidated with chemotherapy. This benefit is 
not seen in overall survival (OS), apparently due to a high second CR rate after salvage therapy. 
However, there was a trend for a better OS for alloHSCT, but not for autoHSCT performed in first 
CR.
In the final section (chapter 9) we inferred that novel groups of AML can be detected by 
combining gene expression (GEP) and DNA-methylation profiles (DMP). It has been shown in 
previous studies that mutations in splice factor (SF) genes occur frequently in Myelodysplastic 
Syndromes (MDS), including Refractory Anemia with Ring Sideroblasts (RARS), Refractory 
Anemia with Excess of Blasts (RAEB) or transformation (RAEB(t)). These SF-gene mutations, 
although less frequently, have also been reported in human acute myeloid leukaemias (AML). 
By using both GEP and DMP-dataset we assessed the differences and similarities between MDS 
and AML with SF-gene mutations. The combined dataset resulted into an optimal hierarchical 
clustering containing 18 patient clusters. Among these clusters we identified, besides previously 
identified AML subgroups also two novel AML subgroups. These two subgroups were not found 
by using GEP or DMP alone. Both clusters (cluster number 3 and 11) contain patients that are 
enriched for RAEB(t) cases and splice factor mutations. However there are differences, cluster 
3 is enriched for mutations in splice factor SRSF2 whereas cluster 11 is significantly enriched 
for mutations in splice factor U2AF35 and SF3B1. Another major difference is the enrichment 
for N-RAS and K-RAS mutations in cluster 3. The most discriminative novel cluster 11 presented 
AMLs with unique erythroid features based on the following findings: 1. Enrichment of pathways 
associated with erythroid development, when differentially expressed and methylated genes 
were analysed. 2. High percentages of erythroblasts. 3. Presence of patient samples with a RAEB 
or a RAEBt. 4. Frequent appearance of ring sideroblasts. Ours is the first report of the clustering of 
splicing mutants in human neoplasia using both gene expression and DNA-methylation profiles.
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Acute Myeloïde Leukemie (AML) is een vorm van leukemie waarbij de uitrijping van bloedcellen 
op een kwaadaardige manier verandert. Alle bloedcellen worden gemaakt in het beenmerg. In 
een normale (gezonde) situatie zullen onrijpe hematopoietische stamcellen in het beenmerg 
via verschillende differentiatie-stadia uitrijpen tot functionele bloedcellen: de rode bloedcellen, 
witte bloed cellen en bloedplaatjes. Dit proces van bloedcelproductie gebeurt dagelijks en met 
miljoenen tegelijk. In een abnormale (ongezonde) situatie kunnen deze cellen ongedifferentieerd 
blijven. De cellen hebben dan geen functie en kunnen vervolgens de normale (gezonde) cellen in 
het beenmerg en bloed verdringen, met als resultaat een te kort aan normale rijpe bloedcellen. 
Om patiënten goed te kunnen behandelen moeten we meer weten over de genetische afwijkingen 
die ten grondslag liggen aan de maligniteit. Er is al veel onderzoek gedaan naar de maligniteit 
in patiënten met AML, zo is bekend dat AML een heterogene ziekte is, dat wil zeggen dat het 
niet één ziekte is maar een verzameling van aandoeningen. Het is ook bekend dat AML vaak 
te wijten is aan genetische afwijkingen. De meest bekende zijn chromosomale veranderingen 
zoals inv(16), of herschikkingen van de chromosomen zoals gebeurt bij translocatie t(15;17) 
en t(8;21). Hierdoor kunnen delen van twee losse genen bij elkaar gebracht worden waardoor 
vervolgens een nieuw fusie-gen ontstaat. Andere bekende afwijkingen in AML zijn subtiele 
mutaties in kanker-kritische genen, zoals “Internal Tandem Duplications” in FLT3 (FLT3ITD) of 
mutaties in nucleophosmin (NPM1) of “CCAAT enhancer binding protein alpha” (CEBPA). Verder 
is bekend dat genetische afwijkingen gerelateerd zijn met prognose. Ondanks de vele verrichtte 
studies en de daardoor verkregen inzichten, worden nog steeds nieuwe genetische afwijkingen 
in patiënten met AML gevonden. Sub classificatie van patiënten zal in de toekomst dan ook 
toenemen. 
In dit proefschrift wordt de rol van C/EBPα in myeloïde leukemie nader onderzocht en in het 
bijzonder bij één specifieke groep van patiënten; namelijk die met een afwijking in het gen dat 
codeert voor C/EBPα. C/EBPα is één van de master regulatoren voor myeloïde differentiatie. 
Een gemuteerd CEBPA codeert voor een niet of deels functioneel C/EBPα-eiwit dat effect 
heeft op de cel differentiatie. Daarnaast wordt er in dit proefschrift een statistische methode 
beschreven dat ontwikkeld is om genoom-breed eiwit-DNA interacties te detecteren met behulp 
van zogenaamde tiling-array en next-generation sequencing technologie (NGS). De methode 
is vervolgens gebruikt om virale integratie-sites te detecteren die mogelijk samenhangen met 
nieuwe tumor suppressor genen. Verder werd de technologie toegepast om (gemuteerde) 
C/EBPα-DNA interacties te identificeren en te associëren met gen-expressie. Daarbij werd de 
rol van C/EBPα in myeloïde/T-lymfoïde transformatie geanalyseerd. Verder werd voor deze 
groep van patiënten het effect van postremissie allogene en autologe hematopoietische 
stamceltransplantatie onderzocht. Tot slot zijn er nieuwe AML subgroepen geïdentificeerd door 
gen-expressie data en DNA methylatie data te combineren.
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In de eerste sectie (hoofdstuk 2, 3 en 4) wordt een statistische methode beschreven die we 
hebben ontwikkeld om data te analyseren die verkregen zijn met behulp van tiling-array of next-
generation sequencing technologie. Deze technieken kunnen worden gebruikt om fundamentele 
biologische vragen te beantwoorden, zoals: “Waar binden transcriptie factoren op het DNA?”, 
“Kunnen we actief en inactief chromatine op het genoom van elkaar onderscheiden?” of “Kunnen 
we gemethyleerde gebieden identificeren in het genoom?”. Het beantwoorden van deze vragen 
kan leiden tot een beter begrip van bijvoorbeeld eiwit-DNA interacties, gen activering of de 
identificatie van belangrijke tumor suppressor genen die onderdrukt worden als gevolg van 
DNA-methylering. Door gebruik te maken van array hybridisatie of next-generation sequencing 
kunnen miljoenen datapunten genoom-breed gemeten worden. De signalen die kandidaat 
gebieden representeren moeten vervolgens onderscheiden worden van niet specifieke signalen 
(achtergrond/technische variatie). De kandidaat gebieden worden gedefinieerd door een toename 
van het signaal, maar er zijn geen definities die a priori beschrijven wat een kandidaat gebied is 
(zoals bijvoorbeeld de grootte of sterkte van het signaal). Dit kan namelijk verschillen tussen de 
verschillende typen experimenten. Tot dusver zijn er verschillende methoden ontwikkeld voor 
de detectie van kandidaat gebieden. Sommige van deze methodieken zijn ontworpen voor één 
bepaald type experiment en kunnen meerdere instellingen vereisen om een kandidaat gebied 
te beschrijven, zoals de minimale sterkte van het signaal, maximale breedte van het kandidaat 
gebied en minimaal aantal datapunten dat voor een kandidaat gebied moet worden gemeten. 
In hoofdstuk 2 wordt een door ons ontwikkelde methode, genaamd HAT (Hypergeometrische 
Analyse van Tiling-arrays) beschreven om kandidaat gebieden te identificeren. We laten zien 
dat HAT voordelen heeft ten opzichte van andere bestaande methodieken. HAT kan namelijk 
kandidaat gebieden detecteren in verschillende type tiling-array experimenten, zoals ChIP-on-
chip en MeDIP-on-chip, zonder extra kennis nodig te hebben over de te verwachte signaalsterkte/ 
grootte van het kandidaat gebied. Alhoewel HAT succesvol is toegepast in tiling-array data, 
passeren we een fase waarin next-generation sequencing technologie de tiling-array technologie 
gaat, zo niet reeds heeft vervangen. In hoofdstuk 3 beschrijven we HATSEQ (Hypergeometrische 
Analyse van Tiling-arrays en Sequence data), gebaseerd op de statistische methode die in HAT 
gebruikt is. HATSEQ heeft aanzienlijke uitbreidingen zodat het ook kan worden toegepast op 
de nieuwe generatie ChIP-sequence data. Als we de resultaten van HATSEQ vergelijken met die 
van andere methoden, dan zien we een grote overlap in de gedetecteerde kandidaat gebieden. 
Desondanks zijn de gebieden gedetecteerd door HATSEQ specifieker. Bovendien kan HATSEQ 
de gedetecteerde kandidaat gebieden bestuderen op hun eventuele biologische betekenis, 
zoals de aanwezigheid van motieven en/of verrijking voor specifieke pathways. HATSEQ is 
overigens ontwikkeld met een grafische gebruikers interface zodat onderzoekers zonder kennis 
van programmeertalen de methode kunnen toepassen. In hoofdstuk 4 laten we in een MeDIP-
on-chip experiment zien dat virale integratie-sites, die mogelijk samenhangen met nieuwe 
tumor suppressor genen, gedetecteerd kunnen worden. We hebben een tumor suppressor-gen 
geïdentificeerd dat geassocieerd is met de overleving van patiënten met AML.
De tweede sectie van mijn proefschrift (hoofdstuk 5 en 6) bevat onderzoek waarbij we de 
functionele rol van de transcriptie factor C/EBPα in myeloïde cel line modelsystemen hebben 
bestudeerd, door gebruik te maken van ChIP-on-chip technologie. We hebben daarvoor gebruik 
gemaakt van de door ons eerder ontwikkelde methode, HAT. In hoofdstuk 5 bestuderen we 
de “binding-sites” van C-terminal mutant C/EBPα en in hoofdstuk 6 is de moleculaire functie 
van C/EBPα onderzocht. In de loop der jaren is veel inzicht verkregen in de rol van C/EBPα 
in hematopoietische ontwikkeling, maar de directe “binding-sites” en de associatie met 
veranderingen in mRNA expressie is nog grotendeels onbekend. Zo laten we in hoofdstuk 6 zien 
dat we een groep van genen gedetecteerd hebben waar C/EBPα in staat was om te binden aan 
promotor sequenties, en de expressie van de gerelateerde genen verlaagd was in een sub groep 
van AML patiënten, de zogenaamde groep van CEBPA-silenced AML patiënten. Deze experimenten 
ondersteunen de hypothese dat C/EBPα niet alleen kan fungeren als een transcriptionele 
activator maar ook als een repressor van genen. Onze experimenten lijken er vooral op te wijzen 
dat expressie van genen, die van belang zijn bij ontwikkeling van T-lymfocyten en waarvan de 
promotor een interactie aangaat met C/EBPα, geremd wordt door deze transcriptie factor. Dit 
is vooral van belang omdat al eerder aangetoond was dat het volledig uitschakelen van CEBPA, 
geassocieerd was met de expressie van T-cel gerelateerde genen. 
In de derde sectie van dit proefschrift (hoofdstuk 7 en 8) is er onderzoek gedaan aan een groep 
van AML patiënten met mutaties in het CEBPA gen. AML patiënten met CEBPA mutaties kunnen 
kortweg in twee subgroepen worden onderverdeeld, namelijk die met een enkele mutatie 
(CEBPAsm) en die met dubbele mutaties (CEBPAdm). Bij CEBPAdm patiënten zijn meestal beide 
allelen betrokken, zodat in de leukemie cellen van deze patiënten geen normaal C/EBPα aanwezig 
is. In hoofdstuk 7 wordt de prognostische waarde en de gen-expressieprofielen van CEBPAdm 
versus CEBPAsm onderzocht. Verder is de rol van andere gen mutaties, namelijk NPM1 mutaties 
en FLT3ITD bestudeerd. We tonen aan dat NPM1 mutaties en of FLT3ITD vaker voor komen bij 
CEBPAsm patiënten dan bij CEBPAdm patiënten met AML. Vervolgens laten wij zien dat CEBPAdm 
een onafhankelijke prognostische factor is voor een gunstige uitkomst. Voor CEBPAsm patiënten 
geldt dat de prognostische waarde wordt gedomineerd door mutaties in NPM1 en/of FLT3ITD. 
Tot slot zijn er in de gen-expressieprofielen opvallende verschillen gedetecteerd. Patiënten met 
CEBPAdm kunnen worden herkend aan een uniek gen-expressieprofiel. Dit bleek niet mogelijk 
voor de CEBPAsm groep. In hoofdstuk 8 bestuderen we het effect van postremissie allogene 
en autologe hematopoietische stamceltransplantatie (alloHSCT, autoHSCT respectievelijk) in 
CEBPAdm patiënten. De effecten van de HSCT worden vergeleken met CEBPAdm patiënten die 
alleen chemotherapie hebben gehad. We tonen aan dat CEBPAdm patiënten profiteren van 
alloHSCT en autoHSCT in de eerste complete remissie met betrekking tot “relapse-free survival” 
in vergelijking met patiënten die alleen chemotherapie gehad hebben. 
In de vierde en laatste sectie (hoofdstuk 9) laten we zien dat nieuwe patiënt groepen in AML 
gedetecteerd kunnen worden door gen-expressie (GEP) en DNA methylatie profielen (DMP) 
te combineren. In eerdere studies was aangetoond dat mutaties in splice factor (SF) genen 
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voorkomen bij myelodysplastische syndromen (MDS), met refractory anemia en ring sideroblasts 
(RARS), en met refractory anemia met excess of blasts (RAEB) of in transformatie (RAEBt). Deze 
splice factor gen mutaties zijn ook gedetecteerd in AML maar in mindere mate. Door gebruik te 
maken van zowel GEP en DMP-datasets konden we de verschillen en overeenkomsten tussen 
RAEB, RAEBt en AML met splice factor gen mutaties analyseren. Met de gecombineerde GEP/
DMP-dataset hebben we een optimale hiërarchische clustering met 18 clusters verkregen. 
De clusters bevatten, naast de eerder gevonden AML subgroepen ook twee nieuwe AML 
subgroepen. Deze twee subgroepen werden niet gevonden door gebruik te maken van alleen 
de GEP of alleen de DMP-dataset. De twee nieuwe clusters (cluster nummer 3 en 11) bevatten 
patiënten die verrijkt zijn voor RAEB, RAEBt en AML met SF-mutaties. Er zijn echter verschillen 
tussen clusters: cluster 3 is verrijkt voor mutaties in splice factor SRSF2 terwijl cluster 11 verrijkt 
is voor mutaties in splice factor U2AF35 en SF3B1. Een ander belangrijk verschil is dat patiënten 
in cluster 11 unieke erythroid eigenschappen hebben. Dit is bepaald op basis van de volgende 
bevindingen: 1. verrijking voor gen-pathways die geassocieerd zijn met erythroid ontwikkeling, 
2. hoge percentages erythroblasten, 3. het veel voorkomen van RAEB of RAEBt patiënten, en 
4. het veel voorkomen van ring sideroblasts. In tegenstelling zien we deze erythroid verrijking 
niet in de patiënten van cluster 3. In dit cluster zijn N-RAS en K-RAS mutaties vaak aanwezig. 
Deze mutaties zijn niet gevonden in cluster 11. Met deze studie laten wij als eerste zien dat 
nieuwe subgroepen in AML geïdentificeerd en beter gekarakteriseerd kunnen worden door gen-
expressie en de DNA-methylatie profielen te combineren.
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TSS  Transcription Start Site
AlloHSCT Allogeneic Haematopoietic Stem Cell Transplantation
AML  Acute Myeloid Leukemia
AutoHSCT Autologous Haematopoietic Stem Cell Transplantation
BM  Bone Marrow
bZIP  Basic leucine zipper
C/EBPα  CCAAT/Enhancer Binding Protein Alpha (protein)
CBF  Core-Binding Factor
CEBPA  CCAAT/Enhancer Binding Protein Alpha (gene)
CEBPAdm  CEBPA Double Mutation
CEBPAsm  CEBPA Single Mutation
ChIP  Chromatin Immunoprecipitation
ChIP-on-chip Chromatin Immunoprecipitation followed by analysis on array
ChIP-Seq Chromatin Immunoprecipitation followed by Sequencing
CID  Cumulative Incidence of Death 
CIR  Cumulative Incidence of Relapse 
CMP  Common Myeloid Progenitor
CN  Cytogenetical Normal
CR(1)  Complete Remission (First)
dHPLC  Denaturing High Performance Liquid Chromatography
DMP  DNA-Methylation Profiling
DNA  Deoxyribonucleic Acid
DNMT  DNA Methyltransferase
E2  β-estradiol
EFS  Event-Free Survival
ER  Estrogen Receptor
ERG  v-ets Erythroblastosis virus E26 oncogene homolog (gene)
ETO  Eight Twenty One (gene)
EVI1  Ecotropic Viral Integration site 1 (gene)
FAB  French American British
FDR  False Discovery Rate
FLT3  FMS-Like Tyrosine kinase 3 (gene)
FWER  Family-Wise Error Rate
G-CSF  Granulocyte Colony-Stimulating Factor
GEO  Gene Expression Omnibus
GEP  Gene Expression Profiling
Gr1.4 MuLV Graffi 1.4 Murine Leukemia Virus
GSEA  Gene Set Enrichment Analysis
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Na jaren onderzoek doen is het zover, mijn proefschrift is af! Er zijn de afgelopen jaren vele 
mensen bij mijn onderzoek betrokken geweest en die wil ik bedanken. 
Allereerst wil ik mijn promotor Ruud Delwel bedanken. Tijdens mijn PhD ben jij benoemd tot 
professor en ik heb daardoor jouw prachtige oratie mee mogen maken. De enthousiasme die jij 
hebt voor de biologie en de manier waarop jij dit kan overbrengen is uitermate bijzonder. Jouw 
ideeën over “slechts” één gen, zoals CEBPA, lijken onuitputtelijk te zijn en daarover hebben we 
dan ook vele uren gesproken. Mijn algemene kennis over de biologie heeft dankzij jou grote 
sprongen gemaakt. Ik hoop dat we in de toekomst contact blijven houden zodat ik van je kan 
blijven leren. Bob Löwenberg, ik wil je bedanken voor de goede samenwerkingen die wij gehad 
hebben bij diverse projecten en voor de gelegenheid om te promoveren binnen de afdeling. 
Marcel Reinders, ik had me met jou geen betere technische begeleider kunnen wensen. In mijn 
1ste jaar klopte ik bij je aan met de vraag of jij me wilde ondersteunen met de technische kant van 
het onderzoek. Geen moment twijfelde je hieraan en nam mij direct op in jouw groep. Bedankt 
voor de ondersteuning die je hebt geboden. Ik ben dan ook ontzettend enthousiast dat ik nu als 
postdoc in jouw groep werk!
Leden van de commissie; Prof.dr. H.R. Delwel, Prof.dr. B. Lowenberg, Prof.dr.ir. M.J.T. Reinders, 
Prof.dr. J.N.J. Philipsen, Prof.dr. l.P. Touw, dr. P.J.M. Valk en Prof.dr. J.J. Goeman bedankt voor 
de beoordeling van het manuscript en het plaatsnemen in de promotiecommissie.
De jaren die ik gewerkt heb op de 13e verdieping was een erg leuke tijd en ik wil iedereen hiervoor 
bedanken. Allereerst de collega’s van de Delwel groep; Marije, door de jaren heen heb ik altijd 
op jouw lab-kwaliteiten kunnen rekenen, zo stond je dagen, weken en zelfs maanden voor 
mij “mogelijk iets interessants” te valideren, zoals een mutatie in honderden patient-samples. 
Super onwijs bedankt hiervoor! Claudia, als het allemaal niet meer lukt, dan ben jij de steun en 
toeverlaat in de Delwel groep. Eric B., of ook wel de “EVI1-man”. Jaren heb ik naar de “blokjes 
en cirkeltjes” gekeken in jouw presentaties die de interacties met EVI1 voorstelden. Hopelijk ga 
ik deze cartoon in een mooi artikel terug zien. Roberto, together we spent many hours working 
on CEBPA, good luck with your research! Lucila, heel veel succes verder met je onderzoek! 
Daarnaast ook de oud collega’s, Bas en Sanne, bedankt voor de discussies die we gehad hebben.
Behalve op de afdeling Hematology in Rotterdam, heb ik ook een paar maanden in New York (VS) 
gewerkt, in de groep van Ari Melnick. Ari, thank you very much for having me in your excellent 
lab. NY is a great city but working with you and your highly experienced team did make it 
complete. My experience of your lab is that “it runs like a Jekko!”, keep up the good work! Kena 
Figueroa, Together with Ari, you provided many insights in DNA-methylation in cancer research. 
I hope to read many more of your “art” in the future! Friends and colleagues of the Melnick lab, 
it is already a while ago that I spent time with you guys. Thank you all very much for guiding 
me through NY and the lunches, dinners, and drinks we had together. Thomas Clozel, I really 
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HAT(SEQ) Hypergeometric Analysis of Tiling-arrays (and Sequence data)
HELP  HpaII tiny fragment Enrichment by Ligation Mediated PCR
HR  Hazard Ratio
HSC  Hematopoietic Stem Cell
IL-3 / -6  Interleukin 3 / -6
Indel  Insertion or Deletion
IP  ImmunoPrecipitation
iPCR  Inverse PCR
ITD  Internal Tandem Duplication
MAS  MicroArray Suite
MDS  Myelodysplastic Syndrome
MeDIP  Myelodysplastic DNA Immunoprecipitation
MeDIP-on-chip Myelodysplastic DNA Immunoprecipitation on array
methyl-seq DNA-methylation profiling by deep-sequencing
mRNA  Messenger RNA
mRNA-seq mRNA profiling by deep-sequencing
mVIS  Methylated Viral Integration Site
MYH11  Myosin, heavy chain 11 (gene)
NOTCH1  Notch homolog 1 (gene)
NPM1  Nucleophosmin (gene)
OS  Overall Survival
PCR  Polymerase Chain Reaction
PTP4A3  Protein Tyrosine Phosphatase type IVA, member 3
PWM  Position Weight Matrices
RAEB(t)  Refractory Anemia with Excess Blasts (in transformation)
RFS  Relapse-Free Survival
RIM  Retroviral Integration Mutagenesis
RMA  Robust Multi Averaging
RNA  Ribonucleic Acid
ROI  Region-Of-Interest
RQ-PCR  Quantitative real-time reverse transcription PCR
RT-PCR  Reverse Transcription PCR
SNP  Single Nucleotide Polymorphism
SNV  Single Nucleotide Variation
STAT  Signal Transducer and Activator of Transcription
TAD  Transactivation Domain
TCR  T-Cell Receptor
TFBS  Transcription Factor Binding Sites
WBC  White Blood Cell
WES  Whole Exome Sequencing
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enjoyed our coffee moments. I see forward to drink another coffee with you! Olivier Elemento, 
it was great to join your weekly meetings and to present my work in your lab too!
De afdeling Hematology bestaat voornamelijk uit biologen maar er zijn ook wat bioinformatici, 
statistici en informatici aanwezig. Allereerst Justine, thank you for the good discussions and many 
laughs we had together! Rowan, kamergenoot en “SNIP-man”, veel succes met de afronding van 
je onderzoek en de keuze die je hierna gaat maken. Mathijs, vaak stond jij ineens weer stilletjes 
over me schouder mee te lezen op mijn beeldscherm, geen idee hoe lang je er dan al stond. 
Bedankt voor deze overweldigende interesse en onze discussies over technische, maar ook 
geheel irrelevante onderwerpen. Heel veel succes met je verdere onderzoek en de afronding 
van je boekje. Remco, er is een quote die heel mooi bij jou past: “There are 10 types of people 
in this world, the ones who do understand binary and the ones who don’t”. Veronika, it is always 
good to talk with you about statistics or the every-day “stuff”. I wish you all the best with the 
adventures that lie ahead of you! Yvette, bedankt voor de goede samenwerking in de projecten 
die we gehad hebben, het is heel fijn om samen met jou te werken. 
In het eerste jaar op de afdeling zat ik op de “kopkamer”, dit was een gezellige maar ook een 
relatief drukke kamer; Renee het was me een waar genoegen om samen met jou gewerkt te 
mogen hebben. Mijn allereerste lab experiment (en ook gelijk de laatste), heb ik dan ook samen 
met jou gedaan. Ik wens je heel veel succes met je postdoc en verdere carrière en heel veel 
geluk samen met Ona en Uri. Su ming, ik denk niet dat veel mensen dit weten maar eigenlijk is 
mijn eerste kennismaking met de afdeling Hematologie dankzij jou geweest. Bedankt hiervoor! 
Laten we nog eens gezellig wat drinken! Mijn overige (oud)kamergenoten, Rasti, Simone, Eric 
V, Lucila, Kerim, Jurgen, Jurre, Rogier, Moja en andere collega’s op de afdeling, Stefan, Marijke, 
Paulette, Roel, Merel, Joyce, Menno, Stevan, Sophie, Davine, Carla, Onno, Annemarie, Goran, 
Janine, Marshall en Farshid, bedankt voor jullie wetenschappelijke input en/of de inspirerende 
praatjes! Jasper en Francois bedankt voor de dagelijkse koffiemomenten en de gezellige lunches. 
Werkgroep leid(st)ers, Peter Valk, Stevan Erkeland, Anita Rijneveld, Marieke von Lindern, Moja 
Jongen-Lavrencic en Ivo Touw bedankt voor al jullie input tijdens de werkbesprekingen. Ivo, 
je bent altijd erg kritisch geweest maar juist daarvan heb ik geleerd. Kirsten, bedankt voor 
het delen van je expertise over de morfologie van cellen. Berna, bedankt voor je hulp bij de 
bepaling van de karyogrammen. Ans en Leenke, de dames van het secretariaat, bedankt voor 
het regelen van en het mij herinneren aan allerlei onvoorziene taken. Jan van Kapel, bedankt 
voor het regelen van de PC en, niet onbelangrijk, de batterijen in mijn muis. Collega’s op de 15e 
verdieping, afdeling Bioinformatica, groep van Peter van der Spek, bedankt voor het voorzien 
van de nodige licenties en de rekenkracht op jullie servers. Het is daarom ook dankzij jullie dat 
ik helemaal los kon gaan en complexe analyses kon draaien. Erik, Martin en Jaap, bedankt voor 
de goede discussies.
Mijn onderzoek was in samenwerking met Delft Bioinformatics Lab (TU-delft). Hier kon ik altijd 
terecht voor een kop koffie en (technische) vraagstukken. Erik van de Akker, buddy en room 
mate tijdens congressen, bedankt voor alle (te) lange discussies. Wat hebben wij gelachen 
op congressen en al helemaal toen we in een Belgisch hotel zaten waar de wc-deur vanuit de 
buitenkant op slot gedraaid moest worden. Heel veel succes met de afronding van je boekje! 
Jan Bot, ik had niet gedacht dat jij nog eens weg zou gaan bij de TU maar volgens mij zit je nu 
helemaal op je plek bij Surf-Sara. Heel veel succes met je toekomstige carrière-stappen! Veel 
dank aan Jeroen de Ridder, we hebben veel gediscussieerd en jij zit vol enthousiasme en gave 
ideeën! Ik hoop dan ook in de komende jaren nog veel van jouw werk terug te kunnen lezen 
en horen. Lodewyk, Dick, Marc, Jurgen, Bastiaan, Alexey, Ahmed, Marcel, Sepideh en Thies 
bedankt voor de nodige wetenschappelijke input tijdens de werkbesprekingen.
Tijdens mijn onderzoeksjaren ben ik bijna altijd met de motor (Monster 620i en 696) naar het 
EMC in Rotterdam gereden. De dagen dat het niet kon (té slecht weer) werkte ik dan ook liever 
thuis. Ik wil hiervoor Ducati bedanken omdat ik altijd probleemloos kon rijden (écht waar?, ja 
écht!) en het mij motivatie gaf om naar het werk te rijden. Het geluid en de daarbij horende 
“shock-waves” uit demperloze-dempers zorgde ervoor dat ik met gemak door de files kon rijden. 
Het was toch ook best leuk dat autoalarmen van geparkeerde auto’s regelmatig afgingen bij het 
langs rijden.
Dan kom ik nu aan het eind van mijn dankwoord en dat is voor mijn vrienden en familie. 
Alhoewel ik regelmatig probeerde uit te leggen wat ik nou de hele dag doe, was het volgens mij 
niet altijd even gemakkelijk te begrijpen voor iedereen. De gedeelten “achter de pc zitten” en 
“koffie drinken” werd daarentegen gelukkig wel goed begrepen. Regelmatig werd mij de vraag 
gesteld: “Hoe gaat het met je afstuderen?” , waarop ik dan weer dacht: “Dat is lang geleden 
zeg, 2007...” maar dan toch antwoordde: “Met mijn promotie gaat het goed!”. Met dit boekje in 
handen kan je nog eens rustig lezen wat ik de afgelopen jaren nu echt gedaan heb.
Jeroen Nieuwkamp, Sjoerd, Pascal, Oliver, Jan Bot, Bas&Nathalie, bedankt voor 
jullie interesse, support en ook zeker voor de niet werk gerelateerde gesprekken! Ik kon overigens 
de kilo’s aan Nederlandse M&M’s die meegebracht werden naar New York (de M&M’s in New 
York smaken echt niet lekker) ook erg waarderen. In het bijzonder wil ik Jeroen Nieuwkamp 
bedanken, jij gaat mij ook bijstaan als mijn paranimf, succes! Irene en Jacques, zonder twijfel 
heb ik de allerbeste schoonouders die ik me had kunnen wensen. Harstikke bedankt voor jullie 
enorme interesse en bewondering in alles wat ik doe. Lieve Fatma-abla en paranimf. Jij bent een 
voorbeeld voor velen en zo ook voor mij. Je hebt mij ook altijd geïnspireerd en gestimuleerd om 
te blijven studeren, bedankt daarvoor! Kadir, jouw nuchterheid kan ik altijd erg waarderen. Je zal 
je daarom ook vast afvragen of al deze melodrama die ik hier schrijf nu ook echt nodig is.
Lieve annem, zonder jouw hulp door alle jaren heen had ik nooit de opleidingen kunnen doen om 
vervolgens te gaan werken aan een promotieonderzoek. Jij legde nooit druk op mijn schouders 
en liet mij altijd mijn eigen keuzes maken. Ik kan je daarom ook niet genoeg bedanken voor de 
onbezorgde tijd en alle steun van de afgelopen jaren!
DankwoordDankwoord
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Lieve Ankie en Senna, wat ben ik blij met jullie! Ank, ondertussen zijn wij alweer bijna 14 jaar 
ontzettend gelukkig samen. Op jou kan ik bouwen en als ik het even niet meer weet of zie, dan 
wijs jij mij weer de weg, letterlijk en figuurlijk (“Het ligt voor je, schat”). Je bent behalve een 
mooie verschijning, ook een lieve en zorgzame mama voor onze mooie, lieve en ontzettend 
vrolijke dochter. Bedankt dat jij er altijd voor mij en haar bent! Senna, ik weet, je kan nog (nét) 
niet lezen maar als mama dit hardop leest dan zal je er misschien wel iets van begrijpen (sorry, 
ik heb er geen Elmo of Pippie plaatjes bij gedaan): Jij bent het mooiste wat mij is overkomen! Jij 
bent het zonnetje en de clown in huis. Altijd maar zingen, dansen, lachen en grappen uithalen. 
Laten we er met z’n allen een ontzettende leuke tijd van blijven maken!
Erdogan
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CURRICULUM VITAE
Erdogan Taskesen werd geboren op 26 februari 1980 in Zierikzee. In september 1996, na het 
behalen van zijn diploma Elektrotechniek aan de Scholengemeenschap Schouwen Duiveland, 
startte hij met de Middelbaar beroepsonderwijs opleiding Elektrotechniek aan het ROC Zeeland 
in Middelburg. Behalve zijn interesse in elektronica ontwikkelde hij een sterke affiniteit met de 
digitale techniek en specialiseerde zich daarom in Computer Interface Techniek waarvoor hij 
in juni 2000 zijn diploma behaalde. Om vervolgens meer te leren over Informatie Technologie, 
begon Erdogan aan zijn volgende opleiding, Hogere Informatica aan de Hogeschool Rotterdam 
en Omstreken (HR&O). Deze opleiding wist hij verkort af te ronden en behaalde in augustus 2003 
zijn ingenieur (ing.) ofwel Bachelor of Science (BSc) diploma. Het laatste jaar aan de HR&O heeft 
hij gewerkt bij Syntess Software in Zierikzee volgens het duale leertraject. Hierdoor ervaarde hij 
dat hij programmeren niet als doel wilde inzetten maar als middel om complexe vraagstukken 
op te lossen. Daarom besloot hij in september 2003 te starten met de studie Bioinformatica 
aan de Technische Universiteit Delft (TU-Delft). Gedurende de laatste negen maanden van 
deze opleiding werkte hij aan zijn afstudeeronderzoek, “Novel approaches for cross-species 
subtype identification”, onder de supervisie van prof.dr.ir. Marcel J.T. Reinders en prof.dr. 
Lodewyk Wessels. Met dit onderzoek behaalde hij in juni 2007 zijn ingenieur (ir.) ofwel Master 
of Science (MSc) diploma Media & Knowledge Engineering met als specialisatie Bioinformatica. 
Tussen de Master en PhD heeft Erdogan als wetenschappelijk programmeur gewerkt aan een 
simulatiemodel met betrekking tot borstkanker-screening, op de afdeling Epidemiologie aan 
de Erasmus University Medical Center (EMC). In april 2008 begon Erdogan als promovendus 
op de afdeling Hematologie in de groep van prof.dr. Ruud Delwel en prof.dr. Bob Löwenberg. 
Het onderzoek beschreven in dit proefschrift vond plaats op de afdeling Hematologie, in 
samenwerking met de TU-Delft, afdeling Delft Bioinformatics Lab (DBL), groep van prof.dr.ir. 
Marcel J.T. Reinders. In 2011 is Erdogan awarded met een KWF fellowship om onderzoek te 
doen naar de integratie van genexpressie en DNA-methylatie profielen in patiënten met Acute 
Myeloïde Leukemie, in de groep van dr. A. Melnick, Cornell Medical College, New York (VS). In 
april 2013 begon hij vervolgens te werken als postdoctoraal onderzoeker op de afdeling DBL van 
de TU-Delft, in samenwerking met Philips. Het doel is om methodieken te ontwikkelen waarmee 
genetische afwijkingen nauwkeuriger in kaart gebracht kunnen worden zodat een zogenaamde 
“targeted therapie” een stap dichter bij komt.
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Name PhD student:  Erdogan Taskesen
Erasmus MC Department:  Hematology
Research School:   Molecular Medicine
PhD period:  April 2008 - April 2013
Promotor(s):  Prof. R. Delwel
Supervisor:  Prof. R. Delwel
PhD training Year ECTS
General academic/research skills
      Whole Genome Sequencing – NACGG 2010 0.3
      NWO, Media training 2010 0.3
      Biomedical English Writing and Communication 2012 4
In-depth courses
      Advanced pattern recognition (Technical University of Delft) 2008 1.5
      MGC Microarray Analysis course 2008 1.2
      Workshop Browsing Genes and Genomes Ensembl 2008 0.6
      Workshop Advanced Browsing Genes and Genomes Ensembl 2008 0.3
      Workshop on Bioinformatic analysis, Tools and services 2008 0.3
      Biomedical Research Techniques VII 2008 1.2
      SNPs and Human Diseases course 2008 1.2
      Basic and Translational Oncology course 2008 1.2
      Biological Interpretation of Gene Expression Data with ExPlain 2010 0.3
      Molecular Diagnostics 2010 0.3
      Complete Genomics 2011 0.3
Oral presentations
      AIO/postdoc meeting (Department of Hematology, 4x) 2008-2012 4
      AIO/postdoc meeting (Delft Bioinformatics Lab, 3x) 2008-2012 1.5
      Journal club (Department of Hematology) 2008-2012 0.5
      Workdiscussion (Department of Hematology, 10x) 2008-2012 5
      Skyline Diagnostics (2x) 2008-2012 1
      Bridge meeting: invited talk Matlab Mathworks 2009 0.5
      Annual conference European Hematology Association (EHA) 2010 1
      Annual conference American Society of Hematology (ASH) 2011 1 
      Dutch Hematology congress 2012 1 
      Annual Center for Translational Molecular Medicine (CTMM) 2012 1
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National and International conferences
      Molecular Medicine Day 2008-2010 0.8
      Dutch Hematology congress 2009-2011 1.8
      Annual conference European Hematology Association (EHA) 2009-2010 2
      The Netherlands Bioinformatics Centre (NBIC) 2009 1
      International Conference on Intelligent Systems for Molecular 
      Biology
2009 1
      Benelux Bioinformatics Congress (BBC) 2009 1
       Annual conference Center for Translational Molecular Medicine 2010 1
      Annual conference American Society of Hematology (ASH) 2011 1
Seminars
      Erasmus Hematology lectures 2008-2012 3
Scientific meetings
      Journal club 2008-2011 2.3
      AIO/ postdoc meetings 2008-2012 1.6
      Work-discussions 2008-2013 4.5
      Labletreat (Delft Bioinformatics Lab, DBL) 2010-2011 1
Other
      Writing application KWF 2010 1
Teaching activities / Supervising students
      Three Bachelor students (“Media knowledge engineering”) 2012 3
Supervising practical training and excursions
      Organisation and supervision invited speaker lunch 2008-2009 0.2
      Analysis of microarray gene expression data using R/BioC and  
      web tools
2011 0.3
Total 55 ect
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Stellingen behorende bij het proefschrift:
Computationele Biologie in Acute Myeloïde Leukemie met Afwijkingen in CEBPA
1. Het gemengde Myeloïde / T-lymfoïde fenotype van “CEBPA silenced” Acute Myeloïde Leukemie is een 
  gevolg van het ontbreken van C/EBPα (dit proefschrift en Wouters BJ et al 2007 Blood 110 (10):3706-14). 
2. C/EBPα kan fungeren als een transcriptionele activator en als onderdrukker van transcriptie 
 (dit proefschrift en Alberich-Jordà, et al. 2012 J. Clin. Invest. 122(12):4490-504).
3. Acute Myeloïde Leukemie met CEBPA dubbele mutaties, en niet met CEBPA enkele mutaties, 
 moet worden beschouwd als een unieke entiteit bij de indeling van de ziekte (dit proefschrift).
4. Autologe en allogene hematopoietische stamceltransplantatie in eerste complete remissie zijn de 
  beste post-remissie therapie opties voor Acute Myeloïde Leukemie patiënten met CEBPA dubbele mutatie 
 (dit proefschrift). 
5. Combineren van genoom-brede mRNA expressie en DNA methylatie patronen in een cohort van 
 Acute Myeloïde Leukemie patiënten leidt tot unieke profielen waarmee nieuwe leukemie-subtypen 
 geïdentificeerd worden (dit proefschrift).
6. De vooruitgang van de moderne biomedische wetenschap wordt mede bepaald door hoe goed de biomedische 
  onderzoekers en bioinformatici in staat zijn om hun onderzoeksvragen aan elkaar uit te leggen.
7. Integratie kent vele uitdagingen; dit geldt voor wetenschappelijke data analyse, maar ook voor het opnemen 
 van bevolkingsgroepen in de maatschappij.
8. Data is digitaal goud.
9. De bruikbaarheid van de data wordt bepaald door de creativiteit van de geest. 
10. There’s a way to do it... find it! (Thomas A. Edison).
Erdoğan Taşkesen
Rotterdam, januari 2013
